Stem definition | Drug id | CAS RN |
---|---|---|
antihyperglycaemics, phenformin derivatives | 1725 | 657-24-9 |
Dose | Unit | Route |
---|---|---|
2 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 99 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 387.10 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 52 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.64 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 7.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 1 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.70 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
July 28, 2006 | EMA | CHEPLAPHARM Arzneimittel GmbH | |
March 3, 1995 | FDA | BRISTOL MYERS SQUIBB |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Lactic acidosis | 13166.00 | 9.82 | 5619 | 309490 | 27736 | 50262279 |
Acute kidney injury | 3422.68 | 9.82 | 5521 | 309588 | 222537 | 50067478 |
Hypoglycaemia | 3047.24 | 9.82 | 2584 | 312525 | 50997 | 50239018 |
Metabolic acidosis | 2105.76 | 9.82 | 1823 | 313286 | 37002 | 50253013 |
Diabetic ketoacidosis | 2031.14 | 9.82 | 1309 | 313800 | 16563 | 50273452 |
Blood glucose increased | 1858.28 | 9.82 | 2255 | 312854 | 69069 | 50220946 |
Glycosylated haemoglobin increased | 962.95 | 9.82 | 676 | 314433 | 9930 | 50280085 |
Ketoacidosis | 956.64 | 9.82 | 473 | 314636 | 3422 | 50286593 |
Diabetes mellitus inadequate control | 932.38 | 9.82 | 722 | 314387 | 12423 | 50277592 |
Hyperkalaemia | 865.90 | 9.82 | 1270 | 313839 | 46819 | 50243196 |
Euglycaemic diabetic ketoacidosis | 736.19 | 9.82 | 357 | 314752 | 2462 | 50287553 |
Hyperglycaemia | 734.23 | 9.82 | 1015 | 314094 | 35390 | 50254625 |
Systemic lupus erythematosus | 666.72 | 9.82 | 56 | 315053 | 140566 | 50149449 |
Pemphigus | 591.90 | 9.82 | 40 | 315069 | 120126 | 50169889 |
Hypoglycaemic coma | 524.93 | 9.82 | 267 | 314842 | 2066 | 50287949 |
Glossodynia | 516.26 | 9.82 | 58 | 315051 | 115511 | 50174504 |
Drug ineffective | 515.98 | 9.82 | 3000 | 312109 | 816333 | 49473682 |
Hand deformity | 488.65 | 9.82 | 35 | 315074 | 100164 | 50189851 |
Synovitis | 484.40 | 9.82 | 92 | 315017 | 123773 | 50166242 |
Drug intolerance | 450.92 | 9.82 | 420 | 314689 | 218684 | 50071331 |
Shock | 440.87 | 9.82 | 592 | 314517 | 20058 | 50269957 |
Contraindicated product administered | 433.99 | 9.82 | 192 | 314917 | 148766 | 50141249 |
Blood glucose decreased | 414.89 | 9.82 | 539 | 314570 | 17672 | 50272343 |
Pancreatitis | 401.96 | 9.82 | 847 | 314262 | 41767 | 50248248 |
Pancreatitis acute | 401.40 | 9.82 | 610 | 314499 | 23202 | 50266813 |
Arthropathy | 400.06 | 9.82 | 244 | 314865 | 157662 | 50132353 |
Treatment failure | 395.32 | 9.82 | 181 | 314928 | 137456 | 50152559 |
Anuria | 372.54 | 9.82 | 403 | 314706 | 10841 | 50279174 |
Infusion related reaction | 363.12 | 9.82 | 313 | 314796 | 169244 | 50120771 |
Pericarditis | 360.32 | 9.82 | 36 | 315073 | 78653 | 50211362 |
Renal failure | 353.01 | 9.82 | 1457 | 313652 | 105176 | 50184839 |
Diarrhoea | 338.26 | 9.82 | 5336 | 309773 | 583140 | 49706875 |
Hyperlactacidaemia | 336.44 | 9.82 | 202 | 314907 | 2231 | 50287784 |
Diabetic metabolic decompensation | 334.79 | 9.82 | 170 | 314939 | 1310 | 50288705 |
Joint swelling | 330.18 | 9.82 | 642 | 314467 | 244644 | 50045371 |
Blood glucose abnormal | 326.87 | 9.82 | 296 | 314813 | 6376 | 50283639 |
Pemphigoid | 315.11 | 9.82 | 275 | 314834 | 5632 | 50284383 |
Alopecia | 309.74 | 9.82 | 665 | 314444 | 244382 | 50045633 |
Swelling | 293.23 | 9.82 | 500 | 314609 | 200372 | 50089643 |
Rheumatoid arthritis | 293.10 | 9.82 | 507 | 314602 | 202043 | 50087972 |
Wound | 291.69 | 9.82 | 147 | 314962 | 105647 | 50184368 |
Vomiting | 286.95 | 9.82 | 4237 | 310872 | 456521 | 49833494 |
Rheumatoid factor positive | 284.97 | 9.82 | 5 | 315104 | 49854 | 50240161 |
Duodenal ulcer perforation | 263.09 | 9.82 | 4 | 315105 | 45607 | 50244408 |
Rash | 262.01 | 9.82 | 1624 | 313485 | 435847 | 49854168 |
Dehydration | 259.16 | 9.82 | 1731 | 313378 | 150718 | 50139297 |
Therapeutic product effect decreased | 245.70 | 9.82 | 291 | 314818 | 135759 | 50154256 |
Haemodialysis | 244.86 | 9.82 | 281 | 314828 | 8081 | 50281934 |
Drug level increased | 240.29 | 9.82 | 431 | 314678 | 18837 | 50271178 |
Hypothermia | 239.11 | 9.82 | 333 | 314776 | 11683 | 50278332 |
Hypersensitivity | 236.73 | 9.82 | 628 | 314481 | 214533 | 50075482 |
Discomfort | 228.35 | 9.82 | 203 | 314906 | 108177 | 50181838 |
Pain | 215.09 | 9.82 | 2439 | 312670 | 576464 | 49713551 |
Infection | 209.63 | 9.82 | 480 | 314629 | 172474 | 50117541 |
Helicobacter infection | 207.28 | 9.82 | 31 | 315078 | 49671 | 50240344 |
Toxicity to various agents | 201.62 | 9.82 | 2116 | 312993 | 210383 | 50079632 |
Off label use | 197.45 | 9.82 | 1946 | 313163 | 472480 | 49817535 |
Muscle injury | 192.95 | 9.82 | 9 | 315100 | 37102 | 50252913 |
Vitamin B12 deficiency | 190.39 | 9.82 | 173 | 314936 | 3743 | 50286272 |
Product use issue | 185.87 | 9.82 | 409 | 314700 | 149066 | 50140949 |
Blood lactic acid increased | 182.95 | 9.82 | 199 | 314910 | 5386 | 50284629 |
Continuous haemodiafiltration | 182.79 | 9.82 | 99 | 315010 | 883 | 50289132 |
Folliculitis | 182.03 | 9.82 | 17 | 315092 | 39208 | 50250807 |
Pancreatic carcinoma | 178.89 | 9.82 | 207 | 314902 | 6007 | 50284008 |
Abdominal discomfort | 178.68 | 9.82 | 788 | 314321 | 230853 | 50059162 |
Rhabdomyolysis | 173.00 | 9.82 | 586 | 314523 | 38441 | 50251574 |
Musculoskeletal stiffness | 172.01 | 9.82 | 337 | 314772 | 128144 | 50161871 |
Drug interaction | 168.73 | 9.82 | 1943 | 313166 | 197678 | 50092337 |
Sleep disorder due to general medical condition, insomnia type | 165.55 | 9.82 | 7 | 315102 | 31440 | 50258575 |
Irritable bowel syndrome | 161.61 | 9.82 | 59 | 315050 | 51382 | 50238633 |
Weight decreased | 160.80 | 9.82 | 2093 | 313016 | 219152 | 50070863 |
Blood glucose fluctuation | 155.89 | 9.82 | 159 | 314950 | 3987 | 50286028 |
Pyrexia | 154.85 | 9.82 | 1567 | 313542 | 378636 | 49911379 |
Diabetes mellitus | 153.53 | 9.82 | 659 | 314450 | 48374 | 50241641 |
Impaired healing | 141.87 | 9.82 | 135 | 314974 | 69651 | 50220364 |
Stomatitis | 137.21 | 9.82 | 264 | 314845 | 101080 | 50188935 |
Febrile neutropenia | 137.01 | 9.82 | 249 | 314860 | 97418 | 50192597 |
Arthralgia | 134.35 | 9.82 | 1924 | 313185 | 436778 | 49853237 |
Maternal exposure during pregnancy | 132.74 | 9.82 | 528 | 314581 | 159250 | 50130765 |
Drug hypersensitivity | 125.13 | 9.82 | 982 | 314127 | 250028 | 50039987 |
Sinusitis | 123.23 | 9.82 | 594 | 314515 | 169964 | 50120051 |
Neurologic neglect syndrome | 118.71 | 9.82 | 87 | 315022 | 1371 | 50288644 |
Psoriasis | 118.58 | 9.82 | 786 | 314323 | 68214 | 50221801 |
Hypomagnesaemia | 117.34 | 9.82 | 364 | 314745 | 22792 | 50267223 |
Intentional overdose | 116.63 | 9.82 | 727 | 314382 | 61777 | 50228238 |
Carotid artery thrombosis | 114.32 | 9.82 | 86 | 315023 | 1413 | 50288602 |
Hepatic enzyme increased | 112.81 | 9.82 | 456 | 314653 | 136924 | 50153091 |
Fatigue | 108.03 | 9.82 | 3473 | 311636 | 704128 | 49585887 |
Acidosis | 107.89 | 9.82 | 213 | 314896 | 10014 | 50280001 |
Nausea | 106.55 | 9.82 | 5387 | 309722 | 700011 | 49590004 |
Tachypnoea | 105.49 | 9.82 | 261 | 314848 | 14316 | 50275699 |
Overdose | 104.94 | 9.82 | 1015 | 314094 | 98712 | 50191303 |
Blood bicarbonate decreased | 103.36 | 9.82 | 105 | 315004 | 2620 | 50287395 |
Neutropenia | 103.02 | 9.82 | 522 | 314587 | 147443 | 50142572 |
Renal impairment | 102.98 | 9.82 | 815 | 314294 | 74846 | 50215169 |
Blood creatinine increased | 102.91 | 9.82 | 819 | 314290 | 75341 | 50214674 |
Ill-defined disorder | 100.63 | 9.82 | 115 | 314994 | 54539 | 50235476 |
Completed suicide | 100.46 | 9.82 | 1259 | 313850 | 130630 | 50159385 |
Personality disorder | 100.05 | 9.82 | 129 | 314980 | 4195 | 50285820 |
C-reactive protein abnormal | 96.02 | 9.82 | 27 | 315082 | 27782 | 50262233 |
Adjustment disorder | 95.82 | 9.82 | 88 | 315021 | 1931 | 50288084 |
Hemiplegia | 95.74 | 9.82 | 168 | 314941 | 7213 | 50282802 |
Ketosis | 95.33 | 9.82 | 52 | 315057 | 471 | 50289544 |
Contusion | 91.69 | 9.82 | 373 | 314736 | 111810 | 50178205 |
Myocardial infarction | 88.26 | 9.82 | 895 | 314214 | 88132 | 50201883 |
Injection site nodule | 87.24 | 9.82 | 106 | 315003 | 3242 | 50286773 |
Polyuria | 85.86 | 9.82 | 157 | 314952 | 6964 | 50283051 |
Product residue present | 84.11 | 9.82 | 109 | 315000 | 3563 | 50286452 |
MELAS syndrome | 81.28 | 9.82 | 30 | 315079 | 91 | 50289924 |
Postprandial hypoglycaemia | 77.38 | 9.82 | 25 | 315084 | 43 | 50289972 |
Vasoplegia syndrome | 76.39 | 9.82 | 60 | 315049 | 1054 | 50288961 |
Urine ketone body present | 76.19 | 9.82 | 83 | 315026 | 2250 | 50287765 |
Ketonuria | 75.32 | 9.82 | 43 | 315066 | 429 | 50289586 |
Blister | 74.93 | 9.82 | 276 | 314833 | 85142 | 50204873 |
Hip arthroplasty | 74.24 | 9.82 | 49 | 315060 | 30380 | 50259635 |
Acetonaemia | 73.77 | 9.82 | 26 | 315083 | 66 | 50289949 |
Diabetic neuropathy | 73.66 | 9.82 | 101 | 315008 | 3490 | 50286525 |
Hepatic steatosis | 71.95 | 9.82 | 322 | 314787 | 24062 | 50265953 |
Rheumatic fever | 71.53 | 9.82 | 10 | 315099 | 16857 | 50273158 |
Angioedema | 69.50 | 9.82 | 437 | 314672 | 37239 | 50252776 |
Hypotension | 69.22 | 9.82 | 1938 | 313171 | 233531 | 50056484 |
Hypoglycaemic encephalopathy | 68.97 | 9.82 | 34 | 315075 | 244 | 50289771 |
Microalbuminuria | 67.63 | 9.82 | 36 | 315073 | 309 | 50289706 |
Anion gap increased | 66.64 | 9.82 | 63 | 315046 | 1436 | 50288579 |
Cardiac arrest | 64.28 | 9.82 | 800 | 314309 | 82851 | 50207164 |
Coma acidotic | 64.12 | 9.82 | 25 | 315084 | 92 | 50289923 |
Anaemia vitamin B12 deficiency | 64.07 | 9.82 | 35 | 315074 | 318 | 50289697 |
Death | 63.73 | 9.82 | 1541 | 313568 | 323838 | 49966177 |
Peripheral swelling | 61.47 | 9.82 | 907 | 314202 | 205029 | 50084986 |
Diabetic retinopathy | 60.91 | 9.82 | 72 | 315037 | 2138 | 50287877 |
Circulatory collapse | 60.44 | 9.82 | 266 | 314843 | 19734 | 50270281 |
Nasopharyngitis | 59.93 | 9.82 | 843 | 314266 | 192084 | 50097931 |
Therapeutic product effect incomplete | 59.67 | 9.82 | 330 | 314779 | 91185 | 50198830 |
Cytomegalovirus infection | 59.18 | 9.82 | 19 | 315090 | 17943 | 50272072 |
Bradycardia | 58.34 | 9.82 | 636 | 314473 | 63790 | 50226225 |
Glomerular filtration rate decreased | 57.04 | 9.82 | 181 | 314928 | 11471 | 50278544 |
Glycosylated haemoglobin decreased | 56.44 | 9.82 | 36 | 315073 | 446 | 50289569 |
Arthritis | 55.84 | 9.82 | 314 | 314795 | 86407 | 50203608 |
Product odour abnormal | 55.16 | 9.82 | 49 | 315060 | 1028 | 50288987 |
Mobility decreased | 55.06 | 9.82 | 283 | 314826 | 79665 | 50210350 |
Insulin resistance | 54.84 | 9.82 | 41 | 315068 | 667 | 50289348 |
Tenosynovitis | 53.53 | 9.82 | 3 | 315106 | 10562 | 50279453 |
Atrioventricular block | 53.37 | 9.82 | 122 | 314987 | 6356 | 50283659 |
Blood ketone body increased | 52.44 | 9.82 | 28 | 315081 | 242 | 50289773 |
Renal tubular necrosis | 51.66 | 9.82 | 160 | 314949 | 10008 | 50280007 |
Cholelithiasis | 51.62 | 9.82 | 409 | 314700 | 37564 | 50252451 |
Amylase increased | 51.24 | 9.82 | 108 | 315001 | 5322 | 50284693 |
Polydipsia | 51.17 | 9.82 | 79 | 315030 | 3045 | 50286970 |
Haemodynamic instability | 51.17 | 9.82 | 137 | 314972 | 7887 | 50282128 |
Rheumatoid nodule | 50.72 | 9.82 | 9 | 315100 | 12726 | 50277289 |
Abdominal pain | 50.54 | 9.82 | 1872 | 313237 | 234356 | 50055659 |
Loss of personal independence in daily activities | 50.51 | 9.82 | 244 | 314865 | 69806 | 50220209 |
Oliguria | 50.11 | 9.82 | 138 | 314971 | 8078 | 50281937 |
Affect lability | 49.87 | 9.82 | 146 | 314963 | 8852 | 50281163 |
Exposure during pregnancy | 49.73 | 9.82 | 1043 | 314066 | 119972 | 50170043 |
Thrombocytopenia | 49.41 | 9.82 | 532 | 314577 | 127141 | 50162874 |
Drug level above therapeutic | 49.27 | 9.82 | 88 | 315021 | 3832 | 50286183 |
Pneumonia | 48.98 | 9.82 | 1894 | 313215 | 376507 | 49913508 |
C-reactive protein increased | 48.83 | 9.82 | 230 | 314879 | 66244 | 50223771 |
Migraine | 48.77 | 9.82 | 272 | 314837 | 75008 | 50215007 |
Blood potassium increased | 48.72 | 9.82 | 217 | 314892 | 16181 | 50273834 |
White blood cell count decreased | 47.76 | 9.82 | 480 | 314629 | 116242 | 50173773 |
Hypovolaemic shock | 47.59 | 9.82 | 102 | 315007 | 5086 | 50284929 |
Macroangiopathy | 47.48 | 9.82 | 20 | 315089 | 94 | 50289921 |
Anhidrosis | 47.31 | 9.82 | 20 | 315089 | 95 | 50289920 |
Drug resistance | 47.11 | 9.82 | 30 | 315079 | 18959 | 50271056 |
Device expulsion | 46.47 | 9.82 | 67 | 315042 | 28755 | 50261260 |
Knee arthroplasty | 46.23 | 9.82 | 96 | 315013 | 35750 | 50254265 |
Toothache | 45.34 | 9.82 | 217 | 314892 | 16677 | 50273338 |
Therapy non-responder | 45.30 | 9.82 | 164 | 314945 | 50858 | 50239157 |
Motor dysfunction | 45.17 | 9.82 | 131 | 314978 | 7900 | 50282115 |
Cerebral venous thrombosis | 45.15 | 9.82 | 57 | 315052 | 1814 | 50288201 |
Product prescribing error | 45.00 | 9.82 | 253 | 314856 | 20708 | 50269307 |
Malaise | 44.99 | 9.82 | 2536 | 312573 | 332996 | 49957019 |
Bone erosion | 44.97 | 9.82 | 9 | 315100 | 11678 | 50278337 |
Lipase increased | 44.89 | 9.82 | 136 | 314973 | 8405 | 50281610 |
Dialysis | 44.73 | 9.82 | 145 | 314964 | 9293 | 50280722 |
Immune-mediated myositis | 44.71 | 9.82 | 43 | 315066 | 1002 | 50289013 |
Suicide attempt | 44.69 | 9.82 | 506 | 314603 | 51226 | 50238789 |
Leukopenia | 44.29 | 9.82 | 243 | 314866 | 67285 | 50222730 |
Latent autoimmune diabetes in adults | 43.69 | 9.82 | 13 | 315096 | 14 | 50290001 |
Myelosuppression | 43.30 | 9.82 | 15 | 315094 | 13502 | 50276513 |
Pancreatic carcinoma metastatic | 42.74 | 9.82 | 58 | 315051 | 1984 | 50288031 |
Diabetic nephropathy | 42.62 | 9.82 | 47 | 315062 | 1292 | 50288723 |
Drug tolerance decreased | 42.41 | 9.82 | 4 | 315105 | 9156 | 50280859 |
Eating disorder | 42.13 | 9.82 | 199 | 314910 | 15210 | 50274805 |
Electrocardiogram T wave peaked | 41.81 | 9.82 | 22 | 315087 | 184 | 50289831 |
Unresponsive to stimuli | 41.78 | 9.82 | 330 | 314779 | 30279 | 50259736 |
Condition aggravated | 40.81 | 9.82 | 1476 | 313633 | 295582 | 49994433 |
Multiple organ dysfunction syndrome | 40.21 | 9.82 | 485 | 314624 | 49852 | 50240163 |
Transplant rejection | 40.04 | 9.82 | 6 | 315103 | 9603 | 50280412 |
Glycosylated haemoglobin abnormal | 39.84 | 9.82 | 17 | 315092 | 83 | 50289932 |
Multiple sclerosis relapse | 39.54 | 9.82 | 136 | 314973 | 42828 | 50247187 |
Sensory loss | 39.53 | 9.82 | 122 | 314987 | 7616 | 50282399 |
Seizure | 39.49 | 9.82 | 507 | 314602 | 117367 | 50172648 |
Hyponatraemia | 39.29 | 9.82 | 828 | 314281 | 95311 | 50194704 |
Tubulointerstitial nephritis | 39.11 | 9.82 | 193 | 314916 | 15018 | 50274997 |
Bone marrow failure | 39.09 | 9.82 | 70 | 315039 | 27554 | 50262461 |
Inflammation | 38.87 | 9.82 | 202 | 314907 | 56710 | 50233305 |
Immunodeficiency | 38.78 | 9.82 | 22 | 315087 | 14806 | 50275209 |
Red blood cell sedimentation rate increased | 38.60 | 9.82 | 78 | 315031 | 29338 | 50260677 |
Myopathy | 38.54 | 9.82 | 135 | 314974 | 9004 | 50281011 |
Neurotoxicity | 38.37 | 9.82 | 22 | 315087 | 14718 | 50275297 |
Pneumocystis jirovecii pneumonia | 38.00 | 9.82 | 22 | 315087 | 14641 | 50275374 |
Haematotoxicity | 37.78 | 9.82 | 3 | 315106 | 7892 | 50282123 |
Hyperglycaemic hyperosmolar nonketotic syndrome | 37.44 | 9.82 | 31 | 315078 | 589 | 50289426 |
Drug abuse | 37.27 | 9.82 | 219 | 314890 | 59627 | 50230388 |
Haemophagocytic lymphohistiocytosis | 36.89 | 9.82 | 5 | 315104 | 8628 | 50281387 |
Prerenal failure | 36.85 | 9.82 | 46 | 315063 | 1447 | 50288568 |
Urine albumin/creatinine ratio abnormal | 36.77 | 9.82 | 9 | 315100 | 0 | 50290015 |
Persistent cloaca | 36.31 | 9.82 | 20 | 315089 | 185 | 50289830 |
Gastroenteritis | 36.29 | 9.82 | 259 | 314850 | 23022 | 50266993 |
Adenocarcinoma pancreas | 36.27 | 9.82 | 38 | 315071 | 984 | 50289031 |
Therapeutic response decreased | 36.12 | 9.82 | 161 | 314948 | 47070 | 50242945 |
Pharyngitis | 36.08 | 9.82 | 209 | 314900 | 17294 | 50272721 |
Foot deformity | 35.81 | 9.82 | 40 | 315069 | 19170 | 50270845 |
Disease progression | 35.28 | 9.82 | 404 | 314705 | 95462 | 50194553 |
Dysarthria | 35.13 | 9.82 | 372 | 314737 | 37031 | 50252984 |
Distributive shock | 34.88 | 9.82 | 34 | 315075 | 806 | 50289209 |
Blood triglycerides increased | 34.59 | 9.82 | 151 | 314958 | 11161 | 50278854 |
Malignant neoplasm progression | 34.56 | 9.82 | 265 | 314844 | 67859 | 50222156 |
Sopor | 34.46 | 9.82 | 227 | 314882 | 19652 | 50270363 |
Left ventricular hypertrophy | 34.26 | 9.82 | 86 | 315023 | 4759 | 50285256 |
Blood creatine phosphokinase increased | 34.21 | 9.82 | 281 | 314828 | 26086 | 50263929 |
Exposure via ingestion | 34.05 | 9.82 | 62 | 315047 | 2741 | 50287274 |
Neutrophil count decreased | 33.94 | 9.82 | 159 | 314950 | 45867 | 50244148 |
Kussmaul respiration | 33.84 | 9.82 | 20 | 315089 | 214 | 50289801 |
Injection site erythema | 33.70 | 9.82 | 301 | 314808 | 74635 | 50215380 |
Injection site reaction | 33.38 | 9.82 | 179 | 314930 | 49853 | 50240162 |
Product use in unapproved indication | 33.18 | 9.82 | 514 | 314595 | 115305 | 50174710 |
Cerebrovascular accident | 32.91 | 9.82 | 797 | 314312 | 93883 | 50196132 |
Decreased appetite | 32.66 | 9.82 | 1547 | 313562 | 199376 | 50090639 |
Cold sweat | 32.49 | 9.82 | 142 | 314967 | 10502 | 50279513 |
Product substitution issue | 32.41 | 9.82 | 173 | 314936 | 13884 | 50276131 |
Allergic reaction to excipient | 32.33 | 9.82 | 21 | 315088 | 269 | 50289746 |
Hospitalisation | 31.83 | 9.82 | 270 | 314839 | 67667 | 50222348 |
Panniculitis | 31.79 | 9.82 | 7 | 315102 | 8496 | 50281519 |
Bladder sphincter atony | 31.73 | 9.82 | 17 | 315092 | 148 | 50289867 |
Accidental overdose | 31.44 | 9.82 | 219 | 314890 | 19314 | 50270701 |
Type 2 diabetes mellitus | 31.41 | 9.82 | 340 | 314769 | 34035 | 50255980 |
Albuminuria | 31.41 | 9.82 | 18 | 315091 | 181 | 50289834 |
Platelet count decreased | 31.28 | 9.82 | 440 | 314669 | 100286 | 50189729 |
Enthesopathy | 31.13 | 9.82 | 4 | 315105 | 7189 | 50282826 |
Body mass index increased | 30.92 | 9.82 | 35 | 315074 | 991 | 50289024 |
High density lipoprotein decreased | 30.71 | 9.82 | 45 | 315064 | 1655 | 50288360 |
Blood pH decreased | 30.71 | 9.82 | 55 | 315054 | 2400 | 50287615 |
Anaemia megaloblastic | 30.69 | 9.82 | 21 | 315088 | 295 | 50289720 |
Pain in jaw | 30.60 | 9.82 | 129 | 314980 | 38299 | 50251716 |
Cytokine release syndrome | 30.53 | 9.82 | 8 | 315101 | 8626 | 50281389 |
Anaemia macrocytic | 30.32 | 9.82 | 56 | 315053 | 2503 | 50287512 |
Haemofiltration | 30.15 | 9.82 | 8 | 315101 | 3 | 50290012 |
Bladder cancer | 29.98 | 9.82 | 65 | 315044 | 3267 | 50286748 |
Intestinal malrotation | 29.79 | 9.82 | 22 | 315087 | 351 | 50289664 |
Suspected suicide | 29.76 | 9.82 | 87 | 315022 | 5270 | 50284745 |
Osteoporosis | 29.70 | 9.82 | 161 | 314948 | 44718 | 50245297 |
Pancreatitis chronic | 29.40 | 9.82 | 51 | 315058 | 2169 | 50287846 |
Herpes zoster | 29.40 | 9.82 | 290 | 314819 | 70496 | 50219519 |
Diabetic ketosis | 29.24 | 9.82 | 17 | 315092 | 176 | 50289839 |
Posterior reversible encephalopathy syndrome | 29.03 | 9.82 | 30 | 315079 | 14898 | 50275117 |
Blood pressure systolic increased | 28.94 | 9.82 | 343 | 314766 | 35106 | 50254909 |
Vitamin B12 decreased | 28.94 | 9.82 | 58 | 315051 | 2757 | 50287258 |
Mucosal inflammation | 28.83 | 9.82 | 140 | 314969 | 40002 | 50250013 |
Insulin C-peptide decreased | 28.41 | 9.82 | 9 | 315100 | 14 | 50290001 |
Pregnancy | 28.33 | 9.82 | 92 | 315017 | 29485 | 50260530 |
Coronary artery disease | 28.08 | 9.82 | 296 | 314813 | 29430 | 50260585 |
Hypophagia | 28.05 | 9.82 | 280 | 314829 | 27448 | 50262567 |
Intentional product use issue | 27.96 | 9.82 | 325 | 314784 | 76593 | 50213422 |
Hemiparesis | 27.83 | 9.82 | 217 | 314892 | 19831 | 50270184 |
Pulmonary fibrosis | 27.82 | 9.82 | 70 | 315039 | 24367 | 50265648 |
Blindness transient | 27.81 | 9.82 | 62 | 315047 | 3176 | 50286839 |
Acute coronary syndrome | 27.81 | 9.82 | 124 | 314985 | 9250 | 50280765 |
Lower respiratory tract infection | 27.77 | 9.82 | 421 | 314688 | 94780 | 50195235 |
Headache | 27.33 | 9.82 | 2750 | 312359 | 503785 | 49786230 |
Foreign body aspiration | 27.21 | 9.82 | 15 | 315094 | 139 | 50289876 |
Blood lactic acid | 26.76 | 9.82 | 13 | 315096 | 90 | 50289925 |
Infective pulmonary exacerbation of cystic fibrosis | 26.71 | 9.82 | 8 | 315101 | 7901 | 50282114 |
Oedematous pancreatitis | 26.59 | 9.82 | 21 | 315088 | 372 | 50289643 |
Osmolar gap | 26.52 | 9.82 | 13 | 315096 | 92 | 50289923 |
Renal abscess | 26.48 | 9.82 | 26 | 315083 | 622 | 50289393 |
Urinary tract discomfort | 26.16 | 9.82 | 17 | 315092 | 218 | 50289797 |
Pancreatic mass | 25.97 | 9.82 | 28 | 315081 | 750 | 50289265 |
Sedation complication | 25.97 | 9.82 | 11 | 315098 | 8755 | 50281260 |
Progressive multifocal leukoencephalopathy | 25.91 | 9.82 | 20 | 315089 | 11437 | 50278578 |
Conjoined twins | 25.76 | 9.82 | 18 | 315091 | 262 | 50289753 |
Granuloma skin | 25.76 | 9.82 | 3 | 315106 | 5815 | 50284200 |
Epstein-Barr virus infection | 25.68 | 9.82 | 6 | 315103 | 6991 | 50283024 |
Diabetic hyperosmolar coma | 25.58 | 9.82 | 20 | 315089 | 349 | 50289666 |
Glucose urine present | 25.11 | 9.82 | 26 | 315083 | 664 | 50289351 |
Shock hypoglycaemic | 25.09 | 9.82 | 13 | 315096 | 105 | 50289910 |
Pancreatic injury | 24.96 | 9.82 | 9 | 315100 | 25 | 50289990 |
Aspergillus infection | 24.73 | 9.82 | 6 | 315103 | 6815 | 50283200 |
Glomerular filtration rate abnormal | 24.55 | 9.82 | 23 | 315086 | 518 | 50289497 |
Thrombotic microangiopathy | 24.53 | 9.82 | 12 | 315097 | 8779 | 50281236 |
Pleural effusion | 24.52 | 9.82 | 358 | 314751 | 81096 | 50208919 |
Mechanical ventilation complication | 24.51 | 9.82 | 6 | 315103 | 0 | 50290015 |
Thirst | 24.50 | 9.82 | 131 | 314978 | 10519 | 50279496 |
Dysentery | 24.43 | 9.82 | 27 | 315082 | 744 | 50289271 |
Cholecystitis chronic | 24.37 | 9.82 | 122 | 314987 | 9547 | 50280468 |
Mouth ulceration | 24.26 | 9.82 | 91 | 315018 | 27933 | 50262082 |
Acute myocardial infarction | 24.23 | 9.82 | 284 | 314825 | 28989 | 50261026 |
Skin ulcer | 23.75 | 9.82 | 126 | 314983 | 35192 | 50254823 |
Temperature perception test abnormal | 23.67 | 9.82 | 8 | 315101 | 17 | 50289998 |
Blood pressure systolic decreased | 23.53 | 9.82 | 84 | 315025 | 5655 | 50284360 |
Hepatic function abnormal | 23.45 | 9.82 | 114 | 314995 | 32567 | 50257448 |
Disability | 23.38 | 9.82 | 27 | 315082 | 12748 | 50277267 |
Apolipoprotein A-I decreased | 23.36 | 9.82 | 8 | 315101 | 18 | 50289997 |
Hyperinsulinaemia | 23.36 | 9.82 | 12 | 315097 | 95 | 50289920 |
Malabsorption | 23.35 | 9.82 | 63 | 315046 | 3643 | 50286372 |
Hyperinsulinaemic hypoglycaemia | 23.25 | 9.82 | 10 | 315099 | 50 | 50289965 |
Polymyalgia rheumatica | 23.23 | 9.82 | 51 | 315058 | 2585 | 50287430 |
Anovulatory cycle | 22.91 | 9.82 | 13 | 315096 | 128 | 50289887 |
Gastrointestinal disorder | 22.90 | 9.82 | 432 | 314677 | 94024 | 50195991 |
Blood insulin decreased | 22.87 | 9.82 | 7 | 315102 | 9 | 50290006 |
Basal cell carcinoma | 22.82 | 9.82 | 72 | 315037 | 23284 | 50266731 |
Cleft lip | 22.74 | 9.82 | 12 | 315097 | 101 | 50289914 |
IIIrd nerve paresis | 22.66 | 9.82 | 13 | 315096 | 131 | 50289884 |
Macular degeneration | 22.65 | 9.82 | 34 | 315075 | 14354 | 50275661 |
Blood growth hormone increased | 22.62 | 9.82 | 20 | 315089 | 417 | 50289598 |
Body temperature decreased | 22.50 | 9.82 | 177 | 314932 | 16218 | 50273797 |
Cholestatic liver injury | 22.42 | 9.82 | 43 | 315066 | 1978 | 50288037 |
Hypoglycaemic unconsciousness | 22.39 | 9.82 | 25 | 315084 | 697 | 50289318 |
Gait inability | 22.26 | 9.82 | 339 | 314770 | 36688 | 50253327 |
Hypovolaemia | 22.17 | 9.82 | 117 | 314992 | 9348 | 50280667 |
Ulcer | 22.13 | 9.82 | 59 | 315050 | 20141 | 50269874 |
Congenital absence of bile ducts | 21.99 | 9.82 | 8 | 315101 | 23 | 50289992 |
Macular oedema | 21.91 | 9.82 | 61 | 315048 | 3593 | 50286422 |
Adverse event | 21.84 | 9.82 | 171 | 314938 | 43592 | 50246423 |
Pruritus genital | 21.72 | 9.82 | 23 | 315086 | 603 | 50289412 |
Non-alcoholic steatohepatitis | 21.72 | 9.82 | 35 | 315074 | 1400 | 50288615 |
Blood phosphorus increased | 21.68 | 9.82 | 49 | 315060 | 2533 | 50287482 |
Asthenia | 21.65 | 9.82 | 2286 | 312823 | 316756 | 49973259 |
Base excess negative | 21.47 | 9.82 | 6 | 315103 | 4 | 50290011 |
Unintentional medical device removal | 21.30 | 9.82 | 4 | 315105 | 5431 | 50284584 |
Stevens-Johnson syndrome | 21.29 | 9.82 | 67 | 315042 | 21685 | 50268330 |
Aphasia | 21.23 | 9.82 | 271 | 314838 | 28223 | 50261792 |
Swollen tongue | 21.20 | 9.82 | 272 | 314837 | 28358 | 50261657 |
Hyperhidrosis | 21.14 | 9.82 | 717 | 314392 | 88709 | 50201306 |
Diabetic foot | 21.13 | 9.82 | 33 | 315076 | 1285 | 50288730 |
Bursitis | 21.10 | 9.82 | 69 | 315040 | 22066 | 50267949 |
Carcinoid tumour of the stomach | 21.09 | 9.82 | 13 | 315096 | 151 | 50289864 |
Fungal infection | 21.07 | 9.82 | 282 | 314827 | 29683 | 50260332 |
Overweight | 21.01 | 9.82 | 54 | 315055 | 3032 | 50286983 |
Blood urea increased | 20.96 | 9.82 | 232 | 314877 | 23353 | 50266662 |
Pollakiuria | 20.91 | 9.82 | 234 | 314875 | 23617 | 50266398 |
Necrotising myositis | 20.89 | 9.82 | 18 | 315091 | 362 | 50289653 |
Complication associated with device | 20.86 | 9.82 | 37 | 315072 | 14618 | 50275397 |
Lymphopenia | 20.85 | 9.82 | 41 | 315068 | 15580 | 50274435 |
Jaundice hepatocellular | 20.82 | 9.82 | 8 | 315101 | 28 | 50289987 |
Mitochondrial enzyme deficiency | 20.82 | 9.82 | 8 | 315101 | 28 | 50289987 |
Increased appetite | 20.73 | 9.82 | 105 | 315004 | 8256 | 50281759 |
Bone density decreased | 20.71 | 9.82 | 23 | 315086 | 11052 | 50278963 |
Sedation | 20.70 | 9.82 | 109 | 315000 | 30501 | 50259514 |
Constipation | 20.69 | 9.82 | 945 | 314164 | 184763 | 50105252 |
Pathogen resistance | 20.64 | 9.82 | 5 | 315104 | 5684 | 50284331 |
Postmenopausal haemorrhage | 20.60 | 9.82 | 41 | 315068 | 1939 | 50288076 |
Metabolic syndrome | 20.59 | 9.82 | 33 | 315076 | 1314 | 50288701 |
Urine output decreased | 20.55 | 9.82 | 123 | 314986 | 10298 | 50279717 |
Generalised tonic-clonic seizure | 20.53 | 9.82 | 89 | 315020 | 26221 | 50263794 |
Hepatosplenomegaly neonatal | 20.43 | 9.82 | 5 | 315104 | 0 | 50290015 |
Multiple cardiac defects | 20.43 | 9.82 | 5 | 315104 | 0 | 50290015 |
CD30 expression | 20.40 | 9.82 | 8 | 315101 | 30 | 50289985 |
Diabetic ulcer | 20.38 | 9.82 | 14 | 315095 | 198 | 50289817 |
Bronchopulmonary aspergillosis | 20.24 | 9.82 | 11 | 315098 | 7581 | 50282434 |
Febrile bone marrow aplasia | 20.22 | 9.82 | 7 | 315102 | 6304 | 50283711 |
Ischaemic stroke | 20.17 | 9.82 | 169 | 314940 | 15779 | 50274236 |
Needle issue | 19.92 | 9.82 | 94 | 315015 | 7181 | 50282834 |
Lymphocyte count decreased | 19.92 | 9.82 | 90 | 315019 | 26217 | 50263798 |
Oxygen saturation immeasurable | 19.92 | 9.82 | 6 | 315103 | 7 | 50290008 |
Resuscitation | 19.87 | 9.82 | 28 | 315081 | 993 | 50289022 |
Congenital bladder anomaly | 19.72 | 9.82 | 13 | 315096 | 171 | 50289844 |
Dry eye | 19.69 | 9.82 | 118 | 314991 | 31977 | 50258038 |
Coordination abnormal | 19.56 | 9.82 | 131 | 314978 | 11403 | 50278612 |
Osmolar gap increased | 19.53 | 9.82 | 7 | 315102 | 19 | 50289996 |
Bronchostenosis | 19.49 | 9.82 | 18 | 315091 | 398 | 50289617 |
Cytomegalovirus viraemia | 19.48 | 9.82 | 3 | 315106 | 4706 | 50285309 |
Dizziness | 19.48 | 9.82 | 2452 | 312657 | 343917 | 49946098 |
Blood parathyroid hormone decreased | 19.42 | 9.82 | 10 | 315099 | 7104 | 50282911 |
Urachal abnormality | 19.22 | 9.82 | 13 | 315096 | 179 | 50289836 |
Epileptic encephalopathy | 19.22 | 9.82 | 15 | 315094 | 261 | 50289754 |
Pulseless electrical activity | 19.18 | 9.82 | 89 | 315020 | 6752 | 50283263 |
Hypoparathyroidism | 19.17 | 9.82 | 21 | 315088 | 573 | 50289442 |
Prothrombin consumption time prolonged | 19.09 | 9.82 | 8 | 315101 | 37 | 50289978 |
Systemic infection | 18.81 | 9.82 | 43 | 315066 | 2240 | 50287775 |
Oral herpes | 18.80 | 9.82 | 66 | 315043 | 20659 | 50269356 |
Metastases to retroperitoneum | 18.79 | 9.82 | 12 | 315097 | 149 | 50289866 |
Hyperphagia | 18.75 | 9.82 | 34 | 315075 | 1498 | 50288517 |
Peritonitis | 18.71 | 9.82 | 43 | 315066 | 15443 | 50274572 |
Choreoathetosis | 18.59 | 9.82 | 18 | 315091 | 423 | 50289592 |
Crush syndrome | 18.59 | 9.82 | 11 | 315098 | 118 | 50289897 |
Decreased bronchial secretion | 18.56 | 9.82 | 9 | 315100 | 62 | 50289953 |
Lupus-like syndrome | 18.54 | 9.82 | 19 | 315090 | 9472 | 50280543 |
Lung disorder | 18.40 | 9.82 | 184 | 314925 | 44615 | 50245400 |
Thalamic infarction | 18.38 | 9.82 | 18 | 315091 | 429 | 50289586 |
Congenital aortic valve stenosis | 18.33 | 9.82 | 9 | 315100 | 64 | 50289951 |
Insulin-like growth factor increased | 18.30 | 9.82 | 24 | 315085 | 794 | 50289221 |
Joint stiffness | 18.29 | 9.82 | 112 | 314997 | 30196 | 50259819 |
No adverse event | 18.28 | 9.82 | 128 | 314981 | 33450 | 50256565 |
Hypervolaemia | 18.27 | 9.82 | 89 | 315020 | 25410 | 50264605 |
Herpes simplex | 18.20 | 9.82 | 11 | 315098 | 7151 | 50282864 |
Fibromyalgia | 17.96 | 9.82 | 186 | 314923 | 44792 | 50245223 |
Immune reconstitution inflammatory syndrome | 17.88 | 9.82 | 6 | 315103 | 5510 | 50284505 |
Thyroglobulin increased | 17.83 | 9.82 | 8 | 315101 | 45 | 50289970 |
Base excess decreased | 17.76 | 9.82 | 9 | 315100 | 69 | 50289946 |
Osteonecrosis of jaw | 17.71 | 9.82 | 124 | 314985 | 32402 | 50257613 |
Blood ketone body | 17.69 | 9.82 | 8 | 315101 | 46 | 50289969 |
Blood cholesterol increased | 17.56 | 9.82 | 240 | 314869 | 54975 | 50235040 |
Basilar artery thrombosis | 17.54 | 9.82 | 11 | 315098 | 132 | 50289883 |
Creatinine renal clearance | 17.51 | 9.82 | 5 | 315104 | 4 | 50290011 |
Genital infection fungal | 17.51 | 9.82 | 12 | 315097 | 169 | 50289846 |
Poisoning | 17.51 | 9.82 | 135 | 314974 | 12294 | 50277721 |
Joint range of motion decreased | 17.44 | 9.82 | 58 | 315051 | 18454 | 50271561 |
Accidental underdose | 17.42 | 9.82 | 21 | 315088 | 637 | 50289378 |
Neuropathy, ataxia, retinitis pigmentosa syndrome | 17.41 | 9.82 | 8 | 315101 | 48 | 50289967 |
Nephrogenic systemic fibrosis | 17.33 | 9.82 | 3 | 315106 | 4319 | 50285696 |
Acute myeloid leukaemia | 17.30 | 9.82 | 43 | 315066 | 15031 | 50274984 |
Atrioventricular block complete | 17.21 | 9.82 | 90 | 315019 | 7165 | 50282850 |
Pancreatic enzymes increased | 17.16 | 9.82 | 21 | 315088 | 647 | 50289368 |
Colitis ulcerative | 17.15 | 9.82 | 51 | 315058 | 16803 | 50273212 |
Creatinine renal clearance abnormal | 17.13 | 9.82 | 16 | 315093 | 359 | 50289656 |
Thyroid cancer recurrent | 17.13 | 9.82 | 7 | 315102 | 30 | 50289985 |
Bicuspid aortic valve | 17.08 | 9.82 | 10 | 315099 | 105 | 50289910 |
Clostridium difficile infection | 16.97 | 9.82 | 91 | 315018 | 25348 | 50264667 |
Eyelid bleeding | 16.95 | 9.82 | 7 | 315102 | 31 | 50289984 |
Autoimmune myositis | 16.93 | 9.82 | 9 | 315100 | 77 | 50289938 |
Device related infection | 16.89 | 9.82 | 69 | 315040 | 20666 | 50269349 |
Dyslipidaemia | 16.86 | 9.82 | 78 | 315031 | 5910 | 50284105 |
Body temperature increased | 16.81 | 9.82 | 120 | 314989 | 31221 | 50258794 |
Hypertensive heart disease | 16.80 | 9.82 | 41 | 315068 | 2229 | 50287786 |
Metastases to kidney | 16.76 | 9.82 | 12 | 315097 | 182 | 50289833 |
Musculoskeletal disorder | 16.59 | 9.82 | 54 | 315055 | 17295 | 50272720 |
Renal injury | 16.58 | 9.82 | 101 | 315008 | 8510 | 50281505 |
Pulmonary hypoplasia | 16.48 | 9.82 | 14 | 315095 | 276 | 50289739 |
Tinnitus | 16.44 | 9.82 | 105 | 315004 | 28027 | 50261988 |
Product complaint | 16.41 | 9.82 | 125 | 314984 | 11341 | 50278674 |
Differential white blood cell count abnormal | 16.40 | 9.82 | 21 | 315088 | 678 | 50289337 |
Hyperventilation | 16.38 | 9.82 | 72 | 315037 | 5337 | 50284678 |
Hypoglycaemia neonatal | 16.35 | 9.82 | 24 | 315085 | 884 | 50289131 |
Skinfold measurement | 16.34 | 9.82 | 4 | 315105 | 0 | 50290015 |
Labelled drug-disease interaction issue | 16.34 | 9.82 | 4 | 315105 | 0 | 50290015 |
Pleural mesothelioma | 16.34 | 9.82 | 4 | 315105 | 0 | 50290015 |
Reactive psychosis | 16.34 | 9.82 | 4 | 315105 | 0 | 50290015 |
Blood lactic acid abnormal | 16.34 | 9.82 | 4 | 315105 | 0 | 50290015 |
Myxoedema coma | 16.29 | 9.82 | 16 | 315093 | 383 | 50289632 |
Persistent left superior vena cava | 16.27 | 9.82 | 7 | 315102 | 35 | 50289980 |
Hyperphosphataemia | 16.27 | 9.82 | 36 | 315073 | 1835 | 50288180 |
Wrong patient received product | 16.26 | 9.82 | 34 | 315075 | 1666 | 50288349 |
Disease recurrence | 16.24 | 9.82 | 67 | 315042 | 20014 | 50270001 |
Medullary thyroid cancer | 16.24 | 9.82 | 10 | 315099 | 116 | 50289899 |
Congenital uterine anomaly | 16.24 | 9.82 | 10 | 315099 | 116 | 50289899 |
Adrenal adenoma | 16.23 | 9.82 | 23 | 315086 | 820 | 50289195 |
Anion gap abnormal | 16.15 | 9.82 | 15 | 315094 | 334 | 50289681 |
Device dislocation | 16.14 | 9.82 | 74 | 315035 | 21472 | 50268543 |
Sprue-like enteropathy | 16.03 | 9.82 | 18 | 315091 | 505 | 50289510 |
Grip strength decreased | 16.02 | 9.82 | 32 | 315077 | 12089 | 50277926 |
Renal tubular disorder | 15.93 | 9.82 | 42 | 315067 | 2395 | 50287620 |
Night sweats | 15.92 | 9.82 | 133 | 314976 | 33441 | 50256574 |
Antipsychotic drug level increased | 15.87 | 9.82 | 49 | 315060 | 3060 | 50286955 |
Skin necrosis | 15.86 | 9.82 | 27 | 315082 | 10840 | 50279175 |
Joint effusion | 15.85 | 9.82 | 36 | 315073 | 12985 | 50277030 |
Skin haemorrhage | 15.85 | 9.82 | 85 | 315024 | 6833 | 50283182 |
Flushing | 15.78 | 9.82 | 308 | 314801 | 66707 | 50223308 |
Cutaneous T-cell dyscrasia | 15.72 | 9.82 | 8 | 315101 | 62 | 50289953 |
Glycosuria | 15.64 | 9.82 | 26 | 315083 | 1068 | 50288947 |
Visceral congestion | 15.59 | 9.82 | 14 | 315095 | 298 | 50289717 |
Monoclonal B-cell lymphocytosis | 15.52 | 9.82 | 7 | 315102 | 40 | 50289975 |
Drug eruption | 15.44 | 9.82 | 85 | 315024 | 23521 | 50266494 |
Inappropriate antidiuretic hormone secretion | 15.43 | 9.82 | 137 | 314972 | 13006 | 50277009 |
Premature labour | 15.42 | 9.82 | 30 | 315079 | 11446 | 50278569 |
Blood pressure inadequately controlled | 15.38 | 9.82 | 61 | 315048 | 4319 | 50285696 |
Catheter site erythema | 15.35 | 9.82 | 3 | 315106 | 3959 | 50286056 |
Intestinal perforation | 15.33 | 9.82 | 26 | 315083 | 10453 | 50279562 |
Urine albumin/creatinine ratio increased | 15.32 | 9.82 | 12 | 315097 | 210 | 50289805 |
Incorrect route of product administration | 15.27 | 9.82 | 62 | 315047 | 18604 | 50271411 |
Pyelonephritis acute | 15.26 | 9.82 | 58 | 315051 | 4025 | 50285990 |
Incorrect dose administered | 15.18 | 9.82 | 402 | 314707 | 48012 | 50242003 |
Neuroendocrine tumour | 15.08 | 9.82 | 18 | 315091 | 540 | 50289475 |
Alkalosis hypochloraemic | 15.08 | 9.82 | 10 | 315099 | 133 | 50289882 |
Malignant mediastinal neoplasm | 14.93 | 9.82 | 18 | 315091 | 546 | 50289469 |
Osteonecrosis | 14.77 | 9.82 | 81 | 315028 | 22436 | 50267579 |
Alveolar osteitis | 14.77 | 9.82 | 16 | 315093 | 431 | 50289584 |
Hyponatraemic encephalopathy | 14.76 | 9.82 | 12 | 315097 | 222 | 50289793 |
Premature delivery | 14.75 | 9.82 | 218 | 314891 | 23445 | 50266570 |
Angina pectoris | 14.69 | 9.82 | 237 | 314872 | 25951 | 50264064 |
Muscle necrosis | 14.64 | 9.82 | 17 | 315092 | 495 | 50289520 |
Pancreatic atrophy | 14.46 | 9.82 | 10 | 315099 | 143 | 50289872 |
Blood pressure diastolic decreased | 14.42 | 9.82 | 164 | 314945 | 16617 | 50273398 |
Optic neuritis | 14.38 | 9.82 | 13 | 315096 | 6877 | 50283138 |
Transcription medication error | 14.36 | 9.82 | 11 | 315098 | 186 | 50289829 |
Staphylococcal infection | 14.33 | 9.82 | 147 | 314962 | 35469 | 50254546 |
Foetal hypokinesia | 14.30 | 9.82 | 16 | 315093 | 447 | 50289568 |
Confusional state | 14.29 | 9.82 | 1344 | 313765 | 184584 | 50105431 |
Diabetic ketoacidotic hyperglycaemic coma | 14.23 | 9.82 | 7 | 315102 | 50 | 50289965 |
Diabetic cheiroarthropathy | 14.12 | 9.82 | 4 | 315105 | 3 | 50290012 |
Diabetes mellitus management | 14.12 | 9.82 | 4 | 315105 | 3 | 50290012 |
Medication error | 14.11 | 9.82 | 309 | 314800 | 35795 | 50254220 |
Treatment noncompliance | 14.09 | 9.82 | 265 | 314844 | 29885 | 50260130 |
Status epilepticus | 14.05 | 9.82 | 40 | 315069 | 13366 | 50276649 |
Device difficult to use | 14.03 | 9.82 | 25 | 315084 | 9861 | 50280154 |
Gallbladder oedema | 14.02 | 9.82 | 11 | 315098 | 193 | 50289822 |
Mental disability | 14.00 | 9.82 | 8 | 315101 | 80 | 50289935 |
Retinal artery thrombosis | 13.91 | 9.82 | 8 | 315101 | 81 | 50289934 |
Pelvic fracture | 13.91 | 9.82 | 32 | 315077 | 11488 | 50278527 |
Cortisol increased | 13.89 | 9.82 | 14 | 315095 | 346 | 50289669 |
Hypertensive crisis | 13.87 | 9.82 | 134 | 314975 | 13020 | 50276995 |
Hypertensive angiopathy | 13.83 | 9.82 | 8 | 315101 | 82 | 50289933 |
Blood growth hormone abnormal | 13.79 | 9.82 | 6 | 315103 | 31 | 50289984 |
Erythema | 13.79 | 9.82 | 758 | 314351 | 145656 | 50144359 |
Salivary hypersecretion | 13.78 | 9.82 | 79 | 315030 | 6512 | 50283503 |
Musculoskeletal pain | 13.75 | 9.82 | 343 | 314766 | 71834 | 50218181 |
Blood electrolytes abnormal | 13.74 | 9.82 | 23 | 315086 | 950 | 50289065 |
Diaphragmatic spasm | 13.59 | 9.82 | 4 | 315105 | 4 | 50290011 |
Venous aneurysm | 13.59 | 9.82 | 4 | 315105 | 4 | 50290011 |
Skin turgor decreased | 13.59 | 9.82 | 16 | 315093 | 473 | 50289542 |
PCO2 decreased | 13.59 | 9.82 | 26 | 315083 | 1194 | 50288821 |
Abnormal loss of weight | 13.55 | 9.82 | 65 | 315044 | 4999 | 50285016 |
Obesity | 13.55 | 9.82 | 162 | 314947 | 16613 | 50273402 |
Injection site swelling | 13.49 | 9.82 | 181 | 314928 | 41592 | 50248423 |
Enterochromaffin cell hyperplasia | 13.46 | 9.82 | 7 | 315102 | 57 | 50289958 |
Eructation | 13.38 | 9.82 | 83 | 315026 | 7038 | 50282977 |
Low density lipoprotein increased | 13.37 | 9.82 | 70 | 315039 | 5576 | 50284439 |
Psoriatic arthropathy | 13.36 | 9.82 | 209 | 314900 | 46823 | 50243192 |
Cardiovascular disorder | 13.34 | 9.82 | 111 | 314998 | 10343 | 50279672 |
Transient ischaemic attack | 13.34 | 9.82 | 278 | 314831 | 31932 | 50258083 |
Rash maculo-papular | 13.33 | 9.82 | 104 | 315005 | 26537 | 50263478 |
Hypereosinophilic syndrome | 13.30 | 9.82 | 12 | 315097 | 257 | 50289758 |
Multiple sclerosis | 13.29 | 9.82 | 74 | 315035 | 20419 | 50269596 |
Vision blurred | 13.28 | 9.82 | 608 | 314501 | 78039 | 50211976 |
Blood cholesterol decreased | 13.24 | 9.82 | 20 | 315089 | 756 | 50289259 |
Urosepsis | 13.23 | 9.82 | 151 | 314958 | 15314 | 50274701 |
Brain stem infarction | 13.22 | 9.82 | 20 | 315089 | 757 | 50289258 |
Sensorimotor disorder | 13.13 | 9.82 | 15 | 315094 | 429 | 50289586 |
Drug half-life increased | 13.12 | 9.82 | 5 | 315104 | 17 | 50289998 |
Flatulence | 13.11 | 9.82 | 257 | 314852 | 29201 | 50260814 |
Autoimmune nephritis | 13.10 | 9.82 | 13 | 315096 | 315 | 50289700 |
Anal incontinence | 13.10 | 9.82 | 119 | 314990 | 11371 | 50278644 |
Adrenal neoplasm | 13.00 | 9.82 | 13 | 315096 | 318 | 50289697 |
Unevaluable event | 12.99 | 9.82 | 205 | 314904 | 45861 | 50244154 |
Femur fracture | 12.96 | 9.82 | 160 | 314949 | 37304 | 50252711 |
Respiratory tract infection | 12.94 | 9.82 | 132 | 314977 | 31885 | 50258130 |
Sinus arrest | 12.92 | 9.82 | 31 | 315078 | 1667 | 50288348 |
Prescription drug used without a prescription | 12.90 | 9.82 | 31 | 315078 | 1669 | 50288346 |
Red cell distribution width abnormal | 12.88 | 9.82 | 9 | 315100 | 131 | 50289884 |
Ascites | 12.84 | 9.82 | 152 | 314957 | 35709 | 50254306 |
Atrial fibrillation | 12.81 | 9.82 | 765 | 314344 | 100980 | 50189035 |
Diet failure | 12.79 | 9.82 | 6 | 315103 | 38 | 50289977 |
Tumour compression | 12.79 | 9.82 | 6 | 315103 | 38 | 50289977 |
Lymphadenopathy | 12.78 | 9.82 | 140 | 314969 | 33359 | 50256656 |
Bladder neoplasm | 12.75 | 9.82 | 16 | 315093 | 506 | 50289509 |
Binge eating | 12.75 | 9.82 | 14 | 315095 | 383 | 50289632 |
Bone pain | 12.71 | 9.82 | 212 | 314897 | 47017 | 50242998 |
Peripheral artery haematoma | 12.66 | 9.82 | 6 | 315103 | 39 | 50289976 |
Electrolyte imbalance | 12.66 | 9.82 | 163 | 314946 | 17006 | 50273009 |
Muscular weakness | 12.65 | 9.82 | 718 | 314391 | 94295 | 50195720 |
Hypergastrinaemia | 12.62 | 9.82 | 8 | 315101 | 98 | 50289917 |
Hepatic cirrhosis | 12.60 | 9.82 | 166 | 314943 | 17411 | 50272604 |
Blood iron decreased | 12.59 | 9.82 | 119 | 314990 | 11496 | 50278519 |
Left atrial dilatation | 12.52 | 9.82 | 31 | 315078 | 1701 | 50288314 |
Atelectasis | 12.39 | 9.82 | 65 | 315044 | 18205 | 50271810 |
Anion gap | 12.38 | 9.82 | 24 | 315085 | 1113 | 50288902 |
Rash erythematous | 12.38 | 9.82 | 148 | 314961 | 34704 | 50255311 |
Spinal compression fracture | 12.38 | 9.82 | 39 | 315070 | 12617 | 50277398 |
Blood osmolarity abnormal | 12.34 | 9.82 | 4 | 315105 | 7 | 50290008 |
Cell death | 12.33 | 9.82 | 36 | 315073 | 2179 | 50287836 |
Haemoglobin increased | 12.27 | 9.82 | 45 | 315064 | 3070 | 50286945 |
Diffuse idiopathic skeletal hyperostosis | 12.26 | 9.82 | 3 | 315106 | 0 | 50290015 |
Bladder pain | 12.26 | 9.82 | 30 | 315079 | 1634 | 50288381 |
Nipple swelling | 12.26 | 9.82 | 3 | 315106 | 0 | 50290015 |
Insulin resistant diabetes | 12.26 | 9.82 | 3 | 315106 | 0 | 50290015 |
Non-high-density lipoprotein cholesterol decreased | 12.26 | 9.82 | 3 | 315106 | 0 | 50290015 |
Fluid intake reduced | 12.21 | 9.82 | 45 | 315064 | 3077 | 50286938 |
Tumour lysis syndrome | 12.21 | 9.82 | 17 | 315092 | 7404 | 50282611 |
Device use error | 12.16 | 9.82 | 9 | 315100 | 5257 | 50284758 |
Ear pain | 12.11 | 9.82 | 115 | 314994 | 28168 | 50261847 |
Pneumonia aspiration | 12.05 | 9.82 | 129 | 314980 | 30875 | 50259140 |
Injection site mass | 12.05 | 9.82 | 150 | 314959 | 15530 | 50274485 |
Neurofibrosarcoma | 12.01 | 9.82 | 9 | 315100 | 147 | 50289868 |
Glycosylated haemoglobin | 12.00 | 9.82 | 7 | 315102 | 73 | 50289942 |
Ectopia cordis | 12.00 | 9.82 | 7 | 315102 | 73 | 50289942 |
Vitamin B6 deficiency | 12.00 | 9.82 | 7 | 315102 | 73 | 50289942 |
Gingival oedema | 12.00 | 9.82 | 7 | 315102 | 73 | 50289942 |
Cholangiectasis acquired | 12.00 | 9.82 | 4 | 315105 | 8 | 50290007 |
Foreign body in reproductive tract | 11.96 | 9.82 | 15 | 315094 | 474 | 50289541 |
Blood lactate dehydrogenase increased | 11.96 | 9.82 | 72 | 315037 | 19490 | 50270525 |
Psychogenic tremor | 11.96 | 9.82 | 5 | 315104 | 23 | 50289992 |
Skin disorder | 11.94 | 9.82 | 94 | 315015 | 23936 | 50266079 |
Pneumonia viral | 11.91 | 9.82 | 15 | 315094 | 6819 | 50283196 |
Chorea | 11.90 | 9.82 | 26 | 315083 | 1314 | 50288701 |
Duodenal ulcer haemorrhage | 11.86 | 9.82 | 35 | 315074 | 2131 | 50287884 |
Nodular rash | 11.86 | 9.82 | 10 | 315099 | 195 | 50289820 |
Parkinsonism | 11.86 | 9.82 | 95 | 315014 | 8752 | 50281263 |
Product blister packaging issue | 11.86 | 9.82 | 9 | 315100 | 150 | 50289865 |
Heart sounds | 11.85 | 9.82 | 17 | 315092 | 613 | 50289402 |
Multiple-drug resistance | 11.85 | 9.82 | 3 | 315106 | 3311 | 50286704 |
Demyelination | 11.84 | 9.82 | 12 | 315097 | 6014 | 50284001 |
Retinopathy proliferative | 11.84 | 9.82 | 6 | 315103 | 46 | 50289969 |
Product size issue | 11.83 | 9.82 | 12 | 315097 | 299 | 50289716 |
Pyelonephritis | 11.78 | 9.82 | 144 | 314965 | 14845 | 50275170 |
Hyperparathyroidism secondary | 11.76 | 9.82 | 26 | 315083 | 1324 | 50288691 |
Food craving | 11.74 | 9.82 | 27 | 315082 | 1412 | 50288603 |
Pancreatic neoplasm | 11.69 | 9.82 | 18 | 315091 | 692 | 50289323 |
Cutaneous vasculitis | 11.68 | 9.82 | 56 | 315053 | 4306 | 50285709 |
Intentional self-injury | 11.67 | 9.82 | 90 | 315019 | 23022 | 50266993 |
Retching | 11.65 | 9.82 | 127 | 314982 | 12735 | 50277280 |
Maternal exposure timing unspecified | 11.63 | 9.82 | 4 | 315105 | 3616 | 50286399 |
Urinary tract infection | 11.57 | 9.82 | 1578 | 313531 | 222442 | 50067573 |
Clostridium difficile colitis | 11.54 | 9.82 | 64 | 315045 | 17678 | 50272337 |
Tunnel vision | 11.52 | 9.82 | 18 | 315091 | 701 | 50289314 |
Duodenal ulcer | 11.52 | 9.82 | 77 | 315032 | 6698 | 50283317 |
Large intestine perforation | 11.52 | 9.82 | 18 | 315091 | 7476 | 50282539 |
Electrocardiogram abnormal | 11.50 | 9.82 | 84 | 315025 | 7521 | 50282494 |
Dystonia | 11.49 | 9.82 | 37 | 315072 | 11889 | 50278126 |
Prolonged expiration | 11.49 | 9.82 | 18 | 315091 | 703 | 50289312 |
Diffuse large B-cell lymphoma | 11.45 | 9.82 | 11 | 315098 | 5651 | 50284364 |
Coronary artery occlusion | 11.42 | 9.82 | 83 | 315026 | 7420 | 50282595 |
Respiratory syncytial virus infection | 11.42 | 9.82 | 9 | 315100 | 5093 | 50284922 |
Coeliac disease | 11.42 | 9.82 | 23 | 315086 | 8662 | 50281353 |
Intestinal obstruction | 11.41 | 9.82 | 107 | 315002 | 26276 | 50263739 |
Blood calcium decreased | 11.24 | 9.82 | 79 | 315030 | 20627 | 50269388 |
Chronic sinusitis | 11.23 | 9.82 | 13 | 315096 | 6132 | 50283883 |
Serotonin syndrome | 11.22 | 9.82 | 99 | 315010 | 24614 | 50265401 |
Ankylosing spondylitis | 11.21 | 9.82 | 17 | 315092 | 7148 | 50282867 |
Genital rash | 11.20 | 9.82 | 14 | 315095 | 441 | 50289574 |
Genital swelling | 11.19 | 9.82 | 8 | 315101 | 121 | 50289894 |
Myocardial ischaemia | 11.14 | 9.82 | 116 | 314993 | 11497 | 50278518 |
Bradyphrenia | 11.12 | 9.82 | 71 | 315038 | 6081 | 50283934 |
Erythromelalgia | 11.08 | 9.82 | 8 | 315101 | 123 | 50289892 |
Diabetic foot infection | 11.05 | 9.82 | 9 | 315100 | 167 | 50289848 |
Hypertriglyceridaemia | 10.95 | 9.82 | 65 | 315044 | 5426 | 50284589 |
Neutropenic sepsis | 10.95 | 9.82 | 48 | 315061 | 14099 | 50275916 |
Product administration error | 10.95 | 9.82 | 178 | 314931 | 19521 | 50270494 |
Central nervous system lesion | 10.94 | 9.82 | 27 | 315082 | 9462 | 50280553 |
Metastases to central nervous system | 10.87 | 9.82 | 35 | 315074 | 11247 | 50278768 |
Microcytic anaemia | 10.87 | 9.82 | 43 | 315066 | 3041 | 50286974 |
Lactate pyruvate ratio increased | 10.82 | 9.82 | 7 | 315102 | 89 | 50289926 |
Urine output increased | 10.81 | 9.82 | 23 | 315086 | 1141 | 50288874 |
Bradyarrhythmia | 10.79 | 9.82 | 31 | 315078 | 1859 | 50288156 |
Grandiosity | 10.78 | 9.82 | 11 | 315098 | 276 | 50289739 |
Vascular device infection | 10.77 | 9.82 | 7 | 315102 | 4377 | 50285638 |
Blood chloride decreased | 10.73 | 9.82 | 60 | 315049 | 4901 | 50285114 |
Impaired work ability | 10.70 | 9.82 | 131 | 314978 | 13509 | 50276506 |
Blood insulin increased | 10.66 | 9.82 | 8 | 315101 | 131 | 50289884 |
Urine ketone body | 10.66 | 9.82 | 8 | 315101 | 131 | 50289884 |
Aerophagia | 10.63 | 9.82 | 4 | 315105 | 13 | 50290002 |
Pneumothorax | 10.63 | 9.82 | 48 | 315061 | 13986 | 50276029 |
Biopsy skin abnormal | 10.62 | 9.82 | 7 | 315102 | 92 | 50289923 |
Cerebellar ischaemia | 10.62 | 9.82 | 5 | 315104 | 32 | 50289983 |
Malignant polyp | 10.61 | 9.82 | 9 | 315100 | 177 | 50289838 |
Macrosomia | 10.58 | 9.82 | 6 | 315103 | 59 | 50289956 |
Early satiety | 10.57 | 9.82 | 18 | 315091 | 754 | 50289261 |
Pulmonary haemorrhage | 10.56 | 9.82 | 15 | 315094 | 6477 | 50283538 |
Large intestine polyp | 10.53 | 9.82 | 80 | 315029 | 7252 | 50282763 |
Genital infection female | 10.50 | 9.82 | 7 | 315102 | 94 | 50289921 |
Increased tendency to bruise | 10.50 | 9.82 | 27 | 315082 | 9329 | 50280686 |
Empty sella syndrome | 10.49 | 9.82 | 5 | 315104 | 33 | 50289982 |
Hypogammaglobulinaemia | 10.48 | 9.82 | 12 | 315097 | 5687 | 50284328 |
Deformity | 10.46 | 9.82 | 21 | 315088 | 7919 | 50282096 |
Metabolic encephalopathy | 10.46 | 9.82 | 61 | 315048 | 5060 | 50284955 |
Pleural fibrosis | 10.43 | 9.82 | 4 | 315105 | 3380 | 50286635 |
Synovial cyst | 10.42 | 9.82 | 22 | 315087 | 8144 | 50281871 |
Insulin C-peptide increased | 10.41 | 9.82 | 6 | 315103 | 61 | 50289954 |
Glucose urine | 10.41 | 9.82 | 4 | 315105 | 14 | 50290001 |
Glomerular filtration rate increased | 10.40 | 9.82 | 12 | 315097 | 347 | 50289668 |
Drug reaction with eosinophilia and systemic symptoms | 10.36 | 9.82 | 120 | 314989 | 28304 | 50261711 |
Blindness | 10.34 | 9.82 | 158 | 314951 | 17111 | 50272904 |
Wrong dose | 10.31 | 9.82 | 19 | 315090 | 848 | 50289167 |
Vitreous haemorrhage | 10.30 | 9.82 | 29 | 315080 | 1719 | 50288296 |
Gastrointestinal carcinoma | 10.29 | 9.82 | 26 | 315083 | 1445 | 50288570 |
Hypertensive emergency | 10.28 | 9.82 | 27 | 315082 | 1536 | 50288479 |
Blood pressure abnormal | 10.25 | 9.82 | 123 | 314986 | 12624 | 50277391 |
Retinal vascular disorder | 10.24 | 9.82 | 9 | 315100 | 186 | 50289829 |
CSF volume increased | 10.20 | 9.82 | 3 | 315106 | 3 | 50290012 |
Aerococcus urinae infection | 10.20 | 9.82 | 3 | 315106 | 3 | 50290012 |
Ovarian cyst torsion | 10.20 | 9.82 | 3 | 315106 | 3 | 50290012 |
Castleman's disease | 10.20 | 9.82 | 3 | 315106 | 3 | 50290012 |
Clear cell endometrial carcinoma | 10.20 | 9.82 | 3 | 315106 | 3 | 50290012 |
Accidental exposure to product | 10.19 | 9.82 | 93 | 315016 | 22964 | 50267051 |
Fat tissue increased | 10.19 | 9.82 | 15 | 315094 | 554 | 50289461 |
Encephalitis | 10.17 | 9.82 | 19 | 315090 | 7361 | 50282654 |
Hormone level abnormal | 10.17 | 9.82 | 33 | 315076 | 2116 | 50287899 |
Diabetic complication | 10.14 | 9.82 | 18 | 315091 | 780 | 50289235 |
Pancreatic failure | 10.14 | 9.82 | 19 | 315090 | 859 | 50289156 |
Bundle branch block left | 10.11 | 9.82 | 70 | 315039 | 6160 | 50283855 |
Scleroderma | 10.09 | 9.82 | 9 | 315100 | 4792 | 50285223 |
Hypoplastic left heart syndrome | 10.09 | 9.82 | 9 | 315100 | 190 | 50289825 |
Purpura | 10.08 | 9.82 | 30 | 315079 | 9881 | 50280134 |
Thirst decreased | 10.02 | 9.82 | 10 | 315099 | 244 | 50289771 |
Endoscopy upper gastrointestinal tract | 10.02 | 9.82 | 5 | 315104 | 37 | 50289978 |
Dyskinesia | 10.01 | 9.82 | 118 | 314991 | 27743 | 50262272 |
Oxygen saturation decreased | 10.01 | 9.82 | 364 | 314745 | 72884 | 50217131 |
Insulin-like growth factor decreased | 10.00 | 9.82 | 12 | 315097 | 362 | 50289653 |
Hypocalcaemia | 10.00 | 9.82 | 228 | 314881 | 26588 | 50263427 |
Aplasia pure red cell | 10.00 | 9.82 | 7 | 315102 | 4208 | 50285807 |
Acute hepatic failure | 9.95 | 9.82 | 57 | 315052 | 15620 | 50274395 |
Vulvovaginal mycotic infection | 9.94 | 9.82 | 55 | 315054 | 4474 | 50285541 |
Foetal macrosomia | 9.94 | 9.82 | 6 | 315103 | 67 | 50289948 |
Vulvovaginitis | 9.93 | 9.82 | 11 | 315098 | 304 | 50289711 |
Lichen planus | 9.92 | 9.82 | 31 | 315078 | 1948 | 50288067 |
Exercise tolerance decreased | 9.92 | 9.82 | 58 | 315051 | 4816 | 50285199 |
Tuberculosis | 9.91 | 9.82 | 31 | 315078 | 10052 | 50279963 |
Neck pain | 9.87 | 9.82 | 275 | 314834 | 56792 | 50233223 |
Transfusion | 9.86 | 9.82 | 44 | 315065 | 12861 | 50277154 |
Coma scale abnormal | 9.85 | 9.82 | 57 | 315052 | 4714 | 50285301 |
Glucose tolerance impaired | 9.83 | 9.82 | 60 | 315049 | 5058 | 50284957 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Lactic acidosis | 9490.52 | 10.83 | 4890 | 264495 | 25357 | 29279785 |
Hypoglycaemia | 1866.39 | 10.83 | 2250 | 267135 | 46096 | 29259046 |
Acute kidney injury | 1850.84 | 10.83 | 5949 | 263436 | 259318 | 29045824 |
Diabetic ketoacidosis | 1456.08 | 10.83 | 1192 | 268193 | 14881 | 29290261 |
Metabolic acidosis | 1409.28 | 10.83 | 1726 | 267659 | 35936 | 29269206 |
Blood glucose increased | 1061.00 | 10.83 | 1916 | 267469 | 57068 | 29248074 |
Euglycaemic diabetic ketoacidosis | 716.70 | 10.83 | 388 | 268997 | 2242 | 29302900 |
Glycosylated haemoglobin increased | 688.19 | 10.83 | 618 | 268767 | 8808 | 29296334 |
Diabetes mellitus inadequate control | 672.05 | 10.83 | 683 | 268702 | 11451 | 29293691 |
Hyperkalaemia | 626.42 | 10.83 | 1584 | 267801 | 59808 | 29245334 |
Pancreatitis | 472.41 | 10.83 | 1000 | 268385 | 33514 | 29271628 |
Ketoacidosis | 459.40 | 10.83 | 329 | 269056 | 3310 | 29301832 |
Hyperglycaemia | 389.11 | 10.83 | 922 | 268463 | 33365 | 29271777 |
Pancreatitis acute | 348.16 | 10.83 | 719 | 268666 | 23666 | 29281476 |
Off label use | 345.20 | 10.83 | 1490 | 267895 | 299310 | 29005832 |
Hyperlactacidaemia | 337.78 | 10.83 | 242 | 269143 | 2436 | 29302706 |
Drug abuse | 302.40 | 10.83 | 176 | 269209 | 79707 | 29225435 |
Pemphigoid | 264.82 | 10.83 | 336 | 269049 | 7245 | 29297897 |
Diabetic metabolic decompensation | 260.89 | 10.83 | 162 | 269223 | 1254 | 29303888 |
Shock | 255.25 | 10.83 | 587 | 268798 | 20817 | 29284325 |
Blood lactic acid increased | 239.55 | 10.83 | 279 | 269106 | 5487 | 29299655 |
Febrile neutropenia | 237.52 | 10.83 | 411 | 268974 | 111829 | 29193313 |
Death | 214.00 | 10.83 | 2040 | 267345 | 340044 | 28965098 |
Hypoglycaemic coma | 213.95 | 10.83 | 169 | 269216 | 1994 | 29303148 |
Blood glucose abnormal | 207.91 | 10.83 | 244 | 269141 | 4839 | 29300303 |
Completed suicide | 207.24 | 10.83 | 1470 | 267915 | 88776 | 29216366 |
Neutropenia | 200.34 | 10.83 | 578 | 268807 | 131133 | 29174009 |
Pyrexia | 196.39 | 10.83 | 1677 | 267708 | 285945 | 29019197 |
Pancreatic carcinoma | 187.77 | 10.83 | 276 | 269109 | 6874 | 29298268 |
Drug ineffective | 175.48 | 10.83 | 2296 | 267089 | 360874 | 28944268 |
Pneumonia | 172.83 | 10.83 | 1976 | 267409 | 318196 | 28986946 |
Intentional overdose | 170.07 | 10.83 | 749 | 268636 | 37779 | 29267363 |
Blood glucose decreased | 167.69 | 10.83 | 352 | 269033 | 11717 | 29293425 |
Blood glucose fluctuation | 166.32 | 10.83 | 184 | 269201 | 3413 | 29301729 |
Product use in unapproved indication | 161.95 | 10.83 | 343 | 269042 | 86532 | 29218610 |
Anuria | 136.91 | 10.83 | 282 | 269103 | 9259 | 29295883 |
Acidosis | 135.93 | 10.83 | 284 | 269101 | 9421 | 29295721 |
Cytomegalovirus infection | 133.14 | 10.83 | 25 | 269360 | 23190 | 29281952 |
Bladder cancer | 128.81 | 10.83 | 285 | 269100 | 9842 | 29295300 |
Platelet count decreased | 125.97 | 10.83 | 508 | 268877 | 104164 | 29200978 |
Vitamin B12 deficiency | 125.52 | 10.83 | 152 | 269233 | 3119 | 29302023 |
Ketonuria | 123.99 | 10.83 | 73 | 269312 | 507 | 29304635 |
Thrombocytopenia | 123.04 | 10.83 | 722 | 268663 | 134101 | 29171041 |
Pancytopenia | 112.22 | 10.83 | 385 | 269000 | 82783 | 29222359 |
Diabetic neuropathy | 112.01 | 10.83 | 154 | 269231 | 3599 | 29301543 |
White blood cell count decreased | 108.40 | 10.83 | 392 | 268993 | 82970 | 29222172 |
Leukopenia | 107.03 | 10.83 | 213 | 269172 | 54990 | 29250152 |
Weight decreased | 105.34 | 10.83 | 1945 | 267440 | 148960 | 29156182 |
Drug resistance | 104.42 | 10.83 | 33 | 269352 | 21507 | 29283635 |
Continuous haemodiafiltration | 103.64 | 10.83 | 79 | 269306 | 881 | 29304261 |
Seizure | 102.78 | 10.83 | 467 | 268918 | 92656 | 29212486 |
Vomiting | 99.12 | 10.83 | 2582 | 266803 | 209678 | 29095464 |
Bone marrow failure | 96.18 | 10.83 | 66 | 269319 | 27383 | 29277759 |
Anion gap increased | 94.94 | 10.83 | 93 | 269292 | 1487 | 29303655 |
Renal failure | 94.70 | 10.83 | 1562 | 267823 | 117037 | 29188105 |
Infusion related reaction | 94.27 | 10.83 | 159 | 269226 | 43727 | 29261415 |
Diabetes mellitus | 93.74 | 10.83 | 653 | 268732 | 39178 | 29265964 |
Toxicity to various agents | 90.70 | 10.83 | 2145 | 267240 | 171516 | 29133626 |
Disease progression | 89.07 | 10.83 | 413 | 268972 | 81503 | 29223639 |
Immune-mediated myositis | 88.30 | 10.83 | 90 | 269295 | 1513 | 29303629 |
Type 2 diabetes mellitus | 86.88 | 10.83 | 297 | 269088 | 13284 | 29291858 |
Treatment failure | 85.81 | 10.83 | 127 | 269258 | 36812 | 29268330 |
Drug dependence | 84.01 | 10.83 | 43 | 269342 | 20938 | 29284204 |
Injection site nodule | 83.65 | 10.83 | 84 | 269301 | 1386 | 29303756 |
Haemodialysis | 80.47 | 10.83 | 236 | 269149 | 9718 | 29295424 |
Diarrhoea | 80.13 | 10.83 | 3749 | 265636 | 328949 | 28976193 |
Stomatitis | 78.29 | 10.83 | 136 | 269249 | 36977 | 29268165 |
Hypomagnesaemia | 78.11 | 10.83 | 341 | 269044 | 17127 | 29288015 |
Ketosis | 76.93 | 10.83 | 48 | 269337 | 375 | 29304767 |
Malignant neoplasm progression | 75.29 | 10.83 | 381 | 269004 | 73478 | 29231664 |
Neutrophil count decreased | 74.62 | 10.83 | 180 | 269205 | 43387 | 29261755 |
Pneumocystis jirovecii pneumonia | 72.41 | 10.83 | 31 | 269354 | 16748 | 29288394 |
Toxic epidermal necrolysis | 71.50 | 10.83 | 38 | 269347 | 18115 | 29287027 |
Graft versus host disease | 71.36 | 10.83 | 4 | 269381 | 9624 | 29295518 |
Product residue present | 69.56 | 10.83 | 100 | 269285 | 2439 | 29302703 |
Lipase increased | 68.68 | 10.83 | 199 | 269186 | 8138 | 29297004 |
Drug level increased | 68.08 | 10.83 | 345 | 269040 | 18442 | 29286700 |
Urine ketone body present | 67.33 | 10.83 | 64 | 269321 | 984 | 29304158 |
MELAS syndrome | 65.49 | 10.83 | 20 | 269365 | 11 | 29305131 |
Glomerular filtration rate decreased | 64.87 | 10.83 | 238 | 269147 | 11028 | 29294114 |
Blood lactic acid | 64.79 | 10.83 | 40 | 269345 | 306 | 29304836 |
Polyuria | 63.83 | 10.83 | 179 | 269206 | 7183 | 29297959 |
Dehydration | 62.79 | 10.83 | 1427 | 267958 | 113321 | 29191821 |
Distributive shock | 61.10 | 10.83 | 59 | 269326 | 926 | 29304216 |
Myocardial infarction | 60.46 | 10.83 | 1372 | 268013 | 108924 | 29196218 |
Neuropathy peripheral | 58.68 | 10.83 | 392 | 268993 | 70635 | 29234507 |
Hypothermia | 58.18 | 10.83 | 201 | 269184 | 9038 | 29296104 |
Bronchopulmonary aspergillosis | 57.92 | 10.83 | 20 | 269365 | 12324 | 29292818 |
Suspected suicide | 57.89 | 10.83 | 119 | 269266 | 3901 | 29301241 |
Overdose | 57.75 | 10.83 | 1035 | 268350 | 78784 | 29226358 |
Macroangiopathy | 56.60 | 10.83 | 16 | 269369 | 3 | 29305139 |
Pancreatic carcinoma metastatic | 56.10 | 10.83 | 94 | 269291 | 2627 | 29302515 |
Blood pH decreased | 55.51 | 10.83 | 82 | 269303 | 2051 | 29303091 |
Intentional product use issue | 55.09 | 10.83 | 200 | 269185 | 42298 | 29262844 |
Myocardial ischaemia | 55.06 | 10.83 | 290 | 269095 | 15738 | 29289404 |
Transplant rejection | 54.83 | 10.83 | 9 | 269376 | 9203 | 29295939 |
Diabetic retinopathy | 54.36 | 10.83 | 70 | 269315 | 1532 | 29303610 |
Posterior reversible encephalopathy syndrome | 52.91 | 10.83 | 9 | 269376 | 8967 | 29296175 |
Anxiety | 52.18 | 10.83 | 511 | 268874 | 84854 | 29220288 |
Toe amputation | 52.04 | 10.83 | 80 | 269305 | 2075 | 29303067 |
Exposure via ingestion | 51.69 | 10.83 | 77 | 269308 | 1941 | 29303201 |
Aspergillus infection | 51.66 | 10.83 | 16 | 269369 | 10565 | 29294577 |
Pancreatitis chronic | 51.40 | 10.83 | 77 | 269308 | 1951 | 29303191 |
Hepatic function abnormal | 50.73 | 10.83 | 185 | 269200 | 39074 | 29266068 |
Hypotension | 50.71 | 10.83 | 2209 | 267176 | 192145 | 29112997 |
Suicide attempt | 49.62 | 10.83 | 502 | 268883 | 33608 | 29271534 |
Acetonaemia | 49.51 | 10.83 | 25 | 269360 | 122 | 29305020 |
Alanine aminotransferase increased | 49.32 | 10.83 | 411 | 268974 | 70533 | 29234609 |
Product odour abnormal | 49.31 | 10.83 | 44 | 269341 | 621 | 29304521 |
Aggression | 48.94 | 10.83 | 163 | 269222 | 35378 | 29269764 |
Kidney transplant rejection | 48.74 | 10.83 | 4 | 269381 | 7001 | 29298141 |
Latent autoimmune diabetes in adults | 48.29 | 10.83 | 18 | 269367 | 33 | 29305109 |
Pathogen resistance | 48.15 | 10.83 | 8 | 269377 | 8108 | 29297034 |
Hospitalisation | 48.12 | 10.83 | 235 | 269150 | 45753 | 29259389 |
Balanoposthitis | 47.61 | 10.83 | 52 | 269333 | 950 | 29304192 |
Myelosuppression | 47.56 | 10.83 | 26 | 269359 | 12201 | 29292941 |
Sepsis | 47.56 | 10.83 | 965 | 268420 | 141717 | 29163425 |
Microalbuminuria | 47.17 | 10.83 | 43 | 269342 | 625 | 29304517 |
Progressive multifocal leukoencephalopathy | 46.68 | 10.83 | 11 | 269374 | 8708 | 29296434 |
Diabetic nephropathy | 46.68 | 10.83 | 71 | 269314 | 1824 | 29303318 |
Arthralgia | 46.31 | 10.83 | 945 | 268440 | 138672 | 29166470 |
Mucosal inflammation | 46.23 | 10.83 | 141 | 269244 | 31454 | 29273688 |
Aspartate aminotransferase increased | 46.19 | 10.83 | 336 | 269049 | 59389 | 29245753 |
Infection | 45.01 | 10.83 | 464 | 268921 | 76287 | 29228855 |
Infective pulmonary exacerbation of cystic fibrosis | 44.98 | 10.83 | 3 | 269382 | 6233 | 29298909 |
Drug intolerance | 44.62 | 10.83 | 258 | 269127 | 48121 | 29257021 |
Rheumatoid arthritis | 44.58 | 10.83 | 147 | 269238 | 32005 | 29273137 |
Urine albumin/creatinine ratio abnormal | 44.49 | 10.83 | 12 | 269373 | 0 | 29305142 |
Anion gap | 43.62 | 10.83 | 43 | 269342 | 693 | 29304449 |
Immune reconstitution inflammatory syndrome | 43.48 | 10.83 | 9 | 269376 | 7793 | 29297349 |
Psoriasis | 43.43 | 10.83 | 467 | 268918 | 31760 | 29273382 |
Coronary artery disease | 43.31 | 10.83 | 603 | 268782 | 43587 | 29261555 |
Cytomegalovirus viraemia | 42.91 | 10.83 | 4 | 269381 | 6316 | 29298826 |
Haemophagocytic lymphohistiocytosis | 42.84 | 10.83 | 21 | 269364 | 10483 | 29294659 |
Condition aggravated | 42.83 | 10.83 | 1010 | 268375 | 145285 | 29159857 |
Therapeutic product effect decreased | 42.69 | 10.83 | 132 | 269253 | 29319 | 29275823 |
Glycosylated haemoglobin abnormal | 42.50 | 10.83 | 21 | 269364 | 97 | 29305045 |
Diabetic ketoacidotic hyperglycaemic coma | 42.46 | 10.83 | 23 | 269362 | 133 | 29305009 |
Deep vein thrombosis | 42.44 | 10.83 | 327 | 269058 | 57072 | 29248070 |
Obesity | 42.17 | 10.83 | 190 | 269195 | 9673 | 29295469 |
Rash | 41.34 | 10.83 | 1366 | 268019 | 188453 | 29116689 |
Interstitial lung disease | 41.20 | 10.83 | 332 | 269053 | 57386 | 29247756 |
Pseudomonas infection | 40.89 | 10.83 | 24 | 269361 | 10828 | 29294314 |
Septic shock | 40.56 | 10.83 | 369 | 269016 | 62191 | 29242951 |
Adenocarcinoma pancreas | 40.54 | 10.83 | 53 | 269332 | 1178 | 29303964 |
Hypoxia | 40.38 | 10.83 | 259 | 269126 | 47120 | 29258022 |
Drug hypersensitivity | 40.33 | 10.83 | 413 | 268972 | 67993 | 29237149 |
Diabetic foot infection | 40.25 | 10.83 | 38 | 269347 | 579 | 29304563 |
Therapy non-responder | 39.71 | 10.83 | 146 | 269239 | 30765 | 29274377 |
Product use issue | 39.49 | 10.83 | 290 | 269095 | 51154 | 29253988 |
Thirst | 38.96 | 10.83 | 139 | 269246 | 6352 | 29298790 |
Clostridium difficile infection | 38.95 | 10.83 | 54 | 269331 | 16087 | 29289055 |
Pancreatic neoplasm | 38.84 | 10.83 | 43 | 269342 | 798 | 29304344 |
Post transplant lymphoproliferative disorder | 38.60 | 10.83 | 3 | 269382 | 5490 | 29299652 |
Coma | 38.53 | 10.83 | 538 | 268847 | 38912 | 29266230 |
Synovitis | 38.39 | 10.83 | 26 | 269359 | 10864 | 29294278 |
Epstein-Barr virus infection | 38.30 | 10.83 | 7 | 269378 | 6622 | 29298520 |
Blood ketone body increased | 38.11 | 10.83 | 30 | 269355 | 352 | 29304790 |
Renal tubular necrosis | 38.07 | 10.83 | 242 | 269143 | 14073 | 29291069 |
Genital infection fungal | 37.22 | 10.83 | 22 | 269363 | 154 | 29304988 |
Haemodynamic instability | 37.16 | 10.83 | 159 | 269226 | 7914 | 29297228 |
Osmolar gap increased | 37.08 | 10.83 | 10 | 269375 | 0 | 29305142 |
Blood bicarbonate decreased | 37.01 | 10.83 | 71 | 269314 | 2211 | 29302931 |
Exposure during pregnancy | 36.59 | 10.83 | 16 | 269369 | 8538 | 29296604 |
Drug interaction | 36.35 | 10.83 | 2170 | 267215 | 195215 | 29109927 |
Depression | 36.30 | 10.83 | 551 | 268834 | 84596 | 29220546 |
Drug reaction with eosinophilia and systemic symptoms | 36.10 | 10.83 | 132 | 269253 | 27860 | 29277282 |
Neoplasm progression | 35.89 | 10.83 | 72 | 269313 | 18540 | 29286602 |
Anaemia | 35.50 | 10.83 | 1483 | 267902 | 199468 | 29105674 |
C-reactive protein abnormal | 35.48 | 10.83 | 8 | 269377 | 6528 | 29298614 |
Neurotoxicity | 35.15 | 10.83 | 49 | 269336 | 14564 | 29290578 |
Staphylococcal infection | 35.06 | 10.83 | 142 | 269243 | 29098 | 29276044 |
Obstructive pancreatitis | 35.00 | 10.83 | 30 | 269355 | 400 | 29304742 |
Foetal exposure during pregnancy | 34.88 | 10.83 | 174 | 269211 | 33693 | 29271449 |
Osmolar gap | 34.82 | 10.83 | 13 | 269372 | 24 | 29305118 |
Haemorrhage | 34.63 | 10.83 | 254 | 269131 | 44818 | 29260324 |
Glycosylated haemoglobin decreased | 34.35 | 10.83 | 27 | 269358 | 316 | 29304826 |
Diabetic ketosis | 33.83 | 10.83 | 17 | 269368 | 82 | 29305060 |
Hyperglycaemic hyperosmolar nonketotic syndrome | 33.59 | 10.83 | 45 | 269340 | 1025 | 29304117 |
Polydipsia | 32.78 | 10.83 | 87 | 269298 | 3378 | 29301764 |
Vitamin B12 decreased | 32.65 | 10.83 | 44 | 269341 | 1008 | 29304134 |
Hallucination | 32.45 | 10.83 | 256 | 269129 | 44456 | 29260686 |
Urine ketone body | 32.41 | 10.83 | 14 | 269371 | 44 | 29305098 |
Haemoptysis | 32.02 | 10.83 | 156 | 269229 | 30394 | 29274748 |
Musculoskeletal stiffness | 31.79 | 10.83 | 205 | 269180 | 37253 | 29267889 |
Insomnia | 31.76 | 10.83 | 593 | 268792 | 88168 | 29216974 |
Naevus flammeus | 31.36 | 10.83 | 19 | 269366 | 140 | 29305002 |
Haematotoxicity | 31.18 | 10.83 | 11 | 269374 | 6688 | 29298454 |
Blood cholesterol | 30.87 | 10.83 | 20 | 269365 | 168 | 29304974 |
Glycosuria | 30.72 | 10.83 | 45 | 269340 | 1117 | 29304025 |
Lumbosacral radiculoplexus neuropathy | 30.59 | 10.83 | 12 | 269373 | 27 | 29305115 |
Blood ketone body | 30.40 | 10.83 | 15 | 269370 | 69 | 29305073 |
Abdominal pain | 30.20 | 10.83 | 1515 | 267870 | 133842 | 29171300 |
Pancreatic neuroendocrine tumour | 30.09 | 10.83 | 21 | 269364 | 202 | 29304940 |
Plasma cell myeloma | 30.05 | 10.83 | 206 | 269179 | 36909 | 29268233 |
Diabetic foot | 30.04 | 10.83 | 64 | 269321 | 2152 | 29302990 |
Hepatic steatosis | 30.00 | 10.83 | 236 | 269149 | 14710 | 29290432 |
Osteonecrosis | 29.93 | 10.83 | 48 | 269337 | 13471 | 29291671 |
Cardiovascular disorder | 29.55 | 10.83 | 160 | 269225 | 8775 | 29296367 |
Vitamin B1 deficiency | 29.18 | 10.83 | 22 | 269363 | 241 | 29304901 |
Aplastic anaemia | 29.17 | 10.83 | 16 | 269369 | 7494 | 29297648 |
Chills | 29.16 | 10.83 | 465 | 268920 | 70835 | 29234307 |
Tongue oedema | 29.07 | 10.83 | 69 | 269316 | 2497 | 29302645 |
Haemoglobin decreased | 29.03 | 10.83 | 758 | 268627 | 107617 | 29197525 |
Acute myocardial infarction | 28.87 | 10.83 | 610 | 268775 | 47828 | 29257314 |
Sinusitis | 28.64 | 10.83 | 189 | 269196 | 34161 | 29270981 |
No adverse event | 28.52 | 10.83 | 74 | 269311 | 17404 | 29287738 |
Syncope | 28.33 | 10.83 | 955 | 268430 | 80416 | 29224726 |
Cytopenia | 28.03 | 10.83 | 29 | 269356 | 9830 | 29295312 |
Antipsychotic drug level decreased | 27.98 | 10.83 | 37 | 269348 | 832 | 29304310 |
Cholelithiasis | 27.72 | 10.83 | 276 | 269109 | 18396 | 29286746 |
Bladder transitional cell carcinoma | 27.69 | 10.83 | 66 | 269319 | 2395 | 29302747 |
Glucose urine present | 27.65 | 10.83 | 39 | 269346 | 934 | 29304208 |
Dystonia | 27.35 | 10.83 | 29 | 269356 | 9720 | 29295422 |
Acute coronary syndrome | 27.20 | 10.83 | 199 | 269186 | 12126 | 29293016 |
5-hydroxyindolacetic acid in urine increased | 27.06 | 10.83 | 20 | 269365 | 212 | 29304930 |
Myelodysplastic syndrome | 27.05 | 10.83 | 78 | 269307 | 17716 | 29287426 |
Cytokine release syndrome | 26.82 | 10.83 | 49 | 269336 | 13070 | 29292072 |
Blood mercury abnormal | 26.78 | 10.83 | 19 | 269366 | 188 | 29304954 |
Joint swelling | 26.69 | 10.83 | 306 | 269079 | 49324 | 29255818 |
Disseminated intravascular coagulation | 26.57 | 10.83 | 93 | 269292 | 19887 | 29285255 |
Diabetic eye disease | 26.41 | 10.83 | 12 | 269373 | 44 | 29305098 |
Anaemia megaloblastic | 26.32 | 10.83 | 18 | 269367 | 167 | 29304975 |
Osteonecrosis of jaw | 26.11 | 10.83 | 71 | 269314 | 16439 | 29288703 |
Colitis | 26.02 | 10.83 | 172 | 269213 | 31076 | 29274066 |
Alveolar capillary dysplasia | 25.95 | 10.83 | 7 | 269378 | 0 | 29305142 |
Diabetic macroangiopathy | 25.82 | 10.83 | 8 | 269377 | 5 | 29305137 |
Acquired phimosis | 25.66 | 10.83 | 13 | 269372 | 64 | 29305078 |
Starvation ketoacidosis | 25.60 | 10.83 | 11 | 269374 | 34 | 29305108 |
Clostridium difficile colitis | 25.57 | 10.83 | 51 | 269334 | 13161 | 29291981 |
Pulmonary haemorrhage | 25.54 | 10.83 | 28 | 269357 | 9242 | 29295900 |
Therapeutic response decreased | 25.42 | 10.83 | 127 | 269258 | 24584 | 29280558 |
Anaemia vitamin B12 deficiency | 25.31 | 10.83 | 21 | 269364 | 267 | 29304875 |
Pneumothorax | 25.15 | 10.83 | 68 | 269317 | 15774 | 29289368 |
Multiple-drug resistance | 25.11 | 10.83 | 3 | 269382 | 3897 | 29301245 |
Epistaxis | 25.07 | 10.83 | 326 | 269059 | 51378 | 29253764 |
Peritonitis | 24.78 | 10.83 | 62 | 269323 | 14762 | 29290380 |
Nausea | 24.61 | 10.83 | 3001 | 266384 | 286254 | 29018888 |
Therapeutic product effect incomplete | 24.54 | 10.83 | 234 | 269151 | 39071 | 29266071 |
Bradyarrhythmia | 24.27 | 10.83 | 55 | 269330 | 1930 | 29303212 |
Pancreatic pseudocyst | 24.13 | 10.83 | 33 | 269352 | 767 | 29304375 |
Lymphocyte count decreased | 24.11 | 10.83 | 92 | 269293 | 19179 | 29285963 |
Coma scale abnormal | 24.08 | 10.83 | 78 | 269307 | 3391 | 29301751 |
Cardiac failure | 24.02 | 10.83 | 916 | 268469 | 78371 | 29226771 |
Hyperoxaluria | 23.96 | 10.83 | 15 | 269370 | 118 | 29305024 |
Stevens-Johnson syndrome | 23.86 | 10.83 | 74 | 269311 | 16423 | 29288719 |
Arthropathy | 23.80 | 10.83 | 108 | 269277 | 21446 | 29283696 |
Rectal haemorrhage | 23.61 | 10.83 | 201 | 269184 | 34348 | 29270794 |
Clear cell renal cell carcinoma | 23.56 | 10.83 | 37 | 269348 | 978 | 29304164 |
Neuropathic arthropathy | 23.52 | 10.83 | 16 | 269369 | 147 | 29304995 |
Suicidal ideation | 23.27 | 10.83 | 203 | 269182 | 34513 | 29270629 |
Burkholderia pseudomallei infection | 23.25 | 10.83 | 10 | 269375 | 31 | 29305111 |
Pollakiuria | 23.19 | 10.83 | 246 | 269139 | 16670 | 29288472 |
Osteoporosis | 23.13 | 10.83 | 39 | 269346 | 10730 | 29294412 |
Pleural effusion | 23.13 | 10.83 | 489 | 268896 | 71419 | 29233723 |
Cardiogenic shock | 23.09 | 10.83 | 272 | 269113 | 18918 | 29286224 |
Expired product administered | 23.06 | 10.83 | 67 | 269318 | 2744 | 29302398 |
Unevaluable event | 23.03 | 10.83 | 168 | 269217 | 29683 | 29275459 |
Needle issue | 22.93 | 10.83 | 94 | 269291 | 4589 | 29300553 |
Substance abuse | 22.88 | 10.83 | 17 | 269368 | 6770 | 29298372 |
Dysphagia | 22.86 | 10.83 | 357 | 269028 | 54569 | 29250573 |
Low density lipoprotein abnormal | 22.81 | 10.83 | 19 | 269366 | 243 | 29304899 |
Cornea verticillata | 22.79 | 10.83 | 10 | 269375 | 33 | 29305109 |
Neuropathy vitamin B12 deficiency | 22.72 | 10.83 | 9 | 269376 | 21 | 29305121 |
Abdominal discomfort | 22.61 | 10.83 | 584 | 268801 | 47319 | 29257823 |
Tumour lysis syndrome | 22.49 | 10.83 | 59 | 269326 | 13825 | 29291317 |
Ascites | 22.44 | 10.83 | 219 | 269166 | 36400 | 29268742 |
Schizophrenia | 22.01 | 10.83 | 118 | 269267 | 6447 | 29298695 |
Renal impairment | 21.94 | 10.83 | 928 | 268457 | 80405 | 29224737 |
Immunosuppressant drug level increased | 21.88 | 10.83 | 8 | 269377 | 4757 | 29300385 |
Psychotic disorder | 21.87 | 10.83 | 103 | 269282 | 20251 | 29284891 |
Product monitoring error | 21.65 | 10.83 | 63 | 269322 | 2582 | 29302560 |
Cerebrovascular accident | 21.53 | 10.83 | 881 | 268504 | 76030 | 29229112 |
Flushing | 21.50 | 10.83 | 165 | 269220 | 28827 | 29276315 |
Type V hyperlipidaemia | 21.40 | 10.83 | 29 | 269356 | 668 | 29304474 |
Dizziness | 21.28 | 10.83 | 2005 | 267380 | 187679 | 29117463 |
Ileus | 21.26 | 10.83 | 64 | 269321 | 14338 | 29290804 |
Acute myeloid leukaemia | 21.20 | 10.83 | 78 | 269307 | 16435 | 29288707 |
Actinic elastosis | 21.16 | 10.83 | 10 | 269375 | 41 | 29305101 |
Genital candidiasis | 21.11 | 10.83 | 11 | 269374 | 58 | 29305084 |
Staphylococcal bacteraemia | 21.07 | 10.83 | 20 | 269365 | 7059 | 29298083 |
Thrombotic microangiopathy | 20.99 | 10.83 | 29 | 269356 | 8652 | 29296490 |
Tongue disorder | 20.92 | 10.83 | 8 | 269377 | 4628 | 29300514 |
Herpes zoster | 20.91 | 10.83 | 174 | 269211 | 29878 | 29275264 |
Albumin urine present | 20.65 | 10.83 | 21 | 269364 | 352 | 29304790 |
Enterococcal infection | 20.62 | 10.83 | 27 | 269358 | 8241 | 29296901 |
Vitreous haemorrhage | 20.54 | 10.83 | 52 | 269333 | 1961 | 29303181 |
Drug withdrawal syndrome | 20.52 | 10.83 | 89 | 269296 | 17895 | 29287247 |
Neoplasm malignant | 20.41 | 10.83 | 82 | 269303 | 16843 | 29288299 |
Malaise | 20.36 | 10.83 | 1703 | 267682 | 157899 | 29147243 |
Large for dates baby | 20.13 | 10.83 | 32 | 269353 | 855 | 29304287 |
Lymphopenia | 20.07 | 10.83 | 60 | 269325 | 13473 | 29291669 |
Food aversion | 20.01 | 10.83 | 20 | 269365 | 328 | 29304814 |
Basilar artery thrombosis | 19.99 | 10.83 | 15 | 269370 | 163 | 29304979 |
Productive cough | 19.98 | 10.83 | 185 | 269200 | 31074 | 29274068 |
Haematuria | 19.93 | 10.83 | 535 | 268850 | 43604 | 29261538 |
Medication error | 19.80 | 10.83 | 287 | 269098 | 20924 | 29284218 |
Status epilepticus | 19.76 | 10.83 | 43 | 269342 | 10751 | 29294391 |
Angina pectoris | 19.71 | 10.83 | 360 | 269025 | 27490 | 29277652 |
Balanitis candida | 19.70 | 10.83 | 13 | 269372 | 113 | 29305029 |
Hepatojugular reflux | 19.64 | 10.83 | 23 | 269362 | 455 | 29304687 |
Renal oncocytoma | 19.60 | 10.83 | 9 | 269376 | 34 | 29305108 |
Body temperature decreased | 19.57 | 10.83 | 165 | 269220 | 10499 | 29294643 |
Intestinal perforation | 19.56 | 10.83 | 27 | 269358 | 8059 | 29297083 |
Aplasia pure red cell | 19.50 | 10.83 | 13 | 269372 | 5478 | 29299664 |
Tenosynovitis | 19.42 | 10.83 | 5 | 269380 | 3728 | 29301414 |
Abnormal behaviour | 19.40 | 10.83 | 127 | 269258 | 23000 | 29282142 |
Epilepsy | 19.38 | 10.83 | 94 | 269291 | 18338 | 29286804 |
Device related infection | 19.33 | 10.83 | 75 | 269310 | 15561 | 29289581 |
Product commingling | 19.29 | 10.83 | 8 | 269377 | 22 | 29305120 |
Pneumonia aspiration | 19.17 | 10.83 | 228 | 269157 | 36509 | 29268633 |
Respiratory arrest | 19.16 | 10.83 | 147 | 269238 | 25686 | 29279456 |
Nipple inflammation | 19.15 | 10.83 | 10 | 269375 | 53 | 29305089 |
Drug level above therapeutic | 19.12 | 10.83 | 70 | 269315 | 3240 | 29301902 |
Bacteraemia | 19.11 | 10.83 | 80 | 269305 | 16243 | 29288899 |
Cytomegalovirus test positive | 18.97 | 10.83 | 4 | 269381 | 3419 | 29301723 |
Leukocytosis | 18.92 | 10.83 | 284 | 269101 | 20858 | 29284284 |
Retroperitoneal fibrosis | 18.87 | 10.83 | 18 | 269367 | 278 | 29304864 |
Tremor | 18.72 | 10.83 | 518 | 268867 | 73020 | 29232122 |
Appendicitis | 18.66 | 10.83 | 32 | 269353 | 8747 | 29296395 |
Gangrene | 18.59 | 10.83 | 82 | 269303 | 4136 | 29301006 |
Abdominal pain upper | 18.55 | 10.83 | 705 | 268680 | 60288 | 29244854 |
Birt-Hogg-Dube syndrome | 18.54 | 10.83 | 5 | 269380 | 0 | 29305142 |
Headache | 18.45 | 10.83 | 1350 | 268035 | 172657 | 29132485 |
pH body fluid abnormal | 18.39 | 10.83 | 7 | 269378 | 14 | 29305128 |
Blood pressure fluctuation | 18.38 | 10.83 | 106 | 269279 | 19788 | 29285354 |
Urine output increased | 18.32 | 10.83 | 34 | 269351 | 1032 | 29304110 |
Drug level below therapeutic | 18.25 | 10.83 | 8 | 269377 | 4263 | 29300879 |
Respiratory failure | 18.14 | 10.83 | 712 | 268673 | 96419 | 29208723 |
Palmar-plantar erythrodysaesthesia syndrome | 18.12 | 10.83 | 71 | 269314 | 14688 | 29290454 |
Conjunctivitis | 18.08 | 10.83 | 28 | 269357 | 7970 | 29297172 |
Plasmapheresis | 18.07 | 10.83 | 18 | 269367 | 294 | 29304848 |
Oxygen saturation decreased | 18.05 | 10.83 | 294 | 269091 | 44643 | 29260499 |
Bronchitis | 18.04 | 10.83 | 232 | 269153 | 36636 | 29268506 |
Gastroenteritis | 18.01 | 10.83 | 185 | 269200 | 12431 | 29292711 |
Glomerular filtration rate increased | 17.99 | 10.83 | 15 | 269370 | 192 | 29304950 |
Nasopharyngitis | 17.96 | 10.83 | 410 | 268975 | 59255 | 29245887 |
Pneumonitis | 17.91 | 10.83 | 166 | 269219 | 27878 | 29277264 |
Pulmonary alveolar haemorrhage | 17.88 | 10.83 | 19 | 269366 | 6361 | 29298781 |
Cystitis haemorrhagic | 17.83 | 10.83 | 11 | 269374 | 4831 | 29300311 |
Erythromelalgia | 17.81 | 10.83 | 9 | 269376 | 44 | 29305098 |
Pain in extremity | 17.80 | 10.83 | 823 | 268562 | 109610 | 29195532 |
Blood triglycerides increased | 17.76 | 10.83 | 187 | 269198 | 12647 | 29292495 |
Anaphylactic reaction | 17.70 | 10.83 | 163 | 269222 | 27410 | 29277732 |
Premature baby | 17.66 | 10.83 | 89 | 269296 | 17191 | 29287951 |
Stenosis | 17.64 | 10.83 | 33 | 269352 | 1008 | 29304134 |
Brain natriuretic peptide abnormal | 17.59 | 10.83 | 18 | 269367 | 304 | 29304838 |
Cytomegalovirus chorioretinitis | 17.50 | 10.83 | 4 | 269381 | 3234 | 29301908 |
Hepatic enzyme decreased | 17.50 | 10.83 | 9 | 269376 | 46 | 29305096 |
Restlessness | 17.39 | 10.83 | 124 | 269261 | 22021 | 29283121 |
Ischaemic cardiomyopathy | 17.34 | 10.83 | 99 | 269286 | 5539 | 29299603 |
Malnutrition | 17.34 | 10.83 | 47 | 269338 | 10894 | 29294248 |
Diabetic foetopathy | 17.32 | 10.83 | 15 | 269370 | 203 | 29304939 |
Hypoalbuminaemia | 17.30 | 10.83 | 43 | 269342 | 10262 | 29294880 |
Liver palpable | 17.29 | 10.83 | 17 | 269368 | 273 | 29304869 |
Pain | 17.23 | 10.83 | 1336 | 268049 | 170096 | 29135046 |
Mydriasis | 17.19 | 10.83 | 18 | 269367 | 6067 | 29299075 |
Cardiotoxicity | 17.16 | 10.83 | 11 | 269374 | 4733 | 29300409 |
Migraine | 17.11 | 10.83 | 57 | 269328 | 12373 | 29292769 |
Amylase increased | 17.09 | 10.83 | 94 | 269291 | 5186 | 29299956 |
Left ventricular dysfunction | 17.01 | 10.83 | 139 | 269246 | 8763 | 29296379 |
Upper respiratory tract infection | 16.99 | 10.83 | 163 | 269222 | 27186 | 29277956 |
Hypovolaemic shock | 16.99 | 10.83 | 104 | 269281 | 5968 | 29299174 |
Blood pressure systolic increased | 16.96 | 10.83 | 231 | 269154 | 16614 | 29288528 |
Autoimmune pancreatitis | 16.95 | 10.83 | 17 | 269368 | 280 | 29304862 |
Serotonin syndrome | 16.89 | 10.83 | 92 | 269293 | 17420 | 29287722 |
Atrial enlargement | 16.87 | 10.83 | 18 | 269367 | 320 | 29304822 |
Akathisia | 16.83 | 10.83 | 22 | 269363 | 6720 | 29298422 |
Haematocrit decreased | 16.77 | 10.83 | 176 | 269209 | 28846 | 29276296 |
Pericardial disease | 16.73 | 10.83 | 19 | 269366 | 363 | 29304779 |
Wheezing | 16.70 | 10.83 | 208 | 269177 | 33032 | 29272110 |
Mucosal dryness | 16.67 | 10.83 | 32 | 269353 | 997 | 29304145 |
Liver disorder | 16.56 | 10.83 | 167 | 269218 | 27582 | 29277560 |
Echocardiogram abnormal | 16.52 | 10.83 | 29 | 269356 | 842 | 29304300 |
Hepatic vein dilatation | 16.51 | 10.83 | 15 | 269370 | 217 | 29304925 |
Klebsiella infection | 16.36 | 10.83 | 26 | 269359 | 7323 | 29297819 |
Product substitution issue | 16.35 | 10.83 | 141 | 269244 | 9031 | 29296111 |
Hyperventilation | 16.30 | 10.83 | 53 | 269332 | 2309 | 29302833 |
Therapy partial responder | 16.30 | 10.83 | 14 | 269371 | 5185 | 29299957 |
Angioedema | 16.22 | 10.83 | 393 | 268992 | 31522 | 29273620 |
Leukoencephalopathy | 16.19 | 10.83 | 7 | 269378 | 3760 | 29301382 |
Hyperlipasaemia | 16.09 | 10.83 | 21 | 269364 | 466 | 29304676 |
Metabolic syndrome | 16.03 | 10.83 | 39 | 269346 | 1434 | 29303708 |
Prerenal failure | 16.02 | 10.83 | 44 | 269341 | 1744 | 29303398 |
Intercapillary glomerulosclerosis | 16.01 | 10.83 | 8 | 269377 | 38 | 29305104 |
Enthesopathy | 16.01 | 10.83 | 7 | 269378 | 3736 | 29301406 |
Herbal interaction | 15.72 | 10.83 | 17 | 269368 | 307 | 29304835 |
Pancreatitis haemorrhagic | 15.72 | 10.83 | 17 | 269368 | 307 | 29304835 |
Anion gap abnormal | 15.66 | 10.83 | 12 | 269373 | 135 | 29305007 |
Scrotal cyst | 15.64 | 10.83 | 5 | 269380 | 4 | 29305138 |
Injection site mass | 15.62 | 10.83 | 94 | 269291 | 5361 | 29299781 |
Encephalitis toxic | 15.60 | 10.83 | 16 | 269369 | 271 | 29304871 |
Pancreaticoduodenectomy | 15.58 | 10.83 | 9 | 269376 | 60 | 29305082 |
Hypoglycaemic encephalopathy | 15.55 | 10.83 | 16 | 269369 | 272 | 29304870 |
Pulmonary toxicity | 15.53 | 10.83 | 13 | 269372 | 4877 | 29300265 |
Brain oedema | 15.51 | 10.83 | 58 | 269327 | 12162 | 29292980 |
Fixed eruption | 15.48 | 10.83 | 34 | 269351 | 1168 | 29303974 |
Sopor | 15.45 | 10.83 | 160 | 269225 | 10774 | 29294368 |
Febrile bone marrow aplasia | 15.44 | 10.83 | 27 | 269358 | 7324 | 29297818 |
Product appearance confusion | 15.34 | 10.83 | 7 | 269378 | 26 | 29305116 |
Acute lung injury | 15.27 | 10.83 | 36 | 269349 | 1297 | 29303845 |
Hypoglycaemic unconsciousness | 15.25 | 10.83 | 26 | 269359 | 737 | 29304405 |
Leukaemoid reaction | 15.24 | 10.83 | 10 | 269375 | 86 | 29305056 |
Insulin C-peptide decreased | 15.23 | 10.83 | 8 | 269377 | 43 | 29305099 |
Renal artery thrombosis | 15.23 | 10.83 | 16 | 269369 | 279 | 29304863 |
Blood cholesterol abnormal | 15.23 | 10.83 | 38 | 269347 | 1420 | 29303722 |
Drug ineffective for unapproved indication | 15.23 | 10.83 | 72 | 269313 | 14142 | 29291000 |
Tendonitis | 15.17 | 10.83 | 31 | 269354 | 7930 | 29297212 |
Disease recurrence | 15.13 | 10.83 | 84 | 269301 | 15830 | 29289312 |
Pulmonary valve disease | 15.10 | 10.83 | 16 | 269369 | 282 | 29304860 |
Lymphoma | 14.99 | 10.83 | 43 | 269342 | 9785 | 29295357 |
Escherichia infection | 14.99 | 10.83 | 24 | 269361 | 6740 | 29298402 |
Kussmaul respiration | 14.96 | 10.83 | 10 | 269375 | 89 | 29305053 |
Fibrillary glomerulonephritis | 14.94 | 10.83 | 8 | 269377 | 45 | 29305097 |
Skinfold measurement | 14.83 | 10.83 | 4 | 269381 | 0 | 29305142 |
Atrioventricular node dysfunction | 14.83 | 10.83 | 4 | 269381 | 0 | 29305142 |
Blood insulin decreased | 14.83 | 10.83 | 4 | 269381 | 0 | 29305142 |
Atrioventricular block first degree | 14.81 | 10.83 | 91 | 269294 | 5228 | 29299914 |
Central obesity | 14.78 | 10.83 | 20 | 269365 | 460 | 29304682 |
Product complaint | 14.76 | 10.83 | 92 | 269293 | 5313 | 29299829 |
Bradycardia | 14.70 | 10.83 | 735 | 268650 | 64894 | 29240248 |
Hypersensitivity | 14.69 | 10.83 | 368 | 269017 | 52535 | 29252607 |
Dermatitis acneiform | 14.67 | 10.83 | 17 | 269368 | 5474 | 29299668 |
Rhabdomyolysis | 14.67 | 10.83 | 686 | 268699 | 60122 | 29245020 |
Hyperammonaemia | 14.63 | 10.83 | 18 | 269367 | 5645 | 29299497 |
Spondylolysis | 14.53 | 10.83 | 8 | 269377 | 48 | 29305094 |
Therapeutic drug monitoring analysis not performed | 14.46 | 10.83 | 20 | 269365 | 470 | 29304672 |
Pulmonary tuberculosis | 14.30 | 10.83 | 11 | 269374 | 4304 | 29300838 |
Pulmonary embolism | 14.29 | 10.83 | 561 | 268824 | 75973 | 29229169 |
Oedematous pancreatitis | 14.27 | 10.83 | 19 | 269366 | 430 | 29304712 |
Coma acidotic | 14.23 | 10.83 | 5 | 269380 | 7 | 29305135 |
Atrioventricular block complete | 14.20 | 10.83 | 123 | 269262 | 7888 | 29297254 |
Irritability | 14.20 | 10.83 | 131 | 269254 | 22021 | 29283121 |
Peritonitis bacterial | 14.15 | 10.83 | 19 | 269366 | 5737 | 29299405 |
Transaminases increased | 14.10 | 10.83 | 135 | 269250 | 22527 | 29282615 |
Hypogammaglobulinaemia | 14.01 | 10.83 | 20 | 269365 | 5887 | 29299255 |
High density lipoprotein decreased | 13.96 | 10.83 | 59 | 269326 | 2920 | 29302222 |
Gingival hypertrophy | 13.96 | 10.83 | 40 | 269345 | 1625 | 29303517 |
Product solubility abnormal | 13.95 | 10.83 | 19 | 269366 | 440 | 29304702 |
Respiratory syncytial virus infection | 13.91 | 10.83 | 8 | 269377 | 3651 | 29301491 |
Lung disorder | 13.79 | 10.83 | 194 | 269191 | 30168 | 29274974 |
Chronic pigmented purpura | 13.77 | 10.83 | 10 | 269375 | 103 | 29305039 |
Pernicious anaemia | 13.76 | 10.83 | 9 | 269376 | 77 | 29305065 |
Anhedonia | 13.75 | 10.83 | 28 | 269357 | 7172 | 29297970 |
Thrombosis | 13.75 | 10.83 | 293 | 269092 | 42752 | 29262390 |
C-reactive protein increased | 13.65 | 10.83 | 303 | 269082 | 43960 | 29261182 |
Bacterial infection | 13.63 | 10.83 | 66 | 269319 | 12882 | 29292260 |
Weight increased | 13.52 | 10.83 | 840 | 268545 | 75827 | 29229315 |
Torsade de pointes | 13.51 | 10.83 | 25 | 269360 | 6636 | 29298506 |
Orbital oedema | 13.51 | 10.83 | 11 | 269374 | 136 | 29305006 |
Inflammation | 13.47 | 10.83 | 137 | 269248 | 22591 | 29282551 |
Hypoparathyroidism | 13.47 | 10.83 | 19 | 269366 | 455 | 29304687 |
Nipple disorder | 13.47 | 10.83 | 12 | 269373 | 169 | 29304973 |
Dyslipidaemia | 13.45 | 10.83 | 98 | 269287 | 5963 | 29299179 |
Pneumatosis intestinalis | 13.44 | 10.83 | 6 | 269379 | 3163 | 29301979 |
Vitamin B1 decreased | 13.43 | 10.83 | 14 | 269371 | 242 | 29304900 |
Intentional self-injury | 13.42 | 10.83 | 63 | 269322 | 12398 | 29292744 |
Graft versus host disease in skin | 13.41 | 10.83 | 7 | 269378 | 3372 | 29301770 |
Sedation | 13.40 | 10.83 | 98 | 269287 | 17307 | 29287835 |
Emotional distress | 13.40 | 10.83 | 73 | 269312 | 13822 | 29291320 |
Staphylococcal sepsis | 13.35 | 10.83 | 39 | 269346 | 8823 | 29296319 |
Myoclonus | 13.35 | 10.83 | 69 | 269316 | 13240 | 29291902 |
Abnormal loss of weight | 13.35 | 10.83 | 67 | 269318 | 3567 | 29301575 |
Subdural hygroma | 13.32 | 10.83 | 15 | 269370 | 284 | 29304858 |
Hypoaesthesia eye | 13.20 | 10.83 | 6 | 269379 | 22 | 29305120 |
Oscillopsia | 13.13 | 10.83 | 7 | 269378 | 39 | 29305103 |
Pyonephrosis | 13.09 | 10.83 | 8 | 269377 | 60 | 29305082 |
Drug dose titration not performed | 13.07 | 10.83 | 14 | 269371 | 250 | 29304892 |
Choluria | 13.06 | 10.83 | 11 | 269374 | 143 | 29304999 |
Alopecia | 13.05 | 10.83 | 111 | 269274 | 18973 | 29286169 |
Hyperdynamic left ventricle | 13.01 | 10.83 | 10 | 269375 | 113 | 29305029 |
Coma uraemic | 12.99 | 10.83 | 7 | 269378 | 40 | 29305102 |
Blood creatinine increased | 12.97 | 10.83 | 921 | 268464 | 84181 | 29220961 |
Tinnitus | 12.97 | 10.83 | 86 | 269299 | 15528 | 29289614 |
Small intestinal obstruction | 12.94 | 10.83 | 68 | 269317 | 12993 | 29292149 |
Exercise tolerance decreased | 12.82 | 10.83 | 74 | 269311 | 4157 | 29300985 |
Urosepsis | 12.79 | 10.83 | 152 | 269233 | 10594 | 29294548 |
Pneumonia bacterial | 12.75 | 10.83 | 43 | 269342 | 9300 | 29295842 |
Tachypnoea | 12.74 | 10.83 | 201 | 269184 | 14914 | 29290228 |
Multiple sclerosis relapse | 12.73 | 10.83 | 57 | 269328 | 11362 | 29293780 |
Hemiparaesthesia | 12.72 | 10.83 | 7 | 269378 | 42 | 29305100 |
Bradypnoea | 12.68 | 10.83 | 3 | 269382 | 2368 | 29302774 |
Cerebellar ischaemia | 12.66 | 10.83 | 10 | 269375 | 118 | 29305024 |
Diabetic gangrene | 12.65 | 10.83 | 12 | 269373 | 184 | 29304958 |
Haematochezia | 12.63 | 10.83 | 249 | 269136 | 36734 | 29268408 |
Benign neoplasm of adrenal gland | 12.62 | 10.83 | 4 | 269381 | 3 | 29305139 |
Hepatobiliary scan abnormal | 12.62 | 10.83 | 4 | 269381 | 3 | 29305139 |
Essential hypertension | 12.62 | 10.83 | 50 | 269335 | 2403 | 29302739 |
Pancreatic duct obstruction | 12.62 | 10.83 | 4 | 269381 | 3 | 29305139 |
Macular oedema | 12.56 | 10.83 | 50 | 269335 | 2408 | 29302734 |
Mouth haemorrhage | 12.56 | 10.83 | 15 | 269370 | 4765 | 29300377 |
Pseudomembranous colitis | 12.55 | 10.83 | 4 | 269381 | 2593 | 29302549 |
Ejection fraction decreased | 12.55 | 10.83 | 210 | 269175 | 15768 | 29289374 |
Lichenification | 12.47 | 10.83 | 14 | 269371 | 264 | 29304878 |
Cardiac septal hypertrophy | 12.47 | 10.83 | 14 | 269371 | 264 | 29304878 |
Bladder papilloma | 12.44 | 10.83 | 6 | 269379 | 26 | 29305116 |
Vasoplegia syndrome | 12.42 | 10.83 | 36 | 269349 | 1472 | 29303670 |
Ventricular enlargement | 12.31 | 10.83 | 18 | 269367 | 446 | 29304696 |
Neonatal respiratory distress syndrome | 12.26 | 10.83 | 10 | 269375 | 3800 | 29301342 |
Vascular resistance systemic decreased | 12.21 | 10.83 | 9 | 269376 | 95 | 29305047 |
Red blood cell count decreased | 12.19 | 10.83 | 162 | 269223 | 25440 | 29279702 |
Rales | 12.13 | 10.83 | 113 | 269272 | 7397 | 29297745 |
Bacterial sepsis | 12.10 | 10.83 | 15 | 269370 | 4688 | 29300454 |
Blood albumin decreased | 12.09 | 10.83 | 60 | 269325 | 11635 | 29293507 |
Bone erosion | 12.07 | 10.83 | 5 | 269380 | 2755 | 29302387 |
Lip swelling | 12.01 | 10.83 | 169 | 269216 | 12241 | 29292901 |
Finger amputation | 12.01 | 10.83 | 11 | 269374 | 161 | 29304981 |
Lichen sclerosus | 11.99 | 10.83 | 5 | 269380 | 14 | 29305128 |
Cardiac discomfort | 11.96 | 10.83 | 18 | 269367 | 458 | 29304684 |
Eosinophilic colitis | 11.95 | 10.83 | 12 | 269373 | 198 | 29304944 |
Blood bilirubin increased | 11.93 | 10.83 | 227 | 269158 | 33666 | 29271476 |
Post-traumatic amnestic disorder | 11.84 | 10.83 | 7 | 269378 | 49 | 29305093 |
Endometriosis male | 11.74 | 10.83 | 5 | 269380 | 15 | 29305127 |
Blood alkaline phosphatase increased | 11.69 | 10.83 | 185 | 269200 | 28221 | 29276921 |
Dermatosis | 11.64 | 10.83 | 14 | 269371 | 285 | 29304857 |
Diabetic vascular disorder | 11.61 | 10.83 | 6 | 269379 | 31 | 29305111 |
Viral infection | 11.59 | 10.83 | 83 | 269302 | 14727 | 29290415 |
Base excess decreased | 11.57 | 10.83 | 12 | 269373 | 206 | 29304936 |
Bundle branch block left | 11.53 | 10.83 | 85 | 269300 | 5192 | 29299950 |
Venous occlusion | 11.52 | 10.83 | 15 | 269370 | 332 | 29304810 |
Alcoholic ketoacidosis | 11.51 | 10.83 | 5 | 269380 | 16 | 29305126 |
Generalised tonic-clonic seizure | 11.50 | 10.83 | 115 | 269270 | 19024 | 29286118 |
Hepatic haematoma | 11.47 | 10.83 | 16 | 269369 | 379 | 29304763 |
Penile infection | 11.46 | 10.83 | 6 | 269379 | 32 | 29305110 |
Hemianopia homonymous | 11.42 | 10.83 | 22 | 269363 | 687 | 29304455 |
Methaemoglobinaemia | 11.42 | 10.83 | 5 | 269380 | 2666 | 29302476 |
Squamous cell carcinoma of skin | 11.41 | 10.83 | 46 | 269339 | 9440 | 29295702 |
Pancreatitis necrotising | 11.41 | 10.83 | 47 | 269338 | 2300 | 29302842 |
Lip oedema | 11.40 | 10.83 | 45 | 269340 | 2159 | 29302983 |
Large intestine perforation | 11.36 | 10.83 | 32 | 269353 | 7324 | 29297818 |
Blood lactate dehydrogenase increased | 11.30 | 10.83 | 116 | 269269 | 19093 | 29286049 |
Body mass index increased | 11.25 | 10.83 | 24 | 269361 | 808 | 29304334 |
Cardiovascular insufficiency | 11.23 | 10.83 | 33 | 269352 | 1360 | 29303782 |
Base excess negative | 11.22 | 10.83 | 4 | 269381 | 6 | 29305136 |
Intraductal papillary-mucinous carcinoma of pancreas | 11.22 | 10.83 | 4 | 269381 | 6 | 29305136 |
Diabetic complication | 11.21 | 10.83 | 21 | 269364 | 642 | 29304500 |
Virologic failure | 11.15 | 10.83 | 6 | 269379 | 2841 | 29302301 |
Pure white cell aplasia | 11.12 | 10.83 | 3 | 269382 | 0 | 29305142 |
Dawn phenomenon | 11.12 | 10.83 | 3 | 269382 | 0 | 29305142 |
Thyroid calcification | 11.12 | 10.83 | 3 | 269382 | 0 | 29305142 |
Diabetic encephalopathy | 11.12 | 10.83 | 3 | 269382 | 0 | 29305142 |
Genital tract inflammation | 11.12 | 10.83 | 3 | 269382 | 0 | 29305142 |
Benign neoplasm of testis | 11.12 | 10.83 | 3 | 269382 | 0 | 29305142 |
Thyroid C-cell hyperplasia | 11.12 | 10.83 | 3 | 269382 | 0 | 29305142 |
Base excess | 11.12 | 10.83 | 3 | 269382 | 0 | 29305142 |
Myasthenic syndrome | 11.10 | 10.83 | 16 | 269369 | 391 | 29304751 |
Erythema | 11.09 | 10.83 | 569 | 268816 | 75037 | 29230105 |
Metastases to the mediastinum | 11.08 | 10.83 | 12 | 269373 | 217 | 29304925 |
Product label issue | 11.08 | 10.83 | 12 | 269373 | 217 | 29304925 |
Foetal malnutrition | 11.08 | 10.83 | 7 | 269378 | 56 | 29305086 |
Back pain | 11.07 | 10.83 | 792 | 268593 | 101492 | 29203650 |
Swollen tongue | 11.06 | 10.83 | 165 | 269220 | 12101 | 29293041 |
Serum ferritin abnormal | 10.95 | 10.83 | 12 | 269373 | 220 | 29304922 |
Heat stroke | 10.91 | 10.83 | 25 | 269360 | 884 | 29304258 |
Electrocardiogram QT interval | 10.90 | 10.83 | 6 | 269379 | 36 | 29305106 |
Body temperature increased | 10.87 | 10.83 | 82 | 269303 | 14383 | 29290759 |
Neuropathic ulcer | 10.87 | 10.83 | 5 | 269380 | 19 | 29305123 |
Arthropod sting | 10.85 | 10.83 | 14 | 269371 | 307 | 29304835 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Lactic acidosis | 22134.48 | 10.40 | 10324 | 483641 | 51086 | 63953681 |
Acute kidney injury | 5247.62 | 10.40 | 10969 | 482996 | 438271 | 63566496 |
Hypoglycaemia | 4563.17 | 10.40 | 4453 | 489512 | 85439 | 63919328 |
Metabolic acidosis | 3524.82 | 10.40 | 3475 | 490490 | 67483 | 63937284 |
Diabetic ketoacidosis | 3059.60 | 10.40 | 2220 | 491745 | 27625 | 63977142 |
Blood glucose increased | 2058.45 | 10.40 | 3105 | 490860 | 94968 | 63909799 |
Hyperkalaemia | 1582.27 | 10.40 | 2804 | 491161 | 98325 | 63906442 |
Euglycaemic diabetic ketoacidosis | 1414.88 | 10.40 | 733 | 493232 | 4677 | 64000090 |
Diabetes mellitus inadequate control | 1278.66 | 10.40 | 1160 | 492805 | 20161 | 63984606 |
Ketoacidosis | 1227.94 | 10.40 | 724 | 493241 | 6139 | 63998628 |
Glycosylated haemoglobin increased | 1202.76 | 10.40 | 991 | 492974 | 15028 | 63989739 |
Hyperglycaemia | 978.21 | 10.40 | 1710 | 492255 | 59258 | 63945509 |
Shock | 713.86 | 10.40 | 1148 | 492817 | 37092 | 63967675 |
Hypoglycaemic coma | 679.58 | 10.40 | 418 | 493547 | 3856 | 64000911 |
Hyperlactacidaemia | 670.67 | 10.40 | 434 | 493531 | 4410 | 64000357 |
Drug ineffective | 659.26 | 10.40 | 3765 | 490200 | 836482 | 63168285 |
Pancreatitis acute | 647.41 | 10.40 | 1171 | 492794 | 41684 | 63963083 |
Pancreatitis | 613.99 | 10.40 | 1389 | 492576 | 58218 | 63946549 |
Pemphigoid | 579.85 | 10.40 | 601 | 493364 | 12385 | 63992382 |
Off label use | 519.52 | 10.40 | 2791 | 491174 | 630015 | 63374752 |
Diabetic metabolic decompensation | 472.87 | 10.40 | 282 | 493683 | 2446 | 64002321 |
Anuria | 459.13 | 10.40 | 643 | 493322 | 18321 | 63986446 |
Renal failure | 458.65 | 10.40 | 2663 | 491302 | 179025 | 63825742 |
Synovitis | 442.70 | 10.40 | 107 | 493858 | 98983 | 63905784 |
Blood lactic acid increased | 422.91 | 10.40 | 458 | 493507 | 9943 | 63994824 |
Drug intolerance | 422.53 | 10.40 | 490 | 493475 | 187502 | 63817265 |
Blood glucose decreased | 419.00 | 10.40 | 685 | 493280 | 22438 | 63982329 |
Systemic lupus erythematosus | 418.45 | 10.40 | 51 | 493914 | 77561 | 63927206 |
Infusion related reaction | 408.44 | 10.40 | 394 | 493571 | 164073 | 63840694 |
Blood glucose abnormal | 398.83 | 10.40 | 413 | 493552 | 8500 | 63996267 |
Treatment failure | 374.99 | 10.40 | 214 | 493751 | 116602 | 63888165 |
Hand deformity | 354.24 | 10.40 | 35 | 493930 | 62736 | 63942031 |
Arthropathy | 340.34 | 10.40 | 257 | 493708 | 120710 | 63884057 |
Vitamin B12 deficiency | 336.42 | 10.40 | 302 | 493663 | 5170 | 63999597 |
Febrile neutropenia | 334.36 | 10.40 | 577 | 493388 | 187080 | 63817687 |
Vomiting | 330.22 | 10.40 | 5988 | 487977 | 545129 | 63459638 |
Joint swelling | 329.38 | 10.40 | 725 | 493240 | 214657 | 63790110 |
Toxicity to various agents | 322.67 | 10.40 | 4223 | 489742 | 359290 | 63645477 |
Pemphigus | 312.65 | 10.40 | 46 | 493919 | 60655 | 63944112 |
Drug level increased | 311.84 | 10.40 | 760 | 493205 | 33436 | 63971331 |
Dehydration | 311.58 | 10.40 | 2774 | 491191 | 213989 | 63790778 |
Intentional overdose | 306.10 | 10.40 | 1433 | 492532 | 88511 | 63916256 |
Glossodynia | 304.81 | 10.40 | 62 | 493903 | 64634 | 63940133 |
Pancreatic carcinoma | 302.15 | 10.40 | 385 | 493580 | 9988 | 63994779 |
Pyrexia | 295.25 | 10.40 | 2796 | 491169 | 555848 | 63448919 |
Haemodialysis | 294.77 | 10.40 | 495 | 493470 | 16582 | 63988185 |
Diarrhoea | 288.67 | 10.40 | 7404 | 486561 | 715300 | 63289467 |
Drug abuse | 285.67 | 10.40 | 356 | 493609 | 132018 | 63872749 |
Rheumatoid arthritis | 285.55 | 10.40 | 513 | 493452 | 163781 | 63840986 |
Completed suicide | 279.13 | 10.40 | 2785 | 491180 | 221629 | 63783138 |
Neutropenia | 271.15 | 10.40 | 934 | 493031 | 238690 | 63766077 |
Hypothermia | 270.32 | 10.40 | 519 | 493446 | 19337 | 63985430 |
Continuous haemodiafiltration | 258.42 | 10.40 | 170 | 493795 | 1780 | 64002987 |
Anion gap increased | 253.21 | 10.40 | 200 | 493765 | 2844 | 64001923 |
Therapeutic product effect decreased | 252.27 | 10.40 | 307 | 493658 | 115044 | 63889723 |
Rash | 242.88 | 10.40 | 2293 | 491672 | 456256 | 63548511 |
Acidosis | 240.86 | 10.40 | 464 | 493501 | 17331 | 63987436 |
Rheumatoid factor positive | 238.86 | 10.40 | 6 | 493959 | 34932 | 63969835 |
Blood glucose fluctuation | 234.74 | 10.40 | 258 | 493707 | 5697 | 63999070 |
Drug hypersensitivity | 234.67 | 10.40 | 980 | 492985 | 236835 | 63767932 |
Arthralgia | 231.02 | 10.40 | 2219 | 491746 | 440041 | 63564726 |
Pericarditis | 230.28 | 10.40 | 95 | 493870 | 62421 | 63942346 |
Hypersensitivity | 228.83 | 10.40 | 756 | 493209 | 195696 | 63809071 |
Alopecia | 222.25 | 10.40 | 597 | 493368 | 165093 | 63839674 |
Stomatitis | 216.93 | 10.40 | 314 | 493651 | 109291 | 63895476 |
Infection | 208.13 | 10.40 | 722 | 493243 | 184158 | 63820609 |
Duodenal ulcer perforation | 201.54 | 10.40 | 17 | 493948 | 34608 | 63970159 |
Blood bicarbonate decreased | 195.19 | 10.40 | 212 | 493753 | 4617 | 64000150 |
Contraindicated product administered | 193.36 | 10.40 | 330 | 493635 | 107499 | 63897268 |
Drug interaction | 193.18 | 10.40 | 3867 | 490098 | 358216 | 63646551 |
Hypomagnesaemia | 186.18 | 10.40 | 670 | 493295 | 36706 | 63968061 |
Bladder cancer | 183.96 | 10.40 | 314 | 493651 | 10660 | 63994107 |
Overdose | 183.83 | 10.40 | 1950 | 492015 | 157616 | 63847151 |
Sinusitis | 182.98 | 10.40 | 543 | 493422 | 145385 | 63859382 |
Product use in unapproved indication | 182.85 | 10.40 | 714 | 493251 | 175904 | 63828863 |
Pain | 176.65 | 10.40 | 3080 | 490885 | 550431 | 63454336 |
Musculoskeletal stiffness | 175.91 | 10.40 | 430 | 493535 | 122776 | 63881991 |
Sleep disorder due to general medical condition, insomnia type | 174.15 | 10.40 | 6 | 493959 | 26264 | 63978503 |
Product use issue | 173.08 | 10.40 | 589 | 493376 | 151126 | 63853641 |
Folliculitis | 171.72 | 10.40 | 16 | 493949 | 30061 | 63974706 |
Swelling | 170.82 | 10.40 | 640 | 493325 | 159578 | 63845189 |
Helicobacter infection | 170.16 | 10.40 | 42 | 493923 | 38320 | 63966447 |
Ketonuria | 169.36 | 10.40 | 106 | 493859 | 1011 | 64003756 |
Cytomegalovirus infection | 166.42 | 10.40 | 40 | 493925 | 37159 | 63967608 |
Weight decreased | 162.20 | 10.40 | 3081 | 490884 | 282658 | 63722109 |
Pneumonia | 161.31 | 10.40 | 3169 | 490796 | 556407 | 63448360 |
Wound | 159.42 | 10.40 | 211 | 493754 | 76266 | 63928501 |
Muscle injury | 153.81 | 10.40 | 13 | 493952 | 26424 | 63978343 |
Diabetic neuropathy | 152.37 | 10.40 | 201 | 493764 | 5400 | 63999367 |
Polyuria | 148.77 | 10.40 | 311 | 493654 | 12332 | 63992435 |
Rhabdomyolysis | 145.28 | 10.40 | 1200 | 492765 | 90526 | 63914241 |
Irritable bowel syndrome | 142.19 | 10.40 | 54 | 493911 | 37315 | 63967452 |
Diabetes mellitus | 141.46 | 10.40 | 933 | 493032 | 65541 | 63939226 |
Blood pH decreased | 140.40 | 10.40 | 171 | 493794 | 4231 | 64000536 |
Maternal exposure during pregnancy | 138.95 | 10.40 | 332 | 493633 | 95552 | 63909215 |
Ketosis | 138.40 | 10.40 | 88 | 493877 | 865 | 64003902 |
Immune-mediated myositis | 138.03 | 10.40 | 134 | 493831 | 2544 | 64002223 |
Injection site nodule | 136.17 | 10.40 | 145 | 493820 | 3085 | 64001682 |
White blood cell count decreased | 135.59 | 10.40 | 684 | 493281 | 157153 | 63847614 |
Hypotension | 130.57 | 10.40 | 3830 | 490135 | 377144 | 63627623 |
C-reactive protein abnormal | 130.40 | 10.40 | 31 | 493934 | 29016 | 63975751 |
Bone marrow failure | 129.60 | 10.40 | 106 | 493859 | 47846 | 63956921 |
Thrombocytopenia | 128.74 | 10.40 | 1095 | 492870 | 222706 | 63782061 |
Drug resistance | 128.20 | 10.40 | 54 | 493911 | 35048 | 63969719 |
Urine ketone body present | 128.14 | 10.40 | 142 | 493823 | 3165 | 64001602 |
Platelet count decreased | 127.48 | 10.40 | 757 | 493208 | 166954 | 63837813 |
MELAS syndrome | 126.21 | 10.40 | 47 | 493918 | 111 | 64004656 |
Base excess decreased | 126.16 | 10.40 | 60 | 493905 | 309 | 64004458 |
Blood creatinine increased | 121.54 | 10.40 | 1581 | 492384 | 134201 | 63870566 |
Myocardial infarction | 119.32 | 10.40 | 1858 | 492107 | 163963 | 63840804 |
Death | 112.77 | 10.40 | 2825 | 491140 | 479880 | 63524887 |
Suicide attempt | 112.45 | 10.40 | 929 | 493036 | 70078 | 63934689 |
Acetonaemia | 110.82 | 10.40 | 50 | 493915 | 223 | 64004544 |
Renal impairment | 108.90 | 10.40 | 1543 | 492422 | 133474 | 63871293 |
Glomerular filtration rate decreased | 105.36 | 10.40 | 360 | 493605 | 19212 | 63985555 |
Impaired healing | 104.82 | 10.40 | 189 | 493776 | 60284 | 63944483 |
Tachypnoea | 102.85 | 10.40 | 440 | 493525 | 26131 | 63978636 |
Contusion | 100.65 | 10.40 | 489 | 493476 | 113476 | 63891291 |
Blood lactic acid | 99.33 | 10.40 | 55 | 493910 | 408 | 64004359 |
Neurologic neglect syndrome | 98.87 | 10.40 | 89 | 493876 | 1529 | 64003238 |
Leukopenia | 98.61 | 10.40 | 419 | 493546 | 100823 | 63903944 |
Discomfort | 98.43 | 10.40 | 305 | 493660 | 80573 | 63924194 |
Neutrophil count decreased | 97.62 | 10.40 | 286 | 493679 | 76910 | 63927857 |
Distributive shock | 95.11 | 10.40 | 93 | 493872 | 1782 | 64002985 |
Diabetic retinopathy | 94.99 | 10.40 | 113 | 493852 | 2726 | 64002041 |
Hypocapnia | 94.55 | 10.40 | 58 | 493907 | 532 | 64004235 |
Seizure | 93.95 | 10.40 | 821 | 493144 | 166071 | 63838696 |
Renal tubular necrosis | 93.32 | 10.40 | 376 | 493589 | 21734 | 63983033 |
Nasopharyngitis | 92.91 | 10.40 | 1006 | 492959 | 195067 | 63809700 |
Pneumocystis jirovecii pneumonia | 92.45 | 10.40 | 48 | 493917 | 27586 | 63977181 |
Haemodynamic instability | 91.70 | 10.40 | 287 | 493678 | 14625 | 63990142 |
Macroangiopathy | 91.08 | 10.40 | 36 | 493929 | 106 | 64004661 |
Transplant rejection | 90.02 | 10.40 | 13 | 493952 | 17388 | 63987379 |
Malignant neoplasm progression | 89.20 | 10.40 | 503 | 493462 | 112368 | 63892399 |
Carotid artery thrombosis | 89.13 | 10.40 | 88 | 493877 | 1707 | 64003060 |
Graft versus host disease | 88.70 | 10.40 | 4 | 493961 | 13809 | 63990958 |
Anaemia vitamin B12 deficiency | 87.23 | 10.40 | 55 | 493910 | 532 | 64004235 |
Suspected suicide | 87.19 | 10.40 | 200 | 493765 | 8454 | 63996313 |
Lipase increased | 86.56 | 10.40 | 275 | 493690 | 14127 | 63990640 |
Hepatic steatosis | 86.35 | 10.40 | 467 | 493498 | 30540 | 63974227 |
Condition aggravated | 86.22 | 10.40 | 2182 | 491783 | 370244 | 63634523 |
Exposure during pregnancy | 84.88 | 10.40 | 307 | 493658 | 77368 | 63927399 |
Disease progression | 84.68 | 10.40 | 686 | 493279 | 140994 | 63863773 |
Blood ketone body increased | 83.51 | 10.40 | 55 | 493910 | 577 | 64004190 |
Hemiplegia | 83.42 | 10.40 | 251 | 493714 | 12517 | 63992250 |
Hepatic enzyme increased | 83.36 | 10.40 | 617 | 493348 | 129326 | 63875441 |
Posterior reversible encephalopathy syndrome | 82.68 | 10.40 | 36 | 493929 | 22910 | 63981857 |
Type 2 diabetes mellitus | 82.64 | 10.40 | 494 | 493471 | 33526 | 63971241 |
Headache | 82.04 | 10.40 | 3270 | 490695 | 526197 | 63478570 |
Myelosuppression | 81.81 | 10.40 | 40 | 493925 | 23790 | 63980977 |
Diabetic nephropathy | 81.26 | 10.40 | 101 | 493864 | 2553 | 64002214 |
Ill-defined disorder | 79.69 | 10.40 | 134 | 493831 | 43918 | 63960849 |
Exposure via ingestion | 79.20 | 10.40 | 138 | 493827 | 4764 | 64000003 |
Urine albumin/creatinine ratio abnormal | 78.69 | 10.40 | 21 | 493944 | 3 | 64004764 |
Therapy non-responder | 78.43 | 10.40 | 251 | 493714 | 65648 | 63939119 |
Product residue present | 77.08 | 10.40 | 109 | 493856 | 3133 | 64001634 |
Bradycardia | 76.92 | 10.40 | 1303 | 492662 | 116916 | 63887851 |
Microalbuminuria | 76.65 | 10.40 | 59 | 493906 | 806 | 64003961 |
Drug level above therapeutic | 75.71 | 10.40 | 165 | 493800 | 6736 | 63998031 |
Bronchopulmonary aspergillosis | 73.58 | 10.40 | 27 | 493938 | 19058 | 63985709 |
Hypovolaemia | 73.23 | 10.40 | 273 | 493692 | 15213 | 63989554 |
Migraine | 73.02 | 10.40 | 241 | 493724 | 62436 | 63942331 |
Polydipsia | 72.98 | 10.40 | 147 | 493818 | 5674 | 63999093 |
Personality disorder | 72.72 | 10.40 | 130 | 493835 | 4581 | 64000186 |
Angioedema | 72.27 | 10.40 | 758 | 493207 | 61063 | 63943704 |
Coma acidotic | 72.07 | 10.40 | 30 | 493935 | 105 | 64004662 |
Psoriasis | 71.90 | 10.40 | 853 | 493112 | 70850 | 63933917 |
Latent autoimmune diabetes in adults | 71.75 | 10.40 | 26 | 493939 | 55 | 64004712 |
Abdominal discomfort | 71.68 | 10.40 | 974 | 492991 | 181348 | 63823419 |
Acute myocardial infarction | 71.51 | 10.40 | 833 | 493132 | 68885 | 63935882 |
Mucosal inflammation | 71.30 | 10.40 | 243 | 493722 | 62341 | 63942426 |
Infective pulmonary exacerbation of cystic fibrosis | 70.88 | 10.40 | 5 | 493960 | 11791 | 63992976 |
Hypoglycaemic encephalopathy | 70.69 | 10.40 | 49 | 493916 | 563 | 64004204 |
Vasoplegia syndrome | 70.23 | 10.40 | 96 | 493869 | 2671 | 64002096 |
Therapeutic product effect incomplete | 69.94 | 10.40 | 484 | 493481 | 102998 | 63901769 |
Aspergillus infection | 68.73 | 10.40 | 20 | 493945 | 16359 | 63988408 |
Neurotoxicity | 67.54 | 10.40 | 66 | 493899 | 27338 | 63977429 |
Inflammation | 67.50 | 10.40 | 264 | 493701 | 65036 | 63939731 |
Rheumatoid nodule | 66.51 | 10.40 | 9 | 493956 | 12642 | 63992125 |
Arthritis | 66.49 | 10.40 | 373 | 493592 | 83441 | 63921326 |
Haemophagocytic lymphohistiocytosis | 66.07 | 10.40 | 26 | 493939 | 17583 | 63987184 |
Pathogen resistance | 65.76 | 10.40 | 9 | 493956 | 12534 | 63992233 |
Tenosynovitis | 65.71 | 10.40 | 7 | 493958 | 11826 | 63992941 |
Epstein-Barr virus infection | 65.38 | 10.40 | 9 | 493956 | 12479 | 63992288 |
Hypovolaemic shock | 65.37 | 10.40 | 200 | 493765 | 10066 | 63994701 |
Progressive multifocal leukoencephalopathy | 65.06 | 10.40 | 29 | 493936 | 18203 | 63986564 |
Pancreatic carcinoma metastatic | 64.30 | 10.40 | 104 | 493861 | 3374 | 64001393 |
Product odour abnormal | 63.80 | 10.40 | 60 | 493905 | 1093 | 64003674 |
Blood potassium increased | 63.58 | 10.40 | 378 | 493587 | 25602 | 63979165 |
Intentional product use issue | 63.48 | 10.40 | 448 | 493517 | 94916 | 63909851 |
Postprandial hypoglycaemia | 63.23 | 10.40 | 24 | 493941 | 61 | 64004706 |
Adjustment disorder | 61.91 | 10.40 | 90 | 493875 | 2655 | 64002112 |
Anaemia megaloblastic | 61.89 | 10.40 | 42 | 493923 | 465 | 64004302 |
Injection site erythema | 61.79 | 10.40 | 305 | 493660 | 70495 | 63934272 |
Bone erosion | 61.55 | 10.40 | 8 | 493957 | 11587 | 63993180 |
Haematotoxicity | 61.48 | 10.40 | 12 | 493953 | 12884 | 63991883 |
Vitamin B12 decreased | 61.21 | 10.40 | 89 | 493876 | 2626 | 64002141 |
Venoocclusive liver disease | 60.89 | 10.40 | 4 | 493961 | 10011 | 63994756 |
Glycosylated haemoglobin abnormal | 60.27 | 10.40 | 27 | 493938 | 118 | 64004649 |
Fatigue | 60.19 | 10.40 | 4928 | 489037 | 743802 | 63260965 |
Hyperglycaemic hyperosmolar nonketotic syndrome | 60.13 | 10.40 | 70 | 493895 | 1649 | 64003118 |
Cytomegalovirus viraemia | 58.63 | 10.40 | 7 | 493958 | 10821 | 63993946 |
Immune reconstitution inflammatory syndrome | 58.62 | 10.40 | 12 | 493953 | 12458 | 63992309 |
Therapeutic response decreased | 58.52 | 10.40 | 204 | 493761 | 51984 | 63952783 |
Thirst | 57.75 | 10.40 | 238 | 493727 | 13899 | 63990868 |
Diabetic ketoacidotic hyperglycaemic coma | 57.44 | 10.40 | 30 | 493935 | 195 | 64004572 |
Hepatic function abnormal | 57.32 | 10.40 | 275 | 493690 | 64038 | 63940729 |
Pancytopenia | 56.89 | 10.40 | 764 | 493201 | 142545 | 63862222 |
PCO2 decreased | 56.71 | 10.40 | 89 | 493876 | 2813 | 64001954 |
Herpes zoster | 56.70 | 10.40 | 364 | 493601 | 78823 | 63925944 |
Osteonecrosis | 56.68 | 10.40 | 80 | 493885 | 28149 | 63976618 |
C-reactive protein increased | 56.48 | 10.40 | 460 | 493505 | 94449 | 63910318 |
Osmolar gap | 56.42 | 10.40 | 26 | 493939 | 123 | 64004644 |
Osteoporosis | 56.07 | 10.40 | 152 | 493813 | 41928 | 63962839 |
Abdominal pain | 56.03 | 10.40 | 2927 | 491038 | 309448 | 63695319 |
Peripheral swelling | 55.11 | 10.40 | 1201 | 492764 | 207952 | 63796815 |
Myocardial ischaemia | 54.80 | 10.40 | 335 | 493630 | 22916 | 63981851 |
Post transplant lymphoproliferative disorder | 54.69 | 10.40 | 5 | 493960 | 9539 | 63995228 |
Cholelithiasis | 54.62 | 10.40 | 561 | 493404 | 44945 | 63959822 |
Cardiac arrest | 54.29 | 10.40 | 1555 | 492410 | 152509 | 63852258 |
Diabetic ketosis | 53.91 | 10.40 | 34 | 493931 | 329 | 64004438 |
Cytokine release syndrome | 52.70 | 10.40 | 49 | 493916 | 20780 | 63983987 |
Adenocarcinoma pancreas | 52.17 | 10.40 | 68 | 493897 | 1805 | 64002962 |
Nausea | 52.12 | 10.40 | 6822 | 487143 | 778978 | 63225789 |
Clostridium difficile infection | 51.74 | 10.40 | 126 | 493839 | 36037 | 63968730 |
Pancreatitis chronic | 51.61 | 10.40 | 96 | 493869 | 3490 | 64001277 |
Osmolar gap increased | 51.17 | 10.40 | 17 | 493948 | 24 | 64004743 |
Insulin resistance | 51.07 | 10.40 | 52 | 493913 | 1048 | 64003719 |
Coronary artery disease | 50.85 | 10.40 | 696 | 493269 | 59737 | 63945030 |
Toe amputation | 50.75 | 10.40 | 94 | 493871 | 3406 | 64001361 |
Flushing | 50.63 | 10.40 | 373 | 493592 | 78275 | 63926492 |
Acute coronary syndrome | 50.54 | 10.40 | 286 | 493679 | 19024 | 63985743 |
Genital infection fungal | 49.76 | 10.40 | 25 | 493940 | 148 | 64004619 |
Malaise | 49.47 | 10.40 | 3597 | 490368 | 392650 | 63612117 |
Amylase increased | 49.40 | 10.40 | 175 | 493790 | 9510 | 63995257 |
Oliguria | 49.36 | 10.40 | 232 | 493733 | 14344 | 63990423 |
Cerebrovascular accident | 49.12 | 10.40 | 1391 | 492574 | 136192 | 63868575 |
Toxic epidermal necrolysis | 48.96 | 10.40 | 135 | 493830 | 37031 | 63967736 |
Mobility decreased | 48.84 | 10.40 | 421 | 493544 | 85419 | 63919348 |
Hospitalisation | 48.74 | 10.40 | 356 | 493609 | 74851 | 63929916 |
Injection site reaction | 48.65 | 10.40 | 188 | 493777 | 46476 | 63958291 |
Device expulsion | 48.60 | 10.40 | 54 | 493911 | 21082 | 63983685 |
Glycosuria | 48.23 | 10.40 | 69 | 493896 | 2005 | 64002762 |
Multiple sclerosis relapse | 48.03 | 10.40 | 158 | 493807 | 40977 | 63963790 |
Swollen joint count increased | 46.96 | 10.40 | 3 | 493962 | 7686 | 63997081 |
Diabetic foot infection | 46.67 | 10.40 | 41 | 493924 | 681 | 64004086 |
Glucose urine present | 46.62 | 10.40 | 60 | 493905 | 1572 | 64003195 |
Neuropathy peripheral | 46.47 | 10.40 | 627 | 493338 | 116898 | 63887869 |
Anhidrosis | 46.18 | 10.40 | 26 | 493939 | 200 | 64004567 |
Gastroenteritis | 46.10 | 10.40 | 387 | 493578 | 29324 | 63975443 |
Glycosylated haemoglobin decreased | 46.00 | 10.40 | 38 | 493927 | 578 | 64004189 |
Pain in jaw | 45.90 | 10.40 | 159 | 493806 | 40596 | 63964171 |
Enthesopathy | 45.88 | 10.40 | 9 | 493956 | 9629 | 63995138 |
Red blood cell sedimentation rate increased | 45.35 | 10.40 | 108 | 493857 | 31127 | 63973640 |
Naevus flammeus | 44.91 | 10.40 | 19 | 493946 | 70 | 64004697 |
Anion gap | 44.73 | 10.40 | 63 | 493902 | 1804 | 64002963 |
Drug dependence | 44.63 | 10.40 | 120 | 493845 | 33192 | 63971575 |
Hip arthroplasty | 44.39 | 10.40 | 59 | 493906 | 21292 | 63983475 |
Lymphocyte count decreased | 44.36 | 10.40 | 161 | 493804 | 40538 | 63964229 |
Eating disorder | 44.05 | 10.40 | 249 | 493716 | 16556 | 63988211 |
Circulatory collapse | 43.95 | 10.40 | 423 | 493542 | 33309 | 63971458 |
Stevens-Johnson syndrome | 43.20 | 10.40 | 127 | 493838 | 34122 | 63970645 |
Product prescribing error | 42.90 | 10.40 | 436 | 493529 | 34833 | 63969934 |
Cardiovascular disorder | 42.75 | 10.40 | 237 | 493728 | 15644 | 63989123 |
Blood ketone body | 42.69 | 10.40 | 21 | 493944 | 118 | 64004649 |
Bladder transitional cell carcinoma | 42.16 | 10.40 | 69 | 493896 | 2261 | 64002506 |
Atrioventricular block | 41.99 | 10.40 | 193 | 493772 | 11822 | 63992945 |
Needle issue | 41.81 | 10.40 | 161 | 493804 | 9111 | 63995656 |
Kussmaul respiration | 41.72 | 10.40 | 30 | 493935 | 367 | 64004400 |
Pleural effusion | 41.19 | 10.40 | 701 | 493264 | 125858 | 63878909 |
Thrombotic microangiopathy | 41.17 | 10.40 | 40 | 493925 | 16615 | 63988152 |
Staphylococcal infection | 41.02 | 10.40 | 224 | 493741 | 50454 | 63954313 |
Insulin C-peptide decreased | 40.95 | 10.40 | 17 | 493948 | 59 | 64004708 |
Dialysis | 40.65 | 10.40 | 245 | 493720 | 16675 | 63988092 |
Osteonecrosis of jaw | 40.52 | 10.40 | 162 | 493803 | 39663 | 63965104 |
Accidental overdose | 40.42 | 10.40 | 414 | 493551 | 33143 | 63971624 |
Base excess negative | 40.13 | 10.40 | 13 | 493952 | 16 | 64004751 |
Pregnancy | 40.06 | 10.40 | 61 | 493904 | 20804 | 63983963 |
Sopor | 39.66 | 10.40 | 374 | 493591 | 29287 | 63975480 |
Rheumatic fever | 39.64 | 10.40 | 11 | 493954 | 9283 | 63995484 |
Pancreatic neoplasm | 39.40 | 10.40 | 51 | 493914 | 1344 | 64003423 |
Loss of personal independence in daily activities | 39.17 | 10.40 | 360 | 493605 | 72094 | 63932673 |
Cardiac failure | 38.65 | 10.40 | 1306 | 492659 | 131067 | 63873700 |
Lymphopenia | 38.63 | 10.40 | 87 | 493878 | 25570 | 63979197 |
Basilar artery thrombosis | 38.53 | 10.40 | 26 | 493939 | 285 | 64004482 |
Alanine aminotransferase increased | 38.45 | 10.40 | 792 | 493173 | 138239 | 63866528 |
High density lipoprotein decreased | 38.44 | 10.40 | 90 | 493875 | 3856 | 64000911 |
Clostridium difficile colitis | 38.05 | 10.40 | 96 | 493869 | 27127 | 63977640 |
Interstitial lung disease | 37.70 | 10.40 | 524 | 493441 | 97208 | 63907559 |
Oral herpes | 37.69 | 10.40 | 70 | 493895 | 22082 | 63982685 |
Blister | 37.67 | 10.40 | 417 | 493548 | 80550 | 63924217 |
Antipsychotic drug level decreased | 37.38 | 10.40 | 41 | 493924 | 903 | 64003864 |
Unintentional medical device removal | 37.35 | 10.40 | 4 | 493961 | 6730 | 63998037 |
Knee arthroplasty | 37.13 | 10.40 | 96 | 493869 | 26903 | 63977864 |
Aspartate aminotransferase increased | 36.59 | 10.40 | 671 | 493294 | 119117 | 63885650 |
Syncope | 36.59 | 10.40 | 1516 | 492449 | 156119 | 63848648 |
Hypoglycaemic unconsciousness | 36.49 | 10.40 | 44 | 493921 | 1077 | 64003690 |
Prerenal failure | 36.45 | 10.40 | 78 | 493887 | 3144 | 64001623 |
Affect lability | 36.44 | 10.40 | 151 | 493814 | 8839 | 63995928 |
Dystonia | 36.37 | 10.40 | 55 | 493910 | 18810 | 63985957 |
Confusional state | 36.29 | 10.40 | 2392 | 491573 | 258752 | 63746015 |
Mouth ulceration | 36.25 | 10.40 | 127 | 493838 | 32317 | 63972450 |
Sedation complication | 36.12 | 10.40 | 17 | 493948 | 10337 | 63994430 |
Obesity | 35.80 | 10.40 | 275 | 493690 | 20287 | 63984480 |
Balanoposthitis | 35.51 | 10.40 | 37 | 493928 | 767 | 64004000 |
Granuloma skin | 35.30 | 10.40 | 3 | 493962 | 6071 | 63998696 |
Acute myeloid leukaemia | 35.25 | 10.40 | 101 | 493864 | 27362 | 63977405 |
Drug reaction with eosinophilia and systemic symptoms | 34.96 | 10.40 | 257 | 493708 | 53960 | 63950807 |
Drug tolerance decreased | 34.46 | 10.40 | 6 | 493959 | 6992 | 63997775 |
Diabetic foot | 34.29 | 10.40 | 73 | 493892 | 2932 | 64001835 |
Angina pectoris | 34.25 | 10.40 | 510 | 493455 | 44571 | 63960196 |
Pollakiuria | 34.24 | 10.40 | 381 | 493584 | 31149 | 63973618 |
Body temperature decreased | 34.20 | 10.40 | 326 | 493639 | 25602 | 63979165 |
Dyslipidaemia | 34.20 | 10.40 | 151 | 493814 | 9091 | 63995676 |
Immunosuppressant drug level increased | 34.09 | 10.40 | 7 | 493958 | 7252 | 63997515 |
Product substitution issue | 34.01 | 10.40 | 244 | 493721 | 17617 | 63987150 |
Nephrogenic systemic fibrosis | 33.99 | 10.40 | 3 | 493962 | 5889 | 63998878 |
Depression | 33.93 | 10.40 | 1107 | 492858 | 182184 | 63822583 |
Hypophagia | 33.74 | 10.40 | 457 | 493508 | 39130 | 63965637 |
Sedation | 33.70 | 10.40 | 183 | 493782 | 41279 | 63963488 |
Urine ketone body | 33.67 | 10.40 | 20 | 493945 | 172 | 64004595 |
Multiple-drug resistance | 33.31 | 10.40 | 5 | 493960 | 6497 | 63998270 |
Intestinal perforation | 33.19 | 10.40 | 41 | 493924 | 15272 | 63989495 |
Cytomegalovirus infection reactivation | 33.02 | 10.40 | 3 | 493962 | 5753 | 63999014 |
Hypervolaemia | 32.79 | 10.40 | 166 | 493799 | 38119 | 63966648 |
Disability | 32.77 | 10.40 | 27 | 493938 | 12145 | 63992622 |
Neoplasm progression | 32.64 | 10.40 | 182 | 493783 | 40782 | 63963985 |
Oedematous pancreatitis | 32.48 | 10.40 | 37 | 493928 | 851 | 64003916 |
Lower respiratory tract infection | 32.45 | 10.40 | 519 | 493446 | 94095 | 63910672 |
Electrocardiogram T wave peaked | 32.32 | 10.40 | 36 | 493929 | 807 | 64003960 |
Basal cell carcinoma | 32.30 | 10.40 | 124 | 493841 | 30714 | 63974053 |
Panniculitis | 31.88 | 10.40 | 14 | 493951 | 8865 | 63995902 |
No adverse event | 31.78 | 10.40 | 112 | 493853 | 28449 | 63976318 |
Unevaluable event | 31.75 | 10.40 | 241 | 493724 | 50248 | 63954519 |
Anxiety | 31.59 | 10.40 | 1250 | 492715 | 201399 | 63803368 |
Pneumothorax | 31.45 | 10.40 | 89 | 493876 | 24209 | 63980558 |
Immunodeficiency | 31.09 | 10.40 | 47 | 493918 | 16077 | 63988690 |
Asthenia | 31.05 | 10.40 | 3738 | 490227 | 424306 | 63580461 |
Dry eye | 30.83 | 10.40 | 116 | 493849 | 28903 | 63975864 |
Blindness transient | 30.76 | 10.40 | 85 | 493880 | 4037 | 64000730 |
Complications of transplanted kidney | 30.74 | 10.40 | 3 | 493962 | 5432 | 63999335 |
Peritonitis | 30.69 | 10.40 | 94 | 493871 | 24929 | 63979838 |
Erythema | 30.67 | 10.40 | 1147 | 492818 | 185923 | 63818844 |
Ulcer | 30.66 | 10.40 | 83 | 493882 | 22907 | 63981860 |
Bradyarrhythmia | 30.57 | 10.40 | 80 | 493885 | 3678 | 64001089 |
Haematuria | 30.51 | 10.40 | 641 | 493324 | 59830 | 63944937 |
Blood triglycerides increased | 30.48 | 10.40 | 248 | 493717 | 18618 | 63986149 |
Medication error | 30.42 | 10.40 | 545 | 493420 | 49421 | 63955346 |
Obstructive pancreatitis | 30.16 | 10.40 | 31 | 493934 | 632 | 64004135 |
5-hydroxyindolacetic acid in urine increased | 30.04 | 10.40 | 20 | 493945 | 214 | 64004553 |
Blood mercury abnormal | 29.78 | 10.40 | 19 | 493946 | 188 | 64004579 |
Hypoxia | 29.74 | 10.40 | 485 | 493480 | 87664 | 63917103 |
Device related infection | 29.65 | 10.40 | 127 | 493838 | 30499 | 63974268 |
Oxygen saturation decreased | 29.49 | 10.40 | 611 | 493354 | 106565 | 63898202 |
Glomerular filtration rate abnormal | 29.45 | 10.40 | 42 | 493923 | 1217 | 64003550 |
Plasma cell myeloma | 29.42 | 10.40 | 219 | 493746 | 45856 | 63958911 |
Coma | 29.39 | 10.40 | 879 | 493086 | 86736 | 63918031 |
Pseudomonas infection | 29.13 | 10.40 | 58 | 493907 | 17825 | 63986942 |
Blood parathyroid hormone decreased | 29.11 | 10.40 | 10 | 493955 | 7356 | 63997411 |
Bursitis | 29.08 | 10.40 | 77 | 493888 | 21408 | 63983359 |
Status epilepticus | 29.05 | 10.40 | 78 | 493887 | 21585 | 63983182 |
Complication associated with device | 29.04 | 10.40 | 44 | 493921 | 15036 | 63989731 |
Aggression | 28.92 | 10.40 | 221 | 493744 | 46011 | 63958756 |
Fibromyalgia | 28.88 | 10.40 | 158 | 493807 | 35573 | 63969194 |
Myelodysplastic syndrome | 28.81 | 10.40 | 111 | 493854 | 27468 | 63977299 |
Allergic reaction to excipient | 28.70 | 10.40 | 20 | 493945 | 232 | 64004535 |
Pulmonary haemorrhage | 28.52 | 10.40 | 35 | 493930 | 13074 | 63991693 |
Wrong patient received product | 28.50 | 10.40 | 78 | 493887 | 3684 | 64001083 |
Lumbosacral radiculoplexus neuropathy | 28.46 | 10.40 | 13 | 493952 | 60 | 64004707 |
Serotonin syndrome | 28.40 | 10.40 | 180 | 493785 | 39102 | 63965665 |
Insomnia | 28.36 | 10.40 | 1232 | 492733 | 196604 | 63808163 |
Haemoptysis | 28.14 | 10.40 | 240 | 493725 | 48808 | 63955959 |
Atrioventricular block complete | 28.06 | 10.40 | 198 | 493767 | 14220 | 63990547 |
Myopathy | 27.80 | 10.40 | 231 | 493734 | 17449 | 63987318 |
Chills | 27.59 | 10.40 | 820 | 493145 | 136444 | 63868323 |
Hypoparathyroidism | 27.55 | 10.40 | 34 | 493931 | 853 | 64003914 |
Decreased appetite | 27.55 | 10.40 | 2507 | 491458 | 278782 | 63725985 |
Cerebral venous thrombosis | 27.51 | 10.40 | 59 | 493906 | 2382 | 64002385 |
Urinary tract discomfort | 27.44 | 10.40 | 22 | 493943 | 320 | 64004447 |
Hypocalcaemia | 27.42 | 10.40 | 461 | 493504 | 41292 | 63963475 |
Product monitoring error | 27.35 | 10.40 | 98 | 493867 | 5356 | 63999411 |
Disease recurrence | 27.34 | 10.40 | 136 | 493829 | 31374 | 63973393 |
Leukocytosis | 27.14 | 10.40 | 423 | 493542 | 37317 | 63967450 |
Enterococcal infection | 27.14 | 10.40 | 40 | 493925 | 13826 | 63990941 |
Generalised tonic-clonic seizure | 27.12 | 10.40 | 186 | 493779 | 39671 | 63965096 |
Hyperventilation | 27.03 | 10.40 | 114 | 493851 | 6726 | 63998041 |
Ascites | 27.02 | 10.40 | 324 | 493641 | 61677 | 63943090 |
Tinnitus | 27.01 | 10.40 | 152 | 493813 | 33981 | 63970786 |
Blood insulin decreased | 26.97 | 10.40 | 9 | 493956 | 13 | 64004754 |
Device use error | 26.97 | 10.40 | 8 | 493957 | 6463 | 63998304 |
Blood pressure fluctuation | 26.64 | 10.40 | 261 | 493704 | 51610 | 63953157 |
Constipation | 26.64 | 10.40 | 1460 | 492505 | 227877 | 63776890 |
Cholestatic liver injury | 26.61 | 10.40 | 75 | 493890 | 3604 | 64001163 |
Coma scale abnormal | 26.52 | 10.40 | 124 | 493841 | 7650 | 63997117 |
Haemofiltration | 26.51 | 10.40 | 12 | 493953 | 54 | 64004713 |
Acquired phimosis | 26.32 | 10.40 | 11 | 493954 | 39 | 64004728 |
Body mass index increased | 26.23 | 10.40 | 45 | 493920 | 1534 | 64003233 |
Osteoarthritis | 26.09 | 10.40 | 335 | 493630 | 63001 | 63941766 |
Blood calcium decreased | 25.96 | 10.40 | 104 | 493861 | 25450 | 63979317 |
Chronic sinusitis | 25.82 | 10.40 | 8 | 493957 | 6284 | 63998483 |
Hypoaesthesia | 25.77 | 10.40 | 840 | 493125 | 138268 | 63866499 |
Metabolic syndrome | 25.60 | 10.40 | 56 | 493909 | 2292 | 64002475 |
Tumour lysis syndrome | 25.31 | 10.40 | 71 | 493894 | 19369 | 63985398 |
Respiratory syncytial virus infection | 25.25 | 10.40 | 12 | 493953 | 7256 | 63997511 |
Anaphylactic reaction | 25.12 | 10.40 | 372 | 493593 | 68292 | 63936475 |
Device issue | 25.07 | 10.40 | 89 | 493876 | 22559 | 63982208 |
Respiratory arrest | 25.00 | 10.40 | 272 | 493693 | 52713 | 63952054 |
Type V hyperlipidaemia | 24.94 | 10.40 | 33 | 493932 | 889 | 64003878 |
Foot deformity | 24.81 | 10.40 | 56 | 493909 | 16448 | 63988319 |
Pain in extremity | 24.80 | 10.40 | 1991 | 491974 | 301094 | 63703673 |
Insulin-like growth factor increased | 24.75 | 10.40 | 45 | 493920 | 1607 | 64003160 |
Cardiogenic shock | 24.69 | 10.40 | 367 | 493598 | 32060 | 63972707 |
Cytomegalovirus chorioretinitis | 24.66 | 10.40 | 4 | 493961 | 4908 | 63999859 |
Tongue oedema | 24.59 | 10.40 | 101 | 493864 | 5889 | 63998878 |
Conjunctivitis | 24.58 | 10.40 | 77 | 493888 | 20277 | 63984490 |
Apolipoprotein A-I decreased | 24.54 | 10.40 | 9 | 493956 | 20 | 64004747 |
Epistaxis | 24.53 | 10.40 | 568 | 493397 | 97563 | 63907204 |
Lung disorder | 24.29 | 10.40 | 323 | 493642 | 60377 | 63944390 |
Ileus | 24.27 | 10.40 | 92 | 493873 | 22874 | 63981893 |
Burkholderia pseudomallei infection | 24.02 | 10.40 | 10 | 493955 | 35 | 64004732 |
Tubulointerstitial nephritis | 24.00 | 10.40 | 351 | 493614 | 30558 | 63974209 |
Blood pressure systolic increased | 23.91 | 10.40 | 521 | 493444 | 48932 | 63955835 |
Erythromelalgia | 23.89 | 10.40 | 16 | 493949 | 173 | 64004594 |
Hyponatraemia | 23.78 | 10.40 | 1376 | 492589 | 146963 | 63857804 |
Musculoskeletal disorder | 23.61 | 10.40 | 65 | 493900 | 17841 | 63986926 |
Brain oedema | 23.61 | 10.40 | 88 | 493877 | 21987 | 63982780 |
Liver disorder | 23.55 | 10.40 | 278 | 493687 | 53073 | 63951694 |
Body temperature increased | 23.54 | 10.40 | 174 | 493791 | 36492 | 63968275 |
Bacteraemia | 23.43 | 10.40 | 116 | 493849 | 26795 | 63977972 |
Graft versus host disease in skin | 23.43 | 10.40 | 6 | 493959 | 5341 | 63999426 |
Injection site warmth | 23.39 | 10.40 | 42 | 493923 | 13420 | 63991347 |
Bone density decreased | 23.35 | 10.40 | 25 | 493940 | 9927 | 63994840 |
Pancreatic pseudocyst | 23.27 | 10.40 | 38 | 493927 | 1243 | 64003524 |
Antipsychotic drug level increased | 23.21 | 10.40 | 89 | 493876 | 5026 | 63999741 |
Macular oedema | 23.18 | 10.40 | 86 | 493879 | 4781 | 63999986 |
Abnormal loss of weight | 23.05 | 10.40 | 115 | 493850 | 7285 | 63997482 |
Device dislocation | 22.93 | 10.40 | 84 | 493881 | 21094 | 63983673 |
Infusion site erythema | 22.90 | 10.40 | 12 | 493953 | 6861 | 63997906 |
Femur fracture | 22.88 | 10.40 | 160 | 493805 | 33975 | 63970792 |
Polymyalgia rheumatica | 22.86 | 10.40 | 67 | 493898 | 3292 | 64001475 |
Cytopenia | 22.85 | 10.40 | 53 | 493912 | 15418 | 63989349 |
Drug ineffective for unapproved indication | 22.85 | 10.40 | 142 | 493823 | 30991 | 63973776 |
Colitis | 22.83 | 10.40 | 314 | 493651 | 58360 | 63946407 |
Retroperitoneal fibrosis | 22.82 | 10.40 | 25 | 493940 | 550 | 64004217 |
Joint range of motion decreased | 22.78 | 10.40 | 74 | 493891 | 19269 | 63985498 |
Coordination abnormal | 22.73 | 10.40 | 194 | 493771 | 14770 | 63989997 |
Vitamin B1 deficiency | 22.64 | 10.40 | 25 | 493940 | 555 | 64004212 |
Actinic elastosis | 22.63 | 10.40 | 10 | 493955 | 42 | 64004725 |
Pulseless electrical activity | 22.53 | 10.40 | 171 | 493794 | 12568 | 63992199 |
Resuscitation | 22.46 | 10.40 | 49 | 493916 | 2002 | 64002765 |
Anion gap abnormal | 22.34 | 10.40 | 24 | 493941 | 516 | 64004251 |
Atrial fibrillation | 22.30 | 10.40 | 1559 | 492406 | 169530 | 63835237 |
Central obesity | 22.27 | 10.40 | 40 | 493925 | 1415 | 64003352 |
Swollen tongue | 22.25 | 10.40 | 384 | 493581 | 34570 | 63970197 |
Enterocolitis | 22.25 | 10.40 | 36 | 493929 | 11982 | 63992785 |
Haemorrhage | 22.23 | 10.40 | 451 | 493514 | 78900 | 63925867 |
Adrenal adenoma | 22.14 | 10.40 | 33 | 493932 | 996 | 64003771 |
Cytomegalovirus test positive | 22.11 | 10.40 | 6 | 493959 | 5138 | 63999629 |
Pneumonia aspiration | 22.07 | 10.40 | 320 | 493645 | 58951 | 63945816 |
Temperature perception test abnormal | 22.05 | 10.40 | 8 | 493957 | 17 | 64004750 |
Neuropathy vitamin B12 deficiency | 21.95 | 10.40 | 9 | 493956 | 30 | 64004737 |
Balanitis candida | 21.87 | 10.40 | 13 | 493952 | 112 | 64004655 |
Non-alcoholic steatohepatitis | 21.79 | 10.40 | 47 | 493918 | 1905 | 64002862 |
Cardiotoxicity | 21.76 | 10.40 | 28 | 493937 | 10246 | 63994521 |
Joint effusion | 21.69 | 10.40 | 44 | 493921 | 13429 | 63991338 |
PO2 increased | 21.55 | 10.40 | 40 | 493925 | 1452 | 64003315 |
Febrile bone marrow aplasia | 21.52 | 10.40 | 33 | 493932 | 11222 | 63993545 |
Back pain | 21.45 | 10.40 | 1637 | 492328 | 248534 | 63756233 |
Vitreous haemorrhage | 21.44 | 10.40 | 62 | 493903 | 3023 | 64001744 |
Sepsis | 21.39 | 10.40 | 1497 | 492468 | 228844 | 63775923 |
Pernicious anaemia | 21.31 | 10.40 | 24 | 493941 | 545 | 64004222 |
Malnutrition | 21.28 | 10.40 | 75 | 493890 | 19050 | 63985717 |
Injection site swelling | 21.27 | 10.40 | 208 | 493757 | 41145 | 63963622 |
Nipple inflammation | 21.26 | 10.40 | 10 | 493955 | 50 | 64004717 |
Dysentery | 21.22 | 10.40 | 30 | 493935 | 862 | 64003905 |
Substance abuse | 21.08 | 10.40 | 24 | 493941 | 9268 | 63995499 |
Hepatojugular reflux | 21.06 | 10.40 | 23 | 493942 | 504 | 64004263 |
Liver palpable | 21.03 | 10.40 | 19 | 493946 | 328 | 64004439 |
Urine output increased | 20.99 | 10.40 | 45 | 493920 | 1816 | 64002951 |
Erectile dysfunction | 20.95 | 10.40 | 167 | 493798 | 12460 | 63992307 |
Neuroendocrine tumour | 20.93 | 10.40 | 34 | 493931 | 1107 | 64003660 |
Aplasia pure red cell | 20.89 | 10.40 | 14 | 493951 | 7000 | 63997767 |
Grip strength decreased | 20.89 | 10.40 | 36 | 493929 | 11688 | 63993079 |
Hyperinsulinaemic hypoglycaemia | 20.86 | 10.40 | 13 | 493952 | 123 | 64004644 |
Injection site bruising | 20.85 | 10.40 | 178 | 493787 | 36195 | 63968572 |
Blood chloride decreased | 20.85 | 10.40 | 112 | 493853 | 7304 | 63997463 |
Anovulatory cycle | 20.82 | 10.40 | 12 | 493953 | 97 | 64004670 |
Haemoglobin decreased | 20.62 | 10.40 | 1253 | 492712 | 193810 | 63810957 |
Neoplasm malignant | 20.60 | 10.40 | 108 | 493857 | 24580 | 63980187 |
Hemiparesis | 20.58 | 10.40 | 332 | 493633 | 29495 | 63975272 |
Suicidal ideation | 20.54 | 10.40 | 372 | 493593 | 66170 | 63938597 |
Psoriatic arthropathy | 20.49 | 10.40 | 222 | 493743 | 43059 | 63961708 |
Product administered to patient of inappropriate age | 20.48 | 10.40 | 5 | 493960 | 4596 | 64000171 |
Large intestine perforation | 20.42 | 10.40 | 41 | 493924 | 12563 | 63992204 |
Ischaemic cardiomyopathy | 20.42 | 10.40 | 105 | 493860 | 6733 | 63998034 |
Hallucination | 20.30 | 10.40 | 414 | 493551 | 72374 | 63932393 |
Adverse event | 20.15 | 10.40 | 199 | 493766 | 39290 | 63965477 |
Joint stiffness | 20.14 | 10.40 | 143 | 493822 | 30261 | 63974506 |
Postmenopausal haemorrhage | 20.13 | 10.40 | 38 | 493927 | 1397 | 64003370 |
Pulmonary arterial hypertension | 20.05 | 10.40 | 113 | 493852 | 25254 | 63979513 |
IIIrd nerve paresis | 20.04 | 10.40 | 14 | 493951 | 163 | 64004604 |
Blood phosphorus increased | 19.99 | 10.40 | 83 | 493882 | 4863 | 63999904 |
Neuropathic arthropathy | 19.96 | 10.40 | 18 | 493947 | 310 | 64004457 |
Mydriasis | 19.88 | 10.40 | 56 | 493909 | 15256 | 63989511 |
Hypogammaglobulinaemia | 19.88 | 10.40 | 30 | 493935 | 10269 | 63994498 |
Starvation ketoacidosis | 19.84 | 10.40 | 12 | 493953 | 107 | 64004660 |
Necrotising myositis | 19.71 | 10.40 | 29 | 493936 | 865 | 64003902 |
Upper respiratory tract infection | 19.71 | 10.40 | 416 | 493549 | 72369 | 63932398 |
Throat irritation | 19.70 | 10.40 | 158 | 493807 | 32553 | 63972214 |
Nipple disorder | 19.69 | 10.40 | 14 | 493951 | 168 | 64004599 |
Fixed eruption | 19.69 | 10.40 | 48 | 493917 | 2111 | 64002656 |
Alveolar osteitis | 19.69 | 10.40 | 20 | 493945 | 402 | 64004365 |
Haematocrit decreased | 19.68 | 10.40 | 297 | 493668 | 54358 | 63950409 |
Diabetic ulcer | 19.66 | 10.40 | 16 | 493949 | 238 | 64004529 |
Multiple organ dysfunction syndrome | 19.51 | 10.40 | 957 | 493008 | 100456 | 63904311 |
Birt-Hogg-Dube syndrome | 19.40 | 10.40 | 5 | 493960 | 0 | 64004767 |
Cold sweat | 19.33 | 10.40 | 202 | 493763 | 16253 | 63988514 |
Drug eruption | 19.33 | 10.40 | 180 | 493785 | 35956 | 63968811 |
Pelvic fracture | 19.22 | 10.40 | 32 | 493933 | 10531 | 63994236 |
Pulmonary valve disease | 19.17 | 10.40 | 16 | 493949 | 247 | 64004520 |
Diabetes mellitus management | 19.17 | 10.40 | 6 | 493959 | 6 | 64004761 |
Pancreatitis haemorrhagic | 19.10 | 10.40 | 23 | 493942 | 562 | 64004205 |
Food aversion | 18.91 | 10.40 | 25 | 493940 | 673 | 64004094 |
Drug withdrawal syndrome | 18.91 | 10.40 | 151 | 493814 | 31140 | 63973627 |
Hyperinsulinaemia | 18.89 | 10.40 | 14 | 493951 | 180 | 64004587 |
Ischaemic stroke | 18.86 | 10.40 | 320 | 493645 | 28715 | 63976052 |
Dysarthria | 18.85 | 10.40 | 592 | 493373 | 58814 | 63945953 |
Poisoning | 18.82 | 10.40 | 253 | 493712 | 21626 | 63983141 |
Deep vein thrombosis | 18.80 | 10.40 | 638 | 493327 | 104544 | 63900223 |
Thrombosis | 18.76 | 10.40 | 405 | 493560 | 70237 | 63934530 |
Hyperoxaluria | 18.75 | 10.40 | 16 | 493949 | 255 | 64004512 |
Aplastic anaemia | 18.75 | 10.40 | 50 | 493915 | 13870 | 63990897 |
Malabsorption | 18.68 | 10.40 | 75 | 493890 | 4328 | 64000439 |
Cystitis haemorrhagic | 18.65 | 10.40 | 20 | 493945 | 7936 | 63996831 |
Intentional self-injury | 18.56 | 10.40 | 138 | 493827 | 28906 | 63975861 |
Colitis ulcerative | 18.52 | 10.40 | 102 | 493863 | 22926 | 63981841 |
Viral infection | 18.49 | 10.40 | 182 | 493783 | 35958 | 63968809 |
Bundle branch block left | 18.49 | 10.40 | 136 | 493829 | 9898 | 63994869 |
Peripheral sensory neuropathy | 18.45 | 10.40 | 37 | 493928 | 11341 | 63993426 |
Renal oncocytoma | 18.42 | 10.40 | 10 | 493955 | 71 | 64004696 |
Albumin urine present | 18.41 | 10.40 | 24 | 493941 | 637 | 64004130 |
Diabetic hyperosmolar coma | 18.41 | 10.40 | 25 | 493940 | 691 | 64004076 |
Venoocclusive disease | 18.39 | 10.40 | 4 | 493961 | 3981 | 64000786 |
Pulmonary tuberculosis | 18.37 | 10.40 | 17 | 493948 | 7227 | 63997540 |
Dizziness | 18.36 | 10.40 | 3647 | 490318 | 426516 | 63578251 |
Incorrect route of product administration | 18.30 | 10.40 | 104 | 493861 | 23194 | 63981573 |
Blood cholesterol | 18.28 | 10.40 | 18 | 493947 | 348 | 64004419 |
Staphylococcal bacteraemia | 18.27 | 10.40 | 32 | 493933 | 10323 | 63994444 |
Glomerular filtration rate increased | 18.20 | 10.40 | 21 | 493944 | 490 | 64004277 |
Akathisia | 18.18 | 10.40 | 38 | 493927 | 11472 | 63993295 |
Vitamin B1 decreased | 18.15 | 10.40 | 17 | 493948 | 308 | 64004459 |
Exercise tolerance decreased | 18.11 | 10.40 | 111 | 493854 | 7599 | 63997168 |
Left ventricular dysfunction | 18.02 | 10.40 | 204 | 493761 | 16750 | 63988017 |
Cytomegalovirus colitis | 18.01 | 10.40 | 4 | 493961 | 3924 | 64000843 |
Bone pain | 18.00 | 10.40 | 256 | 493709 | 47316 | 63957451 |
Anaemia macrocytic | 17.93 | 10.40 | 74 | 493891 | 4324 | 64000443 |
Hepatic vein dilatation | 17.90 | 10.40 | 15 | 493950 | 233 | 64004534 |
Lymphadenopathy | 17.75 | 10.40 | 251 | 493714 | 46435 | 63958332 |
Red blood cell count decreased | 17.75 | 10.40 | 262 | 493703 | 48124 | 63956643 |
Atelectasis | 17.69 | 10.40 | 129 | 493836 | 27137 | 63977630 |
Pneumonitis | 17.69 | 10.40 | 275 | 493690 | 50090 | 63954677 |
Pneumatosis intestinalis | 17.61 | 10.40 | 9 | 493956 | 5220 | 63999547 |
Overweight | 17.53 | 10.40 | 61 | 493904 | 3285 | 64001482 |
Pulmonary toxicity | 17.45 | 10.40 | 24 | 493941 | 8537 | 63996230 |
Product quality issue | 17.42 | 10.40 | 323 | 493642 | 29476 | 63975291 |
Blood creatine phosphokinase increased | 17.40 | 10.40 | 579 | 493386 | 57979 | 63946788 |
Rhinovirus infection | 17.40 | 10.40 | 13 | 493952 | 6143 | 63998624 |
Hypertensive crisis | 17.37 | 10.40 | 215 | 493750 | 18033 | 63986734 |
Disseminated intravascular coagulation | 17.36 | 10.40 | 161 | 493804 | 32187 | 63972580 |
Prothrombin consumption time prolonged | 17.33 | 10.40 | 8 | 493957 | 38 | 64004729 |
Aphasia | 17.31 | 10.40 | 423 | 493542 | 40483 | 63964284 |
Labelled drug-disease interaction medication error | 17.26 | 10.40 | 16 | 493949 | 286 | 64004481 |
Dysuria | 17.23 | 10.40 | 433 | 493532 | 41624 | 63963143 |
Urosepsis | 17.19 | 10.40 | 251 | 493714 | 21843 | 63982924 |
Intercapillary glomerulosclerosis | 17.17 | 10.40 | 9 | 493956 | 59 | 64004708 |
Urine albumin/creatinine ratio increased | 17.17 | 10.40 | 17 | 493948 | 331 | 64004436 |
Neutropenic sepsis | 17.15 | 10.40 | 106 | 493859 | 23166 | 63981601 |
Brain stem infarction | 17.13 | 10.40 | 41 | 493924 | 1782 | 64002985 |
Albuminuria | 17.12 | 10.40 | 23 | 493942 | 629 | 64004138 |
Wrong technique in product usage process | 17.11 | 10.40 | 373 | 493592 | 64601 | 63940166 |
Scrotal cyst | 17.07 | 10.40 | 5 | 493960 | 3 | 64004764 |
Cutaneous vasculitis | 17.02 | 10.40 | 96 | 493869 | 6377 | 63998390 |
Methaemoglobinaemia | 17.02 | 10.40 | 6 | 493959 | 4342 | 64000425 |
Cerebellar ischaemia | 16.95 | 10.40 | 12 | 493953 | 143 | 64004624 |
Leukoencephalopathy | 16.91 | 10.40 | 17 | 493948 | 6950 | 63997817 |
Pleural fibrosis | 16.89 | 10.40 | 5 | 493960 | 4045 | 64000722 |
Blood growth hormone abnormal | 16.85 | 10.40 | 8 | 493957 | 41 | 64004726 |
Mitochondrial enzyme deficiency | 16.71 | 10.40 | 7 | 493958 | 25 | 64004742 |
CD30 expression | 16.70 | 10.40 | 8 | 493957 | 42 | 64004725 |
Drug half-life increased | 16.66 | 10.40 | 11 | 493954 | 116 | 64004651 |
Renal abscess | 16.60 | 10.40 | 27 | 493938 | 880 | 64003887 |
Sensory loss | 16.60 | 10.40 | 134 | 493831 | 10035 | 63994732 |
Microcytic anaemia | 16.58 | 10.40 | 75 | 493890 | 4563 | 64000204 |
Decreased bronchial secretion | 16.57 | 10.40 | 9 | 493956 | 64 | 64004703 |
Product appearance confusion | 16.55 | 10.40 | 8 | 493957 | 43 | 64004724 |
Tooth disorder | 16.53 | 10.40 | 102 | 493863 | 22300 | 63982467 |
Purpura | 16.40 | 10.40 | 72 | 493893 | 17174 | 63987593 |
Azotaemia | 16.38 | 10.40 | 106 | 493859 | 7396 | 63997371 |
Pulmonary alveolar haemorrhage | 16.37 | 10.40 | 31 | 493934 | 9707 | 63995060 |
Fibrillary glomerulonephritis | 16.26 | 10.40 | 8 | 493957 | 45 | 64004722 |
Diabetic gangrene | 16.08 | 10.40 | 12 | 493953 | 156 | 64004611 |
Intestinal obstruction | 16.05 | 10.40 | 189 | 493776 | 36097 | 63968670 |
Therapy partial responder | 16.04 | 10.40 | 34 | 493931 | 10214 | 63994553 |
Hepatic neoplasm | 16.04 | 10.40 | 56 | 493909 | 3021 | 64001746 |
Transfusion | 15.99 | 10.40 | 77 | 493888 | 17917 | 63986850 |
Foreign body aspiration | 15.96 | 10.40 | 15 | 493950 | 273 | 64004494 |
Pneumonia viral | 15.87 | 10.40 | 22 | 493943 | 7800 | 63996967 |
Neuropathy, ataxia, retinitis pigmentosa syndrome | 15.84 | 10.40 | 8 | 493957 | 48 | 64004719 |
Phimosis | 15.83 | 10.40 | 18 | 493947 | 413 | 64004354 |
Liver function test increased | 15.83 | 10.40 | 156 | 493809 | 30814 | 63973953 |
Encephalitis toxic | 15.83 | 10.40 | 15 | 493950 | 276 | 64004491 |
Tongue disorder | 15.82 | 10.40 | 44 | 493921 | 12036 | 63992731 |
Prostatitis | 15.76 | 10.40 | 62 | 493903 | 3544 | 64001223 |
Drug specific antibody present | 15.74 | 10.40 | 10 | 493955 | 5144 | 63999623 |
Bacterial infection | 15.73 | 10.40 | 119 | 493846 | 24831 | 63979936 |
Diffuse large B-cell lymphoma | 15.70 | 10.40 | 35 | 493930 | 10326 | 63994441 |
Unresponsive to stimuli | 15.68 | 10.40 | 501 | 493464 | 49892 | 63954875 |
Cardiovascular insufficiency | 15.67 | 10.40 | 50 | 493915 | 2574 | 64002193 |
Therapeutic drug monitoring analysis not performed | 15.67 | 10.40 | 31 | 493934 | 1181 | 64003586 |
Palmar-plantar erythrodysaesthesia syndrome | 15.65 | 10.40 | 143 | 493822 | 28676 | 63976091 |
Herpes simplex | 15.64 | 10.40 | 36 | 493929 | 10500 | 63994267 |
Pancreatic neuroendocrine tumour | 15.63 | 10.40 | 19 | 493946 | 469 | 64004298 |
Hypoglycaemic seizure | 15.63 | 10.40 | 24 | 493941 | 744 | 64004023 |
Drug use disorder | 15.60 | 10.40 | 14 | 493951 | 6040 | 63998727 |
Blood lactate dehydrogenase increased | 15.53 | 10.40 | 170 | 493795 | 32908 | 63971859 |
Labelled drug-disease interaction issue | 15.52 | 10.40 | 4 | 493961 | 0 | 64004767 |
Atrioventricular node dysfunction | 15.52 | 10.40 | 4 | 493961 | 0 | 64004767 |
Angina unstable | 15.49 | 10.40 | 184 | 493781 | 15283 | 63989484 |
Diabetic complication | 15.48 | 10.40 | 30 | 493935 | 1125 | 64003642 |
Low density lipoprotein decreased | 15.46 | 10.40 | 29 | 493936 | 1061 | 64003706 |
Diabetic vascular disorder | 15.44 | 10.40 | 8 | 493957 | 51 | 64004716 |
Injection site mass | 15.39 | 10.40 | 201 | 493764 | 17069 | 63987698 |
Mechanical ventilation complication | 15.38 | 10.40 | 7 | 493958 | 32 | 64004735 |
Necrotising fasciitis | 15.36 | 10.40 | 81 | 493884 | 5245 | 63999522 |
Haemorrhoids | 15.36 | 10.40 | 114 | 493851 | 23887 | 63980880 |
Pneumonia cytomegaloviral | 15.33 | 10.40 | 7 | 493958 | 4332 | 64000435 |
Synovial cyst | 15.31 | 10.40 | 22 | 493943 | 7685 | 63997082 |
Granuloma | 15.23 | 10.40 | 17 | 493948 | 6624 | 63998143 |
Congenital hydrocephalus | 15.21 | 10.40 | 7 | 493958 | 33 | 64004734 |
Hypoaesthesia eye | 15.19 | 10.40 | 9 | 493956 | 77 | 64004690 |
Multiple sclerosis | 15.17 | 10.40 | 84 | 493881 | 18857 | 63985910 |
Pericardial disease | 15.14 | 10.40 | 19 | 493946 | 485 | 64004282 |
Insulin C-peptide increased | 15.10 | 10.40 | 10 | 493955 | 106 | 64004661 |
Vascular device infection | 15.09 | 10.40 | 15 | 493950 | 6165 | 63998602 |
Spinal compression fracture | 15.09 | 10.40 | 60 | 493905 | 14715 | 63990052 |
Pancreatic mass | 15.08 | 10.40 | 33 | 493932 | 1351 | 64003416 |
Medullary thyroid cancer | 15.07 | 10.40 | 11 | 493954 | 138 | 64004629 |
Duodenal ulcer | 15.03 | 10.40 | 173 | 493792 | 14262 | 63990505 |
Motor dysfunction | 15.00 | 10.40 | 143 | 493822 | 11230 | 63993537 |
Bronchitis | 14.99 | 10.40 | 680 | 493285 | 108063 | 63896704 |
Virologic failure | 14.98 | 10.40 | 4 | 493961 | 3462 | 64001305 |
Blood growth hormone increased | 14.92 | 10.40 | 21 | 493944 | 601 | 64004166 |
Catheter site infection | 14.87 | 10.40 | 13 | 493952 | 5680 | 63999087 |
Genital swelling | 14.86 | 10.40 | 15 | 493950 | 299 | 64004468 |
Low density lipoprotein abnormal | 14.86 | 10.40 | 15 | 493950 | 299 | 64004468 |
Creatinine renal clearance | 14.86 | 10.40 | 6 | 493959 | 19 | 64004748 |
Intracranial pressure increased | 14.85 | 10.40 | 19 | 493946 | 6970 | 63997797 |
Fear of injection | 14.85 | 10.40 | 14 | 493951 | 5898 | 63998869 |
Septic shock | 14.80 | 10.40 | 658 | 493307 | 104779 | 63899988 |
Blindness | 14.78 | 10.40 | 244 | 493721 | 21775 | 63982992 |
Parainfluenzae virus infection | 14.77 | 10.40 | 9 | 493956 | 4734 | 64000033 |
Lupus-like syndrome | 14.76 | 10.40 | 28 | 493937 | 8763 | 63996004 |
Skin necrosis | 14.76 | 10.40 | 58 | 493907 | 14271 | 63990496 |
Drug level below therapeutic | 14.75 | 10.40 | 21 | 493944 | 7363 | 63997404 |
Bone disorder | 14.73 | 10.40 | 72 | 493893 | 16687 | 63988080 |
Hyperhidrosis | 14.69 | 10.40 | 1129 | 492836 | 123791 | 63880976 |
Oesophagitis | 14.69 | 10.40 | 101 | 493864 | 21529 | 63983238 |
Nodular rash | 14.63 | 10.40 | 15 | 493950 | 305 | 64004462 |
Ventricular enlargement | 14.59 | 10.40 | 19 | 493946 | 504 | 64004263 |
Expired product administered | 14.58 | 10.40 | 87 | 493878 | 5900 | 63998867 |
Jaundice hepatocellular | 14.57 | 10.40 | 10 | 493955 | 113 | 64004654 |
Musculoskeletal pain | 14.55 | 10.40 | 493 | 493472 | 80801 | 63923966 |
Herbal interaction | 14.46 | 10.40 | 17 | 493948 | 405 | 64004362 |
Cholecystitis chronic | 14.42 | 10.40 | 121 | 493844 | 9166 | 63995601 |
Paraesthesia | 14.40 | 10.40 | 863 | 493102 | 133659 | 63871108 |
Bronchostenosis | 14.30 | 10.40 | 20 | 493945 | 569 | 64004198 |
Device malfunction | 14.23 | 10.40 | 78 | 493887 | 17555 | 63987212 |
Skin turgor decreased | 14.23 | 10.40 | 21 | 493944 | 628 | 64004139 |
Peripheral arterial occlusive disease | 14.21 | 10.40 | 97 | 493868 | 6890 | 63997877 |
Hyperkinetic heart syndrome | 14.21 | 10.40 | 10 | 493955 | 118 | 64004649 |
Dyskinesia | 14.20 | 10.40 | 214 | 493751 | 39174 | 63965593 |
Atrioventricular block first degree | 14.18 | 10.40 | 135 | 493830 | 10599 | 63994168 |
Varicella zoster virus infection | 14.17 | 10.40 | 6 | 493959 | 3882 | 64000885 |
Cutaneous T-cell dyscrasia | 14.16 | 10.40 | 8 | 493957 | 62 | 64004705 |
Helicobacter gastritis | 14.14 | 10.40 | 43 | 493922 | 2157 | 64002610 |
Pyelonephritis acute | 14.07 | 10.40 | 77 | 493888 | 5057 | 63999710 |
Coma uraemic | 13.99 | 10.40 | 7 | 493958 | 41 | 64004726 |
Wrong dose | 13.99 | 10.40 | 30 | 493935 | 1211 | 64003556 |
Bundle branch block right | 13.98 | 10.40 | 130 | 493835 | 10139 | 63994628 |
Clostridium test positive | 13.98 | 10.40 | 7 | 493958 | 4108 | 64000659 |
Neuropathic ulcer | 13.95 | 10.40 | 8 | 493957 | 64 | 64004703 |
Hepatic enzyme decreased | 13.94 | 10.40 | 9 | 493956 | 91 | 64004676 |
Appendicitis | 13.93 | 10.40 | 55 | 493910 | 13514 | 63991253 |
Respiratory tract infection | 13.91 | 10.40 | 202 | 493763 | 37205 | 63967562 |
Wheezing | 13.88 | 10.40 | 491 | 493474 | 80088 | 63924679 |
Orbital oedema | 13.88 | 10.40 | 14 | 493951 | 279 | 64004488 |
Arrhythmia | 13.87 | 10.40 | 516 | 493449 | 52428 | 63952339 |
Electrolyte imbalance | 13.86 | 10.40 | 271 | 493694 | 24972 | 63979795 |
Scleroderma | 13.84 | 10.40 | 10 | 493955 | 4808 | 63999959 |
Shock hypoglycaemic | 13.82 | 10.40 | 13 | 493952 | 237 | 64004530 |
Pancreatitis necrotising | 13.81 | 10.40 | 55 | 493910 | 3162 | 64001605 |
Mycobacterial infection | 13.79 | 10.40 | 3 | 493962 | 2985 | 64001782 |
Prostatomegaly | 13.77 | 10.40 | 52 | 493913 | 2915 | 64001852 |
Rash erythematous | 13.74 | 10.40 | 276 | 493689 | 48357 | 63956410 |
Paradoxical drug reaction | 13.67 | 10.40 | 16 | 493949 | 6104 | 63998663 |
Aplasia | 13.67 | 10.40 | 20 | 493945 | 6933 | 63997834 |
Cornea verticillata | 13.62 | 10.40 | 9 | 493956 | 95 | 64004672 |
Cerebral haematoma | 13.59 | 10.40 | 98 | 493867 | 7087 | 63997680 |
Muscular weakness | 13.54 | 10.40 | 1142 | 492823 | 126196 | 63878571 |
Diabetic coma | 13.51 | 10.40 | 28 | 493937 | 1103 | 64003664 |
Tunnel vision | 13.48 | 10.40 | 27 | 493938 | 1038 | 64003729 |
Miosis | 13.47 | 10.40 | 54 | 493911 | 13212 | 63991555 |
Genitourinary symptom | 13.47 | 10.40 | 13 | 493952 | 245 | 64004522 |
Treatment noncompliance | 13.45 | 10.40 | 432 | 493533 | 43050 | 63961717 |
Skin papilloma | 13.45 | 10.40 | 12 | 493953 | 5191 | 63999576 |
Electroencephalogram abnormal | 13.45 | 10.40 | 12 | 493953 | 5191 | 63999576 |
Pneumonia fungal | 13.44 | 10.40 | 30 | 493935 | 8847 | 63995920 |
Hyponatraemic encephalopathy | 13.44 | 10.40 | 14 | 493951 | 290 | 64004477 |
Genital rash | 13.44 | 10.40 | 24 | 493941 | 845 | 64003922 |
Extrapyramidal disorder | 13.42 | 10.40 | 91 | 493874 | 19461 | 63985306 |
Clonus | 13.41 | 10.40 | 16 | 493949 | 6051 | 63998716 |
Loss of consciousness | 13.41 | 10.40 | 1315 | 492650 | 147050 | 63857717 |
Pharyngitis streptococcal | 13.37 | 10.40 | 29 | 493936 | 8639 | 63996128 |
Device difficult to use | 13.35 | 10.40 | 35 | 493930 | 9763 | 63995004 |
Diabetic cheiroarthropathy | 13.30 | 10.40 | 4 | 493961 | 3 | 64004764 |
Red blood cells urine positive | 13.26 | 10.40 | 9 | 493956 | 4469 | 64000298 |
Bladder neoplasm | 13.23 | 10.40 | 33 | 493932 | 1473 | 64003294 |
Bacterial sepsis | 13.19 | 10.40 | 23 | 493942 | 7434 | 63997333 |
Gastrointestinal disorder | 13.18 | 10.40 | 557 | 493408 | 89152 | 63915615 |
Infusion site extravasation | 13.11 | 10.40 | 20 | 493945 | 6817 | 63997950 |
Temperature regulation disorder | 13.10 | 10.40 | 8 | 493957 | 4203 | 64000564 |
Genital tract inflammation | 13.08 | 10.40 | 6 | 493959 | 28 | 64004739 |
Retinal artery thrombosis | 13.01 | 10.40 | 9 | 493956 | 103 | 64004664 |
Neck pain | 13.01 | 10.40 | 365 | 493600 | 61168 | 63943599 |
Coeliac disease | 12.99 | 10.40 | 23 | 493942 | 7389 | 63997378 |
Pneumonia bacterial | 12.98 | 10.40 | 65 | 493900 | 14970 | 63989797 |
Osteopenia | 12.96 | 10.40 | 68 | 493897 | 15472 | 63989295 |
Pruritus genital | 12.86 | 10.40 | 26 | 493939 | 1006 | 64003761 |
Urethral intrinsic sphincter deficiency | 12.83 | 10.40 | 5 | 493960 | 14 | 64004753 |
Bladder sphincter atony | 12.80 | 10.40 | 9 | 493956 | 106 | 64004661 |
Lymphoma | 12.78 | 10.40 | 59 | 493906 | 13882 | 63990885 |
Venous aneurysm | 12.78 | 10.40 | 4 | 493961 | 4 | 64004763 |
Carbohydrate metabolism disorder | 12.76 | 10.40 | 6 | 493959 | 30 | 64004737 |
Blood lactic acid abnormal | 12.76 | 10.40 | 6 | 493959 | 30 | 64004737 |
Cardiopulmonary failure | 12.75 | 10.40 | 86 | 493879 | 6084 | 63998683 |
Catheter site erythema | 12.75 | 10.40 | 11 | 493954 | 4838 | 63999929 |
Post-traumatic amnestic disorder | 12.75 | 10.40 | 7 | 493958 | 51 | 64004716 |
Autoimmune pancreatitis | 12.71 | 10.40 | 19 | 493946 | 575 | 64004192 |
Crush syndrome | 12.71 | 10.40 | 11 | 493954 | 179 | 64004588 |
Transient ischaemic attack | 12.65 | 10.40 | 435 | 493530 | 43747 | 63961020 |
Optic neuritis | 12.65 | 10.40 | 27 | 493938 | 8089 | 63996678 |
Rales | 12.64 | 10.40 | 175 | 493790 | 15054 | 63989713 |
Lip swelling | 12.63 | 10.40 | 327 | 493638 | 31580 | 63973187 |
Endometriosis male | 12.58 | 10.40 | 5 | 493960 | 15 | 64004752 |
Bladder pain | 12.58 | 10.40 | 36 | 493929 | 1745 | 64003022 |
Pruritus | 12.58 | 10.40 | 2152 | 491813 | 310248 | 63694519 |
Plasmapheresis | 12.57 | 10.40 | 19 | 493946 | 581 | 64004186 |
Clear cell renal cell carcinoma | 12.54 | 10.40 | 41 | 493924 | 2138 | 64002629 |
Carcinoid tumour of the stomach | 12.51 | 10.40 | 11 | 493954 | 183 | 64004584 |
Hypoperfusion | 12.49 | 10.40 | 43 | 493922 | 2303 | 64002464 |
Blood cholesterol increased | 12.45 | 10.40 | 290 | 493675 | 49776 | 63954991 |
Base excess | 12.38 | 10.40 | 8 | 493957 | 81 | 64004686 |
pH urine decreased | 12.35 | 10.40 | 5 | 493960 | 16 | 64004751 |
Glycosylated haemoglobin | 12.35 | 10.40 | 5 | 493960 | 16 | 64004751 |
Alcoholic ketoacidosis | 12.35 | 10.40 | 5 | 493960 | 16 | 64004751 |
Intervertebral disc degeneration | 12.34 | 10.40 | 55 | 493910 | 13065 | 63991702 |
Ear infection | 12.34 | 10.40 | 117 | 493848 | 23287 | 63981480 |
Gingival oedema | 12.31 | 10.40 | 7 | 493958 | 55 | 64004712 |
Food craving | 12.29 | 10.40 | 31 | 493934 | 1393 | 64003374 |
Cortisol increased | 12.27 | 10.40 | 16 | 493949 | 425 | 64004342 |
Hypochromic anaemia | 12.26 | 10.40 | 43 | 493922 | 2325 | 64002442 |
Cryptococcosis | 12.25 | 10.40 | 3 | 493962 | 2752 | 64002015 |
Myoclonus | 12.23 | 10.40 | 128 | 493837 | 24990 | 63979777 |
Differential white blood cell count abnormal | 12.22 | 10.40 | 36 | 493929 | 1774 | 64002993 |
Premature labour | 12.17 | 10.40 | 25 | 493940 | 7595 | 63997172 |
Central venous catheterisation | 12.16 | 10.40 | 3 | 493962 | 2738 | 64002029 |
Schizophrenia | 12.15 | 10.40 | 135 | 493830 | 11033 | 63993734 |
Blood albumin decreased | 12.14 | 10.40 | 103 | 493862 | 20970 | 63983797 |
Drug abuser | 12.12 | 10.40 | 16 | 493949 | 5792 | 63998975 |
Bladder papilloma | 12.12 | 10.40 | 5 | 493960 | 17 | 64004750 |
Cardiac failure chronic | 12.08 | 10.40 | 114 | 493851 | 8927 | 63995840 |
Joint dislocation | 12.07 | 10.40 | 46 | 493919 | 11419 | 63993348 |
Carcinoid tumour | 12.07 | 10.40 | 16 | 493949 | 432 | 64004335 |
Hyperlipasaemia | 12.06 | 10.40 | 25 | 493940 | 985 | 64003782 |
Adrenal cyst | 12.06 | 10.40 | 8 | 493957 | 85 | 64004682 |
Fungaemia | 12.04 | 10.40 | 7 | 493958 | 3778 | 64000989 |
Acute lymphocytic leukaemia recurrent | 12.04 | 10.40 | 8 | 493957 | 4018 | 64000749 |
Lipids abnormal | 12.01 | 10.40 | 17 | 493948 | 489 | 64004278 |
Small intestinal obstruction | 11.94 | 10.40 | 119 | 493846 | 23454 | 63981313 |
Meningitis | 11.93 | 10.40 | 29 | 493936 | 8300 | 63996467 |
Renal artery thrombosis | 11.93 | 10.40 | 16 | 493949 | 437 | 64004330 |
Neutrophilia | 11.92 | 10.40 | 90 | 493875 | 6604 | 63998163 |
Venous pressure jugular | 11.91 | 10.40 | 5 | 493960 | 18 | 64004749 |
Anaphylactic shock | 11.91 | 10.40 | 162 | 493803 | 30166 | 63974601 |
Mucosal dryness | 11.85 | 10.40 | 50 | 493915 | 2951 | 64001816 |
Eructation | 11.84 | 10.40 | 115 | 493850 | 9076 | 63995691 |
Pyelonephritis | 11.84 | 10.40 | 192 | 493773 | 17074 | 63987693 |
Blood ketone body present | 11.81 | 10.40 | 7 | 493958 | 60 | 64004707 |
Oxygen saturation immeasurable | 11.74 | 10.40 | 6 | 493959 | 37 | 64004730 |
Cellulitis of male external genital organ | 11.74 | 10.40 | 6 | 493959 | 37 | 64004730 |
Acanthosis | 11.71 | 10.40 | 15 | 493950 | 391 | 64004376 |
Foetal death | 11.71 | 10.40 | 17 | 493948 | 5913 | 63998854 |
Physical examination abnormal | 11.66 | 10.40 | 12 | 493953 | 245 | 64004522 |
Oedema | 11.66 | 10.40 | 580 | 493385 | 91355 | 63913412 |
Lichenification | 11.65 | 10.40 | 20 | 493945 | 682 | 64004085 |
Cholangiocarcinoma | 11.64 | 10.40 | 38 | 493927 | 1980 | 64002787 |
Transitional cell carcinoma urethra | 11.64 | 10.40 | 3 | 493962 | 0 | 64004767 |
Malignant neoplasm of thymus | 11.64 | 10.40 | 3 | 493962 | 0 | 64004767 |
Diabetic dyslipidaemia | 11.64 | 10.40 | 3 | 493962 | 0 | 64004767 |
Babinski reflex test | 11.64 | 10.40 | 3 | 493962 | 0 | 64004767 |
Pancreatic enzymes abnormal | 11.64 | 10.40 | 3 | 493962 | 0 | 64004767 |
Diet failure | 11.61 | 10.40 | 6 | 493959 | 38 | 64004729 |
Epileptic encephalopathy | 11.60 | 10.40 | 15 | 493950 | 395 | 64004372 |
Low density lipoprotein increased | 11.57 | 10.40 | 100 | 493865 | 7640 | 63997127 |
Aortic stenosis | 11.57 | 10.40 | 86 | 493879 | 6279 | 63998488 |
Skin induration | 11.57 | 10.40 | 9 | 493956 | 4166 | 64000601 |
Drug-disease interaction | 11.55 | 10.40 | 21 | 493944 | 750 | 64004017 |
Skin disorder | 11.55 | 10.40 | 146 | 493819 | 27534 | 63977233 |
Ankylosing spondylitis | 11.53 | 10.40 | 29 | 493936 | 8205 | 63996562 |
Deformity | 11.53 | 10.40 | 19 | 493946 | 6278 | 63998489 |
Food allergy | 11.51 | 10.40 | 27 | 493938 | 7824 | 63996943 |
Blood glucose normal | 11.50 | 10.40 | 5 | 493960 | 20 | 64004747 |
Thyroid cancer recurrent | 11.50 | 10.40 | 5 | 493960 | 20 | 64004747 |
Product solubility abnormal | 11.50 | 10.40 | 22 | 493943 | 817 | 64003950 |
Peripheral vascular disorder | 11.49 | 10.40 | 95 | 493870 | 7166 | 63997601 |
Arthritis bacterial | 11.46 | 10.40 | 27 | 493938 | 7812 | 63996955 |
Eyelid bleeding | 11.43 | 10.40 | 7 | 493958 | 64 | 64004703 |
Oral candidiasis | 11.42 | 10.40 | 118 | 493847 | 23094 | 63981673 |
Intestinal ischaemia | 11.40 | 10.40 | 137 | 493828 | 11412 | 63993355 |
Coronary artery bypass | 11.40 | 10.40 | 80 | 493885 | 5735 | 63999032 |
Catheter site haemorrhage | 11.38 | 10.40 | 11 | 493954 | 4580 | 64000187 |
Red cell distribution width abnormal | 11.37 | 10.40 | 11 | 493954 | 208 | 64004559 |
Body mass index abnormal | 11.37 | 10.40 | 11 | 493954 | 208 | 64004559 |
Malignant mediastinal neoplasm | 11.31 | 10.40 | 17 | 493948 | 517 | 64004250 |
Blood bicarbonate abnormal | 11.28 | 10.40 | 9 | 493956 | 130 | 64004637 |
Pancreatic enzymes increased | 11.27 | 10.40 | 27 | 493938 | 1174 | 64003593 |
Endoscopy upper gastrointestinal tract | 11.25 | 10.40 | 8 | 493957 | 96 | 64004671 |
Genital infection female | 11.25 | 10.40 | 7 | 493958 | 66 | 64004701 |
Acid base balance abnormal | 11.24 | 10.40 | 13 | 493952 | 304 | 64004463 |
Gamma-glutamyltransferase abnormal | 11.23 | 10.40 | 16 | 493949 | 463 | 64004304 |
Stenosis | 11.22 | 10.40 | 35 | 493930 | 1780 | 64002987 |
Leukaemia recurrent | 11.20 | 10.40 | 3 | 493962 | 2591 | 64002176 |
Respiratory depression | 11.19 | 10.40 | 120 | 493845 | 23323 | 63981444 |
Accidental underdose | 11.17 | 10.40 | 19 | 493946 | 643 | 64004124 |
Acute hepatic failure | 11.17 | 10.40 | 137 | 493828 | 25975 | 63978792 |
Product administration error | 11.14 | 10.40 | 284 | 493681 | 27359 | 63977408 |
Penile infection | 11.13 | 10.40 | 5 | 493960 | 22 | 64004745 |
Hyperphagia | 11.11 | 10.40 | 40 | 493925 | 2191 | 64002576 |
Anaesthetic complication | 11.10 | 10.40 | 3 | 493962 | 2576 | 64002191 |
Blood sodium decreased | 11.05 | 10.40 | 300 | 493665 | 29182 | 63975585 |
Hypertensive angiopathy | 11.05 | 10.40 | 8 | 493957 | 99 | 64004668 |
Right ventricular failure | 11.04 | 10.40 | 108 | 493857 | 21363 | 63983404 |
Gingival hypertrophy | 11.03 | 10.40 | 46 | 493919 | 2701 | 64002066 |
Catheter management | 10.97 | 10.40 | 6 | 493959 | 3349 | 64001418 |
Psychogenic tremor | 10.96 | 10.40 | 5 | 493960 | 23 | 64004744 |
Autoimmune myositis | 10.96 | 10.40 | 10 | 493955 | 175 | 64004592 |
Chronic pigmented purpura | 10.96 | 10.40 | 10 | 493955 | 175 | 64004592 |
Cough | 10.96 | 10.40 | 2093 | 491872 | 300055 | 63704712 |
Drug level decreased | 10.95 | 10.40 | 48 | 493917 | 11455 | 63993312 |
Adrenomegaly | 10.93 | 10.40 | 14 | 493951 | 365 | 64004402 |
Bladder cancer recurrent | 10.87 | 10.40 | 15 | 493950 | 421 | 64004346 |
Hepatosplenomegaly | 10.87 | 10.40 | 15 | 493950 | 5328 | 63999439 |
Left atrial dilatation | 10.85 | 10.40 | 46 | 493919 | 2720 | 64002047 |
Diabetic macroangiopathy | 10.83 | 10.40 | 9 | 493956 | 138 | 64004629 |
Empty sella syndrome | 10.83 | 10.40 | 7 | 493958 | 71 | 64004696 |
Prescription drug used without a prescription | 10.80 | 10.40 | 44 | 493921 | 2556 | 64002211 |
Pancreatic failure | 10.79 | 10.40 | 30 | 493935 | 1430 | 64003337 |
Clostridial infection | 10.79 | 10.40 | 14 | 493951 | 5105 | 63999662 |
Peripheral artery haematoma | 10.78 | 10.40 | 6 | 493959 | 45 | 64004722 |
Psychotic disorder | 10.77 | 10.40 | 193 | 493772 | 34385 | 63970382 |
Infusion site pain | 10.76 | 10.40 | 42 | 493923 | 10355 | 63994412 |
Duodenal ulcer haemorrhage | 10.68 | 10.40 | 84 | 493881 | 6241 | 63998526 |
Upper respiratory tract inflammation | 10.67 | 10.40 | 8 | 493957 | 3774 | 64000993 |
Skin lesion | 10.62 | 10.40 | 206 | 493759 | 36276 | 63968491 |
Inferior vena cava dilatation | 10.62 | 10.40 | 20 | 493945 | 734 | 64004033 |
Enterococcal bacteraemia | 10.62 | 10.40 | 3 | 493962 | 2502 | 64002265 |
Cardiorenal syndrome | 10.57 | 10.40 | 27 | 493938 | 1223 | 64003544 |
Emphysematous pyelonephritis | 10.56 | 10.40 | 11 | 493954 | 228 | 64004539 |
Postoperative wound infection | 10.54 | 10.40 | 42 | 493923 | 10294 | 63994473 |
Blood pressure inadequately controlled | 10.51 | 10.40 | 74 | 493891 | 5310 | 63999457 |
Soft tissue disorder | 10.51 | 10.40 | 6 | 493959 | 3270 | 64001497 |
Increased tendency to bruise | 10.49 | 10.40 | 36 | 493929 | 9219 | 63995548 |
Lichen sclerosus | 10.48 | 10.40 | 22 | 493943 | 875 | 64003892 |
Bladder transitional cell carcinoma stage III | 10.47 | 10.40 | 5 | 493960 | 26 | 64004741 |
Embolism venous | 10.45 | 10.40 | 7 | 493958 | 3500 | 64001267 |
Hypomania | 10.41 | 10.40 | 17 | 493948 | 5637 | 63999130 |
None
Source | Code | Description |
---|---|---|
ATC | A10BA02 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Biguanides |
ATC | A10BD02 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD03 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD05 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD07 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD08 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD10 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD11 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD13 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD14 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD15 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD16 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD17 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD18 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD20 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD22 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD23 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD25 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD26 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD27 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
FDA CS | M0002471 | Biguanides |
FDA EPC | N0000175565 | Biguanide |
MeSH PA | D007004 | Hypoglycemic Agents |
CHEBI has role | CHEBI:35526 | antidiabetic |
CHEBI has role | CHEBI:35703 | Xenobiotic |
CHEBI has role | CHEBI:78298 | environmental contaminants |
CHEBI has role | CHEBI:176497 | geroprotectors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
Treatment Refractory Type 2 Diabetes Mellitus | indication | ||
Gestational diabetes mellitus | off-label use | 11687002 | DOID:11714 |
Polycystic ovaries | off-label use | 69878008 | |
Weight loss | off-label use | 89362005 | |
Polycystic ovary syndrome | off-label use | 237055002 | DOID:11612 |
Prevention of Type 2 Diabetes Mellitus | off-label use | ||
Alcoholism | contraindication | 7200002 | |
Weight gain finding | contraindication | 8943002 | |
Asthenia | contraindication | 13791008 | |
Pulmonary edema | contraindication | 19242006 | DOID:11396 |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Acute vomiting | contraindication | 23971007 | |
Severe adrenal insufficiency | contraindication | 24867002 | |
Alcohol intoxication | contraindication | 25702006 | |
Shock | contraindication | 27942005 | |
Dehydration | contraindication | 34095006 | |
Macular retinal edema | contraindication | 37231002 | DOID:4449 |
Infectious disease | contraindication | 40733004 | |
Body fluid retention | contraindication | 43498006 | |
End stage renal disease | contraindication | 46177005 | DOID:784 |
Chronic heart failure | contraindication | 48447003 | |
Lymphocytopenia | contraindication | 48813009 | DOID:614 |
Hepatic porphyria | contraindication | 55056006 | DOID:3133 |
Ketoacidosis | contraindication | 56051008 | |
Acute nephropathy | contraindication | 58574008 | |
Metabolic acidosis | contraindication | 59455009 | |
Hepatic failure | contraindication | 59927004 | |
Hemolytic anemia | contraindication | 61261009 | DOID:583 |
Glucose-6-phosphate dehydrogenase deficiency anemia | contraindication | 62403005 | |
Acute infectious disease | contraindication | 63171007 | |
Osteoporosis | contraindication | 64859006 | DOID:11476 |
Hypopituitarism | contraindication | 74728003 | DOID:9406 |
Cardiogenic shock | contraindication | 89138009 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Lactic acidosis | contraindication | 91273001 | DOID:3650 |
Fracture of bone | contraindication | 125605004 | |
Liver function tests abnormal | contraindication | 166603001 | |
Cobalamin deficiency | contraindication | 190634004 | |
Angina pectoris | contraindication | 194828000 | |
Decompensated cardiac failure | contraindication | 195111005 | |
Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
Impaired renal function disorder | contraindication | 197663003 | |
Cerebrovascular accident | contraindication | 230690007 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Drug-induced hepatitis | contraindication | 235876009 | |
Hypoglycemic disorder | contraindication | 237630007 | |
Sepsis syndrome | contraindication | 238150007 | |
Edema | contraindication | 267038008 | |
Osteopenia | contraindication | 312894000 | |
Primary adrenocortical insufficiency | contraindication | 373662000 | |
Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
Fever | contraindication | 386661006 | |
Surgical procedure | contraindication | 387713003 | |
Malignant tumor of urinary bladder | contraindication | 399326009 | DOID:11054 |
Severe diarrhea | contraindication | 409587002 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Disorder of coronary artery | contraindication | 414024009 | |
Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
Traumatic injury | contraindication | 417746004 | |
Fever greater than 100.4 Fahrenheit | contraindication | 426000000 | |
Severe Hypoxemia | contraindication | ||
Prolonged-Severe Nausea and Vomiting | contraindication | ||
Radiography with IV Iodinated Contrast Agent | contraindication | ||
Severe Autonomic Insufficiency | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.63 | Basic |
pKa2 | 3.34 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
1GM;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | 6699871 | July 26, 2022 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
1GM;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | 7125873 | July 26, 2022 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN |
1GM;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | 7125873 | July 26, 2022 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST |
1GM;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | 7125873 | July 26, 2022 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN |
500MG;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | 6699871 | July 26, 2022 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
500MG;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | 7125873 | July 26, 2022 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN |
500MG;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | 7125873 | July 26, 2022 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST |
500MG;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | 7125873 | July 26, 2022 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN |
1GM;EQ 100MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | 6699871 | July 26, 2022 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE |
1GM;EQ 100MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | 7125873 | July 26, 2022 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE |
1GM;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | 6699871 | July 26, 2022 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE |
1GM;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | 7125873 | July 26, 2022 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE |
500MG;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | 6699871 | July 26, 2022 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE |
500MG;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | 7125873 | July 26, 2022 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE |
1GM;EQ 2.5MG BASE | KOMBIGLYZE XR | ASTRAZENECA AB | N200678 | Nov. 5, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | RE44186 | July 31, 2023 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE |
1GM;EQ 2.5MG BASE | KOMBIGLYZE XR | ASTRAZENECA AB | N200678 | Nov. 5, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | RE44186 | July 31, 2023 | METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN |
1GM;EQ 5MG BASE | KOMBIGLYZE XR | ASTRAZENECA AB | N200678 | Nov. 5, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | RE44186 | July 31, 2023 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE |
1GM;EQ 5MG BASE | KOMBIGLYZE XR | ASTRAZENECA AB | N200678 | Nov. 5, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | RE44186 | July 31, 2023 | METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN |
500MG;EQ 5MG BASE | KOMBIGLYZE XR | ASTRAZENECA AB | N200678 | Nov. 5, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | RE44186 | July 31, 2023 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE |
500MG;EQ 5MG BASE | KOMBIGLYZE XR | ASTRAZENECA AB | N200678 | Nov. 5, 2010 | RX | TABLET, EXTENDED RELEASE | ORAL | RE44186 | July 31, 2023 | METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN |
10MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | RE44186 | July 31, 2023 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
2.5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | RE44186 | July 31, 2023 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | RE44186 | July 31, 2023 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | RE44186 | July 31, 2023 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
EQ 12.5MG BASE;1GM | KAZANO | TAKEDA PHARMS USA | N203414 | Jan. 25, 2013 | RX | TABLET | ORAL | 8173663 | March 15, 2025 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN |
EQ 12.5MG BASE;500MG | KAZANO | TAKEDA PHARMS USA | N203414 | Jan. 25, 2013 | RX | TABLET | ORAL | 8173663 | March 15, 2025 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN |
150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8222219 | April 11, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
2.5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | July 28, 2017 | RX | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
2.5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 6515117 | Oct. 4, 2025 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
1GM;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | 7326708 | Nov. 24, 2026 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
500MG;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | 7326708 | Nov. 24, 2026 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
1GM;EQ 100MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | 7326708 | Nov. 24, 2026 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE |
1GM;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | 7326708 | Nov. 24, 2026 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE |
500MG;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | 7326708 | Nov. 24, 2026 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9173859 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9173859 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
10MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
2.5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | July 28, 2017 | RX | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
10MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
2.5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
5MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | 8501698 | June 20, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8513202 | Dec. 3, 2027 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
EQ 12.5MG BASE;1GM | KAZANO | TAKEDA PHARMS USA | N203414 | Jan. 25, 2013 | RX | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
EQ 12.5MG BASE;500MG | KAZANO | TAKEDA PHARMS USA | N203414 | Jan. 25, 2013 | RX | TABLET | ORAL | 7807689 | June 27, 2028 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
1GM;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | 8414921 | July 21, 2028 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN |
500MG;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | 8414921 | July 21, 2028 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN |
150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;1GM | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;500MG | INVOKAMET | JANSSEN PHARMS | N204353 | Aug. 8, 2014 | RX | TABLET | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
150MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;1GM | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS |
50MG;500MG | INVOKAMET XR | JANSSEN PHARMS | N205879 | Sept. 20, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 7943582 | Feb. 26, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
10MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8685934 | May 26, 2030 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE |
10MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8685934 | May 26, 2030 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE |
2.5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | July 28, 2017 | RX | TABLET, EXTENDED RELEASE | ORAL | 8685934 | May 26, 2030 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE |
5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8685934 | May 26, 2030 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE |
5MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | 8685934 | May 26, 2030 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8846695 | June 4, 2030 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8846695 | June 4, 2030 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8846695 | June 4, 2030 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10406172 | June 15, 2030 | METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10406172 | June 15, 2030 | METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10406172 | June 15, 2030 | METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10406172 | June 15, 2030 | METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
2.5MG;1GM | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | 8080580 | July 13, 2030 | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES |
2.5MG;500MG | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | 8080580 | July 13, 2030 | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES |
7.5MG;1GM | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | 8080580 | July 13, 2030 | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES |
7.5MG;500MG | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | 8080580 | July 13, 2030 | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES |
2.5MG;1GM | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | 9439902 | Oct. 21, 2030 | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES |
2.5MG;500MG | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | 9439902 | Oct. 21, 2030 | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES |
7.5MG;1GM | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | 9439902 | Oct. 21, 2030 | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES |
7.5MG;500MG | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | 9439902 | Oct. 21, 2030 | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES |
10MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN |
10MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN |
12.5MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN |
12.5MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN |
25MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN |
25MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN |
5MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN |
5MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9555001 | March 6, 2033 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9555001 | March 6, 2033 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9555001 | March 6, 2033 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9555001 | March 6, 2033 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
12.5MG;1GM | SYNJARDY | BOEHRINGER INGELHEIM | N206111 | Aug. 26, 2015 | RX | TABLET | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
12.5MG;1GM | SYNJARDY | BOEHRINGER INGELHEIM | N206111 | Aug. 26, 2015 | RX | TABLET | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2 |
12.5MG;500MG | SYNJARDY | BOEHRINGER INGELHEIM | N206111 | Aug. 26, 2015 | RX | TABLET | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
12.5MG;500MG | SYNJARDY | BOEHRINGER INGELHEIM | N206111 | Aug. 26, 2015 | RX | TABLET | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2 |
5MG;1GM | SYNJARDY | BOEHRINGER INGELHEIM | N206111 | Aug. 26, 2015 | RX | TABLET | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
5MG;1GM | SYNJARDY | BOEHRINGER INGELHEIM | N206111 | Aug. 26, 2015 | RX | TABLET | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2 |
5MG;500MG | SYNJARDY | BOEHRINGER INGELHEIM | N206111 | Aug. 26, 2015 | RX | TABLET | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
5MG;500MG | SYNJARDY | BOEHRINGER INGELHEIM | N206111 | Aug. 26, 2015 | RX | TABLET | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2 |
10MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
10MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2 |
12.5MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
12.5MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2 |
25MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
25MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2 |
5MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
5MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2 |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2 |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2 |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2 |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2 |
10MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
12.5MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
25MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
5MG;1GM | SYNJARDY XR | BOEHRINGER INGELHEIM | N208658 | Dec. 9, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
10MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | May 2, 2022 | NEW PRODUCT |
2.5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | May 2, 2022 | NEW PRODUCT |
5MG;1GM;EQ 2.5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | May 2, 2022 | NEW PRODUCT |
5MG;1GM;EQ 5MG BASE | QTERNMET XR | ASTRAZENECA AB | N210874 | May 2, 2019 | DISCN | TABLET, EXTENDED RELEASE | ORAL | May 2, 2022 | NEW PRODUCT |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
1GM;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | Aug. 12, 2022 | INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS |
500MG;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | Aug. 12, 2022 | INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS |
1GM;EQ 100MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Aug. 12, 2022 | INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS |
1GM;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Aug. 12, 2022 | INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS |
500MG;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Aug. 12, 2022 | INFORMATION ADDED TO THE LABELING REGARDING EFFICACY AND SAFETY OF THE CONTINUATION OF SITAGLIPTIN COMPARED WITH THE WITHDRAWAL OF SITAGLIPTIN DURING INITIATION AND TITRATION OF INSULIN GLARGINE IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS |
10MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 18, 2022 | TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS |
10MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 18, 2022 | TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS |
2.5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | July 28, 2017 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 18, 2022 | TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS |
5MG;1GM | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 18, 2022 | TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS |
5MG;500MG | XIGDUO XR | ASTRAZENECA AB | N205649 | Oct. 29, 2014 | RX | TABLET, EXTENDED RELEASE | ORAL | Oct. 18, 2022 | TO REDUCE THE RISK OF HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE OR MULTIPLE CARDIOVASCULAR RISK FACTORS |
2.5MG;1GM | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | Dec. 19, 2022 | NEW CHEMICAL ENTITY |
2.5MG;500MG | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | Dec. 19, 2022 | NEW CHEMICAL ENTITY |
7.5MG;1GM | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | Dec. 19, 2022 | NEW CHEMICAL ENTITY |
7.5MG;500MG | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | Dec. 19, 2022 | NEW CHEMICAL ENTITY |
1GM;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | Feb. 12, 2023 | PEDIATRIC EXCLUSIVITY |
500MG;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | Feb. 12, 2023 | PEDIATRIC EXCLUSIVITY |
1GM;EQ 100MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Feb. 12, 2023 | PEDIATRIC EXCLUSIVITY |
1GM;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Feb. 12, 2023 | PEDIATRIC EXCLUSIVITY |
500MG;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Feb. 12, 2023 | PEDIATRIC EXCLUSIVITY |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
1GM;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | Dec. 4, 2023 | ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING |
500MG;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | Dec. 4, 2023 | ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING |
1GM;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Dec. 4, 2023 | ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING |
500MG;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | Dec. 4, 2023 | ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING |
1GM;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | June 4, 2024 | PEDIATRIC EXCLUSIVITY |
500MG;EQ 50MG BASE | JANUMET | MERCK SHARP DOHME | N022044 | March 30, 2007 | RX | TABLET | ORAL | June 4, 2024 | PEDIATRIC EXCLUSIVITY |
1GM;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | June 4, 2024 | PEDIATRIC EXCLUSIVITY |
500MG;EQ 50MG BASE | JANUMET XR | MERCK SHARP DOHME | N202270 | Feb. 2, 2012 | RX | TABLET, EXTENDED RELEASE | ORAL | June 4, 2024 | PEDIATRIC EXCLUSIVITY |
2.5MG;1GM | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | Sept. 17, 2024 | REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV |
2.5MG;500MG | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | Sept. 17, 2024 | REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV |
7.5MG;1GM | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | Sept. 17, 2024 | REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV |
7.5MG;500MG | SEGLUROMET | MERCK SHARP DOHME | N209806 | Dec. 19, 2017 | RX | TABLET | ORAL | Sept. 17, 2024 | REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Mitochondrial complex I (NADH dehydrogenase) | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
5'-AMP-activated protein kinase subunit beta-1 | Kinase | WOMBAT-PK | |||||||
Dipeptidyl peptidase 4 | Enzyme | IC50 | 4.54 | CHEMBL | |||||
Solute carrier family 22 member 1 | Transporter | IC50 | 2.70 | WOMBAT-PK | |||||
Solute carrier family 22 member 2 | Transporter | IC50 | 3.40 | WOMBAT-PK | |||||
Solute carrier family 22 member 3 | Transporter | Km | 2.50 | WOMBAT-PK |
ID | Source |
---|---|
4023979 | VUID |
N0000021984 | NUI |
D00944 | KEGG_DRUG |
1115-70-4 | SECONDARY_CAS_RN |
4020898 | VANDF |
4023979 | VANDF |
C0025598 | UMLSCUI |
CHEBI:6801 | CHEBI |
MF8 | PDB_CHEM_ID |
CHEMBL1431 | ChEMBL_ID |
4091 | PUBCHEM_CID |
DB00331 | DRUGBANK_ID |
CHEMBL1703 | ChEMBL_ID |
D008687 | MESH_DESCRIPTOR_UI |
965 | INN_ID |
4779 | IUPHAR_LIGAND_ID |
9100L32L2N | UNII |
151827 | RXNORM |
41717 | MMSL |
5063 | MMSL |
592 | MMSL |
d03807 | MMSL |
003483 | NDDF |
004534 | NDDF |
109081006 | SNOMEDCT_US |
109083009 | SNOMEDCT_US |
372567009 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
JANUMET XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-0078 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | NDA | 30 sections |
JANUMET XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-0080 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 30 sections |
JANUMET XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-0081 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 30 sections |
JANUMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-0575 | TABLET, FILM COATED | 500 mg | ORAL | NDA | 29 sections |
JANUMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-0577 | TABLET, FILM COATED | 1000 mg | ORAL | NDA | 29 sections |
SEGLUROMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-5369 | TABLET, FILM COATED | 500 mg | ORAL | NDA | 30 sections |
SEGLUROMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-5370 | TABLET, FILM COATED | 500 mg | ORAL | NDA | 30 sections |
SEGLUROMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-5373 | TABLET, FILM COATED | 1000 mg | ORAL | NDA | 30 sections |
SEGLUROMET | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0006-5374 | TABLET, FILM COATED | 1000 mg | ORAL | NDA | 30 sections |
Glipizide and Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-7455 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 27 sections |
Glipizide and Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-7456 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 27 sections |
Glipizide and Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-7457 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 27 sections |
Glyburide and Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0228-2751 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 27 sections |
Glyburide and Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0228-2752 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 27 sections |
Glyburide and Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0228-2753 | TABLET, FILM COATED | 500 mg | ORAL | ANDA | 27 sections |
KOMBIGLYZEXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6125 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 30 sections |
KOMBIGLYZEXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6135 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | NDA | 30 sections |
KOMBIGLYZEXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6145 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6225 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6225 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6250 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6250 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6260 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6260 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6270 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6270 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6280 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 30 sections |
XIGDUOXR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0310-6280 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | NDA | 30 sections |
Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6001 | TABLET, FILM COATED, EXTENDED RELEASE | 1000 mg | ORAL | ANDA | 29 sections |
Metformin Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6002 | TABLET, FILM COATED, EXTENDED RELEASE | 500 mg | ORAL | ANDA | 29 sections |